ZA200609236B - Amido compounds and their use as pharmaceuticals - Google Patents
Amido compounds and their use as pharmaceuticals Download PDFInfo
- Publication number
- ZA200609236B ZA200609236B ZA200609236A ZA200609236A ZA200609236B ZA 200609236 B ZA200609236 B ZA 200609236B ZA 200609236 A ZA200609236 A ZA 200609236A ZA 200609236 A ZA200609236 A ZA 200609236A ZA 200609236 B ZA200609236 B ZA 200609236B
- Authority
- ZA
- South Africa
- Prior art keywords
- carbonyl
- pyrrolidin
- spiro
- cyclopropyl
- pyridine
- Prior art date
Links
- 239000003814 drug Substances 0.000 title claims description 8
- 125000003368 amide group Chemical group 0.000 title 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 193
- 125000000217 alkyl group Chemical group 0.000 claims description 146
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 146
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 144
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 138
- 125000003118 aryl group Chemical group 0.000 claims description 130
- 125000001072 heteroaryl group Chemical group 0.000 claims description 110
- 125000005843 halogen group Chemical group 0.000 claims description 94
- -1 heteroary] Chemical group 0.000 claims description 92
- 150000001875 compounds Chemical class 0.000 claims description 91
- 125000003342 alkenyl group Chemical group 0.000 claims description 80
- 125000003545 alkoxy group Chemical group 0.000 claims description 79
- 125000000304 alkynyl group Chemical group 0.000 claims description 75
- 125000001188 haloalkyl group Chemical group 0.000 claims description 71
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 53
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 50
- 125000003282 alkyl amino group Chemical group 0.000 claims description 47
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 43
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 42
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 40
- 125000005466 alkylenyl group Chemical group 0.000 claims description 34
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 34
- 150000003839 salts Chemical class 0.000 claims description 34
- 229910052760 oxygen Inorganic materials 0.000 claims description 31
- 125000004429 atom Chemical group 0.000 claims description 28
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 27
- 238000000034 method Methods 0.000 claims description 26
- 229910052717 sulfur Inorganic materials 0.000 claims description 26
- 125000004432 carbon atom Chemical group C* 0.000 claims description 25
- 239000000651 prodrug Substances 0.000 claims description 24
- 229940002612 prodrug Drugs 0.000 claims description 24
- 229910002091 carbon monoxide Inorganic materials 0.000 claims description 23
- 230000000694 effects Effects 0.000 claims description 22
- 239000000203 mixture Substances 0.000 claims description 21
- 206010020772 Hypertension Diseases 0.000 claims description 20
- 229910052799 carbon Inorganic materials 0.000 claims description 20
- 125000005885 heterocycloalkylalkyl group Chemical group 0.000 claims description 20
- 229960002478 aldosterone Drugs 0.000 claims description 19
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims description 19
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 claims description 18
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 claims description 18
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 18
- 125000004447 heteroarylalkenyl group Chemical group 0.000 claims description 17
- 125000005312 heteroarylalkynyl group Chemical group 0.000 claims description 17
- 125000005015 aryl alkynyl group Chemical group 0.000 claims description 16
- 229910052739 hydrogen Inorganic materials 0.000 claims description 16
- 208000008589 Obesity Diseases 0.000 claims description 15
- 125000005018 aryl alkenyl group Chemical group 0.000 claims description 15
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 15
- 235000020824 obesity Nutrition 0.000 claims description 15
- 206010022489 Insulin Resistance Diseases 0.000 claims description 14
- 208000001145 Metabolic Syndrome Diseases 0.000 claims description 14
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 14
- 125000004104 aryloxy group Chemical group 0.000 claims description 14
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 13
- 239000002253 acid Substances 0.000 claims description 12
- 125000004966 cyanoalkyl group Chemical group 0.000 claims description 11
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 11
- 125000002102 aryl alkyloxo group Chemical group 0.000 claims description 10
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims description 10
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
- 125000005114 heteroarylalkoxy group Chemical group 0.000 claims description 10
- 125000005326 heteroaryloxy alkyl group Chemical group 0.000 claims description 10
- 125000005553 heteroaryloxy group Chemical group 0.000 claims description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 125000005160 aryl oxy alkyl group Chemical group 0.000 claims description 8
- 125000005356 cycloalkylalkenyl group Chemical group 0.000 claims description 8
- 125000005357 cycloalkylalkynyl group Chemical group 0.000 claims description 8
- 230000014509 gene expression Effects 0.000 claims description 8
- 125000003386 piperidinyl group Chemical group 0.000 claims description 8
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 7
- 201000010099 disease Diseases 0.000 claims description 7
- 201000001421 hyperglycemia Diseases 0.000 claims description 7
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims description 6
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 6
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 6
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 6
- 206010012601 diabetes mellitus Diseases 0.000 claims description 5
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 5
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 4
- 206010012289 Dementia Diseases 0.000 claims description 4
- 208000032928 Dyslipidaemia Diseases 0.000 claims description 4
- 208000017170 Lipid metabolism disease Diseases 0.000 claims description 4
- 125000004414 alkyl thio group Chemical group 0.000 claims description 4
- 125000004103 aminoalkyl group Chemical group 0.000 claims description 4
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims description 4
- 125000004465 cycloalkenyloxy group Chemical group 0.000 claims description 4
- 125000000000 cycloalkoxy group Chemical group 0.000 claims description 4
- 125000005112 cycloalkylalkoxy group Chemical group 0.000 claims description 4
- 125000004985 dialkyl amino alkyl group Chemical group 0.000 claims description 4
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 4
- 125000004995 haloalkylthio group Chemical group 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 4
- 125000004971 nitroalkyl group Chemical group 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 4
- 125000003003 spiro group Chemical group 0.000 claims description 4
- 208000010412 Glaucoma Diseases 0.000 claims description 3
- 208000002705 Glucose Intolerance Diseases 0.000 claims description 3
- 206010018429 Glucose tolerance impaired Diseases 0.000 claims description 3
- 206010019280 Heart failures Diseases 0.000 claims description 3
- 208000001132 Osteoporosis Diseases 0.000 claims description 3
- 229920000180 alkyd Polymers 0.000 claims description 3
- 208000010877 cognitive disease Diseases 0.000 claims description 3
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 3
- 230000006378 damage Effects 0.000 claims description 3
- 230000002526 effect on cardiovascular system Effects 0.000 claims description 3
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 3
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 3
- 125000006568 (C4-C7) heterocycloalkyl group Chemical group 0.000 claims description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 2
- 206010002383 Angina Pectoris Diseases 0.000 claims description 2
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 2
- 201000001320 Atherosclerosis Diseases 0.000 claims description 2
- 208000028698 Cognitive impairment Diseases 0.000 claims description 2
- 206010070901 Diabetic dyslipidaemia Diseases 0.000 claims description 2
- 208000035150 Hypercholesterolemia Diseases 0.000 claims description 2
- 206010061218 Inflammation Diseases 0.000 claims description 2
- 208000018262 Peripheral vascular disease Diseases 0.000 claims description 2
- 208000007536 Thrombosis Diseases 0.000 claims description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 2
- 125000003302 alkenyloxy group Chemical group 0.000 claims description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 claims description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
- 208000029078 coronary artery disease Diseases 0.000 claims description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 208000006575 hypertriglyceridemia Diseases 0.000 claims description 2
- 230000004054 inflammatory process Effects 0.000 claims description 2
- 230000008816 organ damage Effects 0.000 claims description 2
- 125000004193 piperazinyl group Chemical group 0.000 claims description 2
- 230000002792 vascular Effects 0.000 claims description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 259
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Natural products C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims 43
- RFIOZSIHFNEKFF-UHFFFAOYSA-M piperazine-1-carboxylate Chemical compound [O-]C(=O)N1CCNCC1 RFIOZSIHFNEKFF-UHFFFAOYSA-M 0.000 claims 28
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 claims 19
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 18
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims 14
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 12
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 11
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 10
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims 10
- IBBMAWULFFBRKK-UHFFFAOYSA-N picolinamide Chemical compound NC(=O)C1=CC=CC=N1 IBBMAWULFFBRKK-UHFFFAOYSA-N 0.000 claims 9
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 9
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 claims 8
- 125000004043 oxo group Chemical group O=* 0.000 claims 7
- 125000004089 sulfido group Chemical group [S-]* 0.000 claims 7
- DNUTZBZXLPWRJG-UHFFFAOYSA-M piperidine-1-carboxylate Chemical compound [O-]C(=O)N1CCCCC1 DNUTZBZXLPWRJG-UHFFFAOYSA-M 0.000 claims 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims 5
- KXDAEFPNCMNJSK-UHFFFAOYSA-N benzene carboxamide Natural products NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims 5
- JHHZLHWJQPUNKB-UHFFFAOYSA-N pyrrolidin-3-ol Chemical compound OC1CCNC1 JHHZLHWJQPUNKB-UHFFFAOYSA-N 0.000 claims 5
- 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 4
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims 4
- METKIMKYRPQLGS-UHFFFAOYSA-N atenolol Chemical compound CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-UHFFFAOYSA-N 0.000 claims 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims 3
- BRDKSYZPIQLKJI-UHFFFAOYSA-N spiro[2-benzofuran-3,3'-pyrrolidine]-1-one Chemical compound C12=CC=CC=C2C(=O)OC21CCNC2 BRDKSYZPIQLKJI-UHFFFAOYSA-N 0.000 claims 3
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 claims 2
- KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 claims 2
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 claims 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims 2
- AIMMVWOEOZMVMS-UHFFFAOYSA-N cyclopropanecarboxamide Chemical compound NC(=O)C1CC1 AIMMVWOEOZMVMS-UHFFFAOYSA-N 0.000 claims 2
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 2
- WLNMKQODTIGTQA-UHFFFAOYSA-N ethyl 4-[5-[1-(3-pyridin-3-ylpyrrolidine-1-carbonyl)cyclopropyl]pyridin-2-yl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OCC)CCN1C1=CC=C(C2(CC2)C(=O)N2CC(CC2)C=2C=NC=CC=2)C=N1 WLNMKQODTIGTQA-UHFFFAOYSA-N 0.000 claims 2
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 2
- WJRBRSLFGCUECM-UHFFFAOYSA-N hydantoin Chemical compound O=C1CNC(=O)N1 WJRBRSLFGCUECM-UHFFFAOYSA-N 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 claims 2
- 235000005152 nicotinamide Nutrition 0.000 claims 2
- 239000011570 nicotinamide Substances 0.000 claims 2
- 229960003966 nicotinamide Drugs 0.000 claims 2
- IVXQBCUBSIPQGU-UHFFFAOYSA-N piperazine-1-carboxamide Chemical compound NC(=O)N1CCNCC1 IVXQBCUBSIPQGU-UHFFFAOYSA-N 0.000 claims 2
- 125000000446 sulfanediyl group Chemical group *S* 0.000 claims 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N tetrahydropyridine hydrochloride Natural products C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 2
- AOTSYJYWLHHSCN-UHFFFAOYSA-N (3-hydroxypyrrolidin-1-yl)-(1-phenylcyclopropyl)methanone Chemical compound C1C(O)CCN1C(=O)C1(C=2C=CC=CC=2)CC1 AOTSYJYWLHHSCN-UHFFFAOYSA-N 0.000 claims 1
- JYNQSQLPIBPYCX-UHFFFAOYSA-N (4-benzyl-4-hydroxypiperidin-1-yl)-[1-(4-chlorophenyl)cyclopropyl]methanone Chemical compound C1CN(C(=O)C2(CC2)C=2C=CC(Cl)=CC=2)CCC1(O)CC1=CC=CC=C1 JYNQSQLPIBPYCX-UHFFFAOYSA-N 0.000 claims 1
- VBOULPMHVYMUBH-UHFFFAOYSA-N (4-benzylidenepiperidin-1-yl)-[1-(4-chlorophenyl)cyclopropyl]methanone Chemical compound C1=CC(Cl)=CC=C1C1(C(=O)N2CCC(CC2)=CC=2C=CC=CC=2)CC1 VBOULPMHVYMUBH-UHFFFAOYSA-N 0.000 claims 1
- OYVHXJGRJJOMNC-UHFFFAOYSA-N 1'-(1-quinolin-4-ylcyclopropanecarbonyl)spiro[2-benzofuran-3,3'-pyrrolidine]-1-one Chemical compound C1CC2(C3=CC=CC=C3C(=O)O2)CN1C(=O)C1(C=2C3=CC=CC=C3N=CC=2)CC1 OYVHXJGRJJOMNC-UHFFFAOYSA-N 0.000 claims 1
- APAYAOUCALXXIR-UHFFFAOYSA-N 1'-(1-quinolin-4-ylcyclopropanecarbonyl)spiro[5h-furo[3,4-c]pyridine-1,3'-pyrrolidine]-3,4-dione Chemical compound OC1=NC=CC2=C1C(=O)OC2(C1)CCN1C(=O)C1(C=2C3=CC=CC=C3N=CC=2)CC1 APAYAOUCALXXIR-UHFFFAOYSA-N 0.000 claims 1
- IPRVQASLOXXFLC-UHFFFAOYSA-N 1'-(1-quinolin-6-ylcyclopropanecarbonyl)spiro[2-benzofuran-3,3'-pyrrolidine]-1-one Chemical compound C1CC2(C3=CC=CC=C3C(=O)O2)CN1C(=O)C1(C=2C=C3C=CC=NC3=CC=2)CC1 IPRVQASLOXXFLC-UHFFFAOYSA-N 0.000 claims 1
- MQXYLWVEBAEUHR-UHFFFAOYSA-N 1'-[1-(2-chlorophenyl)cyclopropanecarbonyl]spiro[furo[3,4-c]pyridine-1,3'-pyrrolidine]-3-one Chemical compound ClC1=CC=CC=C1C1(C(=O)N2CC3(CC2)C2=CC=NC=C2C(=O)O3)CC1 MQXYLWVEBAEUHR-UHFFFAOYSA-N 0.000 claims 1
- FKRPKJISKALYRG-UHFFFAOYSA-N 1'-[1-(2-fluoro-4-pyridin-2-ylphenyl)cyclopropanecarbonyl]spiro[2-benzofuran-3,3'-pyrrolidine]-1-one Chemical compound FC1=CC(C=2N=CC=CC=2)=CC=C1C1(C(=O)N2CC3(CC2)C2=CC=CC=C2C(=O)O3)CC1 FKRPKJISKALYRG-UHFFFAOYSA-N 0.000 claims 1
- AKMGZVLGRKYCCP-UHFFFAOYSA-N 1'-[1-(4-chloro-2-fluorophenyl)cyclopropanecarbonyl]spiro[2-benzofuran-3,3'-pyrrolidine]-1-one Chemical compound FC1=CC(Cl)=CC=C1C1(C(=O)N2CC3(CC2)C2=CC=CC=C2C(=O)O3)CC1 AKMGZVLGRKYCCP-UHFFFAOYSA-N 0.000 claims 1
- CAKMKMFBUFKNJL-UHFFFAOYSA-N 1'-[1-(4-chlorophenyl)cyclobutanecarbonyl]spiro[2-benzofuran-3,3'-pyrrolidine]-1-one Chemical compound C1=CC(Cl)=CC=C1C1(C(=O)N2CC3(CC2)C2=CC=CC=C2C(=O)O3)CCC1 CAKMKMFBUFKNJL-UHFFFAOYSA-N 0.000 claims 1
- FCZRLAWZOZVCQN-UHFFFAOYSA-N 1'-[1-(4-cyclopentyloxyphenyl)cyclopropanecarbonyl]spiro[furo[3,4-c]pyridine-1,3'-pyrrolidine]-3-one Chemical compound C1CC2(C3=CC=NC=C3C(=O)O2)CN1C(=O)C1(C=2C=CC(OC3CCCC3)=CC=2)CC1 FCZRLAWZOZVCQN-UHFFFAOYSA-N 0.000 claims 1
- OYDDTTIWTTUWPX-UHFFFAOYSA-N 1'-[1-(4-fluorophenyl)cyclopropanecarbonyl]spiro[furo[3,4-b]pyridine-5,3'-pyrrolidine]-7-one Chemical compound C1=CC(F)=CC=C1C1(C(=O)N2CC3(CC2)C2=CC=CN=C2C(=O)O3)CC1 OYDDTTIWTTUWPX-UHFFFAOYSA-N 0.000 claims 1
- YHDXPYADZRTNFX-UHFFFAOYSA-N 1'-[1-(4-indazol-2-ylphenyl)cyclopropanecarbonyl]spiro[furo[3,4-c]pyridine-1,3'-pyrrolidine]-3-one Chemical compound C1CC2(C3=CC=NC=C3C(=O)O2)CN1C(=O)C1(C=2C=CC(=CC=2)N2N=C3C=CC=CC3=C2)CC1 YHDXPYADZRTNFX-UHFFFAOYSA-N 0.000 claims 1
- VZXUEIDZMLODPX-UHFFFAOYSA-N 1'-[1-(4-methoxyphenyl)cyclopropanecarbonyl]spiro[furo[3,4-b]pyridine-5,3'-pyrrolidine]-7-one Chemical compound C1=CC(OC)=CC=C1C1(C(=O)N2CC3(CC2)C2=CC=CN=C2C(=O)O3)CC1 VZXUEIDZMLODPX-UHFFFAOYSA-N 0.000 claims 1
- RXROPABRIXZVOS-UHFFFAOYSA-N 1'-[1-(4-methoxyphenyl)cyclopropanecarbonyl]spiro[furo[3,4-c]pyridine-1,3'-pyrrolidine]-3-one Chemical compound C1=CC(OC)=CC=C1C1(C(=O)N2CC3(CC2)C2=CC=NC=C2C(=O)O3)CC1 RXROPABRIXZVOS-UHFFFAOYSA-N 0.000 claims 1
- OFWRRISOFTZSIZ-UHFFFAOYSA-N 1'-[1-(4-morpholin-4-ylphenyl)cyclopropanecarbonyl]spiro[2-benzofuran-3,3'-pyrrolidine]-1-one Chemical compound C1CC2(C3=CC=CC=C3C(=O)O2)CN1C(=O)C1(C=2C=CC(=CC=2)N2CCOCC2)CC1 OFWRRISOFTZSIZ-UHFFFAOYSA-N 0.000 claims 1
- NBQKGMIFXHGUMA-UHFFFAOYSA-N 1'-[1-(4-phenoxyphenyl)cyclopropanecarbonyl]spiro[furo[3,4-c]pyridine-1,3'-pyrrolidine]-3-one Chemical compound C1CC2(C3=CC=NC=C3C(=O)O2)CN1C(=O)C1(C=2C=CC(OC=3C=CC=CC=3)=CC=2)CC1 NBQKGMIFXHGUMA-UHFFFAOYSA-N 0.000 claims 1
- LLGDNOPHQCCLSG-UHFFFAOYSA-N 1'-[1-(4-pyrrolidin-1-ylphenyl)cyclopropanecarbonyl]spiro[2-benzofuran-3,3'-pyrrolidine]-1-one Chemical compound C1CC2(C3=CC=CC=C3C(=O)O2)CN1C(=O)C1(C=2C=CC(=CC=2)N2CCCC2)CC1 LLGDNOPHQCCLSG-UHFFFAOYSA-N 0.000 claims 1
- KCGUDAGCQIIQAO-UHFFFAOYSA-N 1'-[1-(4-tert-butyl-1,3-thiazol-2-yl)cyclopropanecarbonyl]spiro[2-benzofuran-3,3'-pyrrolidine]-1-one Chemical compound CC(C)(C)C1=CSC(C2(CC2)C(=O)N2CC3(CC2)C2=CC=CC=C2C(=O)O3)=N1 KCGUDAGCQIIQAO-UHFFFAOYSA-N 0.000 claims 1
- YMDNEWWPWJPVIH-UHFFFAOYSA-N 1'-[1-(6-quinolin-3-ylpyridin-3-yl)cyclopropanecarbonyl]spiro[furo[3,4-c]pyridine-1,3'-pyrrolidine]-3-one Chemical compound C1CC2(C3=CC=NC=C3C(=O)O2)CN1C(=O)C1(C=2C=NC(=CC=2)C=2C=C3C=CC=CC3=NC=2)CC1 YMDNEWWPWJPVIH-UHFFFAOYSA-N 0.000 claims 1
- XNJAKPADYBAHIA-UHFFFAOYSA-N 1'-[1-[2-fluoro-4-(2-oxopyrrolidin-1-yl)phenyl]cyclopropanecarbonyl]spiro[2-benzofuran-3,3'-pyrrolidine]-1-one Chemical compound FC1=CC(N2C(CCC2)=O)=CC=C1C1(C(=O)N2CC3(CC2)C2=CC=CC=C2C(=O)O3)CC1 XNJAKPADYBAHIA-UHFFFAOYSA-N 0.000 claims 1
- PSRLMYUTEXXCAB-UHFFFAOYSA-N 1'-[1-[2-fluoro-4-(4-propanoylpiperazin-1-yl)phenyl]cyclopropanecarbonyl]spiro[2-benzofuran-3,3'-pyrrolidine]-1-one Chemical compound C1CN(C(=O)CC)CCN1C1=CC=C(C2(CC2)C(=O)N2CC3(CC2)C2=CC=CC=C2C(=O)O3)C(F)=C1 PSRLMYUTEXXCAB-UHFFFAOYSA-N 0.000 claims 1
- XYSUYPJQDMWSBO-UHFFFAOYSA-N 1'-[1-[2-fluoro-4-[4-(2-methylpropanoyl)piperazin-1-yl]phenyl]cyclopropanecarbonyl]spiro[2-benzofuran-3,3'-pyrrolidine]-1-one Chemical compound C1CN(C(=O)C(C)C)CCN1C1=CC=C(C2(CC2)C(=O)N2CC3(CC2)C2=CC=CC=C2C(=O)O3)C(F)=C1 XYSUYPJQDMWSBO-UHFFFAOYSA-N 0.000 claims 1
- WXAIAGURAZEBGP-UHFFFAOYSA-N 1'-[1-[2-fluoro-4-[4-(3-methylbutanoyl)piperazin-1-yl]phenyl]cyclopropanecarbonyl]spiro[furo[3,4-c]pyridine-1,3'-pyrrolidine]-3-one Chemical compound C1CN(C(=O)CC(C)C)CCN1C1=CC=C(C2(CC2)C(=O)N2CC3(CC2)C2=CC=NC=C2C(=O)O3)C(F)=C1 WXAIAGURAZEBGP-UHFFFAOYSA-N 0.000 claims 1
- QHBCIOSTRXMKBB-UHFFFAOYSA-N 1'-[1-[4-(1-acetylpiperidin-4-yl)phenyl]cyclopropanecarbonyl]spiro[2-benzofuran-3,3'-pyrrolidine]-1-one Chemical compound C1CN(C(=O)C)CCC1C1=CC=C(C2(CC2)C(=O)N2CC3(CC2)C2=CC=CC=C2C(=O)O3)C=C1 QHBCIOSTRXMKBB-UHFFFAOYSA-N 0.000 claims 1
- IHDNLRRNDILNCT-UHFFFAOYSA-N 1'-[1-[4-(2-amino-1,3-thiazol-4-yl)phenyl]cyclopropanecarbonyl]spiro[furo[3,4-c]pyridine-1,3'-pyrrolidine]-3-one Chemical compound S1C(N)=NC(C=2C=CC(=CC=2)C2(CC2)C(=O)N2CC3(CC2)C2=CC=NC=C2C(=O)O3)=C1 IHDNLRRNDILNCT-UHFFFAOYSA-N 0.000 claims 1
- JMEYGOXSQWWYKN-UHFFFAOYSA-N 1'-[1-[4-(2-oxoazetidin-1-yl)phenyl]cyclopropanecarbonyl]spiro[2-benzofuran-3,3'-pyrrolidine]-1-one Chemical compound C1CC2(C3=CC=CC=C3C(=O)O2)CN1C(=O)C1(C=2C=CC(=CC=2)N2C(CC2)=O)CC1 JMEYGOXSQWWYKN-UHFFFAOYSA-N 0.000 claims 1
- LSOYZBIMLHJLRO-UHFFFAOYSA-N 1'-[1-[4-(2-oxopyrrolidin-1-yl)phenyl]cyclopropanecarbonyl]spiro[furo[3,4-c]pyridine-1,3'-pyrrolidine]-3-one Chemical compound C1CC2(C3=CC=NC=C3C(=O)O2)CN1C(=O)C1(C=2C=CC(=CC=2)N2C(CCC2)=O)CC1 LSOYZBIMLHJLRO-UHFFFAOYSA-N 0.000 claims 1
- NCUUAOFFPQNPFQ-UHFFFAOYSA-N 1'-[1-[4-(2-pyridin-3-yl-1,3-thiazol-4-yl)phenyl]cyclopropanecarbonyl]spiro[2-benzofuran-3,3'-pyrrolidine]-1-one Chemical compound C1CC2(C3=CC=CC=C3C(=O)O2)CN1C(=O)C1(C=2C=CC(=CC=2)C=2N=C(SC=2)C=2C=NC=CC=2)CC1 NCUUAOFFPQNPFQ-UHFFFAOYSA-N 0.000 claims 1
- PENDCSNRMSYZMW-UHFFFAOYSA-N 1'-[1-[4-(4-methyl-2-oxopiperazin-1-yl)phenyl]cyclopropanecarbonyl]spiro[2-benzofuran-3,3'-pyrrolidine]-1-one Chemical compound O=C1CN(C)CCN1C1=CC=C(C2(CC2)C(=O)N2CC3(CC2)C2=CC=CC=C2C(=O)O3)C=C1 PENDCSNRMSYZMW-UHFFFAOYSA-N 0.000 claims 1
- QHYNKGNLVZBXFL-UHFFFAOYSA-N 1'-[1-[4-(pyridin-2-yloxymethyl)phenyl]cyclopropanecarbonyl]spiro[2-benzofuran-3,3'-pyrrolidine]-1-one Chemical compound C1CC2(C3=CC=CC=C3C(=O)O2)CN1C(=O)C1(C=2C=CC(COC=3N=CC=CC=3)=CC=2)CC1 QHYNKGNLVZBXFL-UHFFFAOYSA-N 0.000 claims 1
- YJVCMTREOYLMHE-AATRIKPKSA-N 1'-[1-[4-[(e)-2-pyridin-4-ylethenyl]phenyl]cyclopropanecarbonyl]spiro[2-benzofuran-3,3'-pyrrolidine]-1-one Chemical compound C1CC2(C3=CC=CC=C3C(=O)O2)CN1C(=O)C1(C=2C=CC(\C=C\C=3C=CN=CC=3)=CC=2)CC1 YJVCMTREOYLMHE-AATRIKPKSA-N 0.000 claims 1
- WQJNMXJGJXLUID-UHFFFAOYSA-N 1'-[1-[4-[2-(trifluoromethyl)-1h-imidazol-5-yl]phenyl]cyclopropanecarbonyl]spiro[2-benzofuran-3,3'-pyrrolidine]-1-one Chemical compound N1C(C(F)(F)F)=NC(C=2C=CC(=CC=2)C2(CC2)C(=O)N2CC3(CC2)C2=CC=CC=C2C(=O)O3)=C1 WQJNMXJGJXLUID-UHFFFAOYSA-N 0.000 claims 1
- HAMIHAZNCBXTQF-UHFFFAOYSA-N 1'-[1-[4-[4-(2-cyclopropylacetyl)piperazin-1-yl]-2-fluorophenyl]cyclopropanecarbonyl]spiro[2-benzofuran-3,3'-pyrrolidine]-1-one Chemical compound FC1=CC(N2CCN(CC2)C(=O)CC2CC2)=CC=C1C1(C(=O)N2CC3(CC2)C2=CC=CC=C2C(=O)O3)CC1 HAMIHAZNCBXTQF-UHFFFAOYSA-N 0.000 claims 1
- WLWZBYTXJZDLBI-UHFFFAOYSA-N 1'-[1-[4-[4-(cyclopropanecarbonyl)piperazin-1-yl]phenyl]cyclobutanecarbonyl]spiro[2-benzofuran-3,3'-pyrrolidine]-1-one Chemical compound C1CN(C=2C=CC(=CC=2)C2(CCC2)C(=O)N2CC3(CC2)C2=CC=CC=C2C(=O)O3)CCN1C(=O)C1CC1 WLWZBYTXJZDLBI-UHFFFAOYSA-N 0.000 claims 1
- UKXPSDJDWKOMTN-UHFFFAOYSA-N 1'-[1-[6-(1,3-dihydroisoindol-2-yl)pyridin-3-yl]cyclopropanecarbonyl]spiro[2-benzofuran-3,3'-pyrrolidine]-1-one Chemical compound C1CC2(C3=CC=CC=C3C(=O)O2)CN1C(=O)C1(C=2C=NC(=CC=2)N2CC3=CC=CC=C3C2)CC1 UKXPSDJDWKOMTN-UHFFFAOYSA-N 0.000 claims 1
- DIBGREJZXCQCIO-UHFFFAOYSA-N 1'-[1-[6-(3,3-difluoropyrrolidin-1-yl)pyridin-3-yl]cyclopropanecarbonyl]spiro[2-benzofuran-3,3'-pyrrolidine]-1-one Chemical compound C1C(F)(F)CCN1C1=CC=C(C2(CC2)C(=O)N2CC3(CC2)C2=CC=CC=C2C(=O)O3)C=N1 DIBGREJZXCQCIO-UHFFFAOYSA-N 0.000 claims 1
- PXDGZBRUWXZKGE-UHFFFAOYSA-N 1'-[1-[6-(3-hydroxypyrrolidin-1-yl)pyridin-3-yl]cyclopropanecarbonyl]spiro[2-benzofuran-3,3'-pyrrolidine]-1-one Chemical compound C1C(O)CCN1C1=CC=C(C2(CC2)C(=O)N2CC3(CC2)C2=CC=CC=C2C(=O)O3)C=N1 PXDGZBRUWXZKGE-UHFFFAOYSA-N 0.000 claims 1
- GOUPHYSJTBXXFT-UHFFFAOYSA-N 1'-[1-[6-[4-(4-fluorophenyl)piperazin-1-yl]pyridin-3-yl]cyclopropanecarbonyl]spiro[furo[3,4-c]pyridine-1,3'-pyrrolidine]-3-one Chemical compound C1=CC(F)=CC=C1N1CCN(C=2N=CC(=CC=2)C2(CC2)C(=O)N2CC3(CC2)C2=CC=NC=C2C(=O)O3)CC1 GOUPHYSJTBXXFT-UHFFFAOYSA-N 0.000 claims 1
- XAGZJIQIVXSURR-UHFFFAOYSA-N 1-[4-(trifluoromethyl)phenyl]piperidin-2-one Chemical group C1=CC(C(F)(F)F)=CC=C1N1C(=O)CCCC1 XAGZJIQIVXSURR-UHFFFAOYSA-N 0.000 claims 1
- OFPWQEVNKHBJMA-UHFFFAOYSA-N 1-[4-[1-(3-pyridin-4-ylpyrrolidine-1-carbonyl)cyclopropyl]phenyl]pyrrolidin-2-one Chemical compound C1CC1(C=1C=CC(=CC=1)N1C(CCC1)=O)C(=O)N(C1)CCC1C1=CC=NC=C1 OFPWQEVNKHBJMA-UHFFFAOYSA-N 0.000 claims 1
- CXSIJCFABSXMSD-UHFFFAOYSA-N 1-[4-[5-[1-(3-pyridin-3-ylpyrrolidine-1-carbonyl)cyclopropyl]pyridin-2-yl]piperazin-1-yl]ethanone Chemical compound C1CN(C(=O)C)CCN1C1=CC=C(C2(CC2)C(=O)N2CC(CC2)C=2C=NC=CC=2)C=N1 CXSIJCFABSXMSD-UHFFFAOYSA-N 0.000 claims 1
- RHDYQUZYHZWTCI-UHFFFAOYSA-N 1-methoxy-4-phenylbenzene Chemical compound C1=CC(OC)=CC=C1C1=CC=CC=C1 RHDYQUZYHZWTCI-UHFFFAOYSA-N 0.000 claims 1
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 125000004201 2,4-dichlorophenyl group Chemical group [H]C1=C([H])C(*)=C(Cl)C([H])=C1Cl 0.000 claims 1
- 125000004215 2,4-difluorophenyl group Chemical group [H]C1=C([H])C(*)=C(F)C([H])=C1F 0.000 claims 1
- KVVDRQDTODKIJD-UHFFFAOYSA-N 2-cyclopropylacetic acid Chemical compound OC(=O)CC1CC1 KVVDRQDTODKIJD-UHFFFAOYSA-N 0.000 claims 1
- 125000004847 2-fluorobenzyl group Chemical group [H]C1=C([H])C(F)=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- OKACSYPNGKLQTN-UHFFFAOYSA-N 2-methyl-1-[4-[4-[1-(3-phenylpyrrolidine-1-carbonyl)cyclopropyl]phenyl]piperazin-1-yl]propan-1-one Chemical compound C1CN(C(=O)C(C)C)CCN1C1=CC=C(C2(CC2)C(=O)N2CC(CC2)C=2C=CC=CC=2)C=C1 OKACSYPNGKLQTN-UHFFFAOYSA-N 0.000 claims 1
- DGBFKGHNQAKNPW-UHFFFAOYSA-N 2-methyl-1-[4-[5-[1-(3-phenylpyrrolidine-1-carbonyl)cyclopropyl]pyridin-2-yl]piperazin-1-yl]propan-1-one Chemical compound C1CN(C(=O)C(C)C)CCN1C1=CC=C(C2(CC2)C(=O)N2CC(CC2)C=2C=CC=CC=2)C=N1 DGBFKGHNQAKNPW-UHFFFAOYSA-N 0.000 claims 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims 1
- XAGYENKRKRZQFF-UHFFFAOYSA-N 3,3a,4,9b-tetrahydro-1h-chromeno[3,4-c]pyrrol-2-yl-[1-(4-chlorophenyl)cyclopropyl]methanone Chemical compound C1=CC(Cl)=CC=C1C1(C(=O)N2CC3C4=CC=CC=C4OCC3C2)CC1 XAGYENKRKRZQFF-UHFFFAOYSA-N 0.000 claims 1
- UPJCNZADSULHEV-UHFFFAOYSA-N 3-[4-[1-(3-phenylpyrrolidine-1-carbonyl)cyclopropyl]phenyl]-1,3-oxazolidin-2-one Chemical compound C1CC1(C=1C=CC(=CC=1)N1C(OCC1)=O)C(=O)N(C1)CCC1C1=CC=CC=C1 UPJCNZADSULHEV-UHFFFAOYSA-N 0.000 claims 1
- 125000006284 3-fluorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C(F)=C1[H])C([H])([H])* 0.000 claims 1
- DPBWFNDFMCCGGJ-UHFFFAOYSA-N 4-Piperidine carboxamide Chemical compound NC(=O)C1CCNCC1 DPBWFNDFMCCGGJ-UHFFFAOYSA-N 0.000 claims 1
- FUISNRYDIRMMGM-UHFFFAOYSA-N 4-[1-(3-oxospiro[2-benzofuran-1,3'-pyrrolidine]-1'-carbonyl)cyclopropyl]benzonitrile Chemical compound C1CC2(C3=CC=CC=C3C(=O)O2)CN1C(=O)C1(C=2C=CC(=CC=2)C#N)CC1 FUISNRYDIRMMGM-UHFFFAOYSA-N 0.000 claims 1
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 claims 1
- NUDJQKRTLNEUBE-UHFFFAOYSA-N 4-fluoro-1'-(1-quinolin-4-ylcyclopropanecarbonyl)spiro[furo[3,4-c]pyridine-1,3'-pyrrolidine]-3-one Chemical compound FC1=NC=CC2=C1C(=O)OC2(C1)CCN1C(=O)C1(C=2C3=CC=CC=C3N=CC=2)CC1 NUDJQKRTLNEUBE-UHFFFAOYSA-N 0.000 claims 1
- BFUSQALOKJVZQS-UHFFFAOYSA-N 4-methoxy-1'-(1-quinolin-4-ylcyclopropanecarbonyl)spiro[furo[3,4-c]pyridine-1,3'-pyrrolidine]-3-one Chemical compound COC1=NC=CC2=C1C(=O)OC2(C1)CCN1C(=O)C1(C=2C3=CC=CC=C3N=CC=2)CC1 BFUSQALOKJVZQS-UHFFFAOYSA-N 0.000 claims 1
- LUQVCHRDAGWYMG-UHFFFAOYSA-N 4-phenylbenzamide Chemical compound C1=CC(C(=O)N)=CC=C1C1=CC=CC=C1 LUQVCHRDAGWYMG-UHFFFAOYSA-N 0.000 claims 1
- PQWFDAKBPGXILW-UHFFFAOYSA-N 6-chloro-1'-[1-[4-(trifluoromethyl)phenyl]cyclopropanecarbonyl]spiro[furo[3,4-c]pyridine-1,3'-pyrrolidine]-3-one Chemical compound C1=CC(C(F)(F)F)=CC=C1C1(C(=O)N2CC3(CC2)C2=CC(Cl)=NC=C2C(=O)O3)CC1 PQWFDAKBPGXILW-UHFFFAOYSA-N 0.000 claims 1
- DQQQCMRHRRYHEF-UHFFFAOYSA-N 7-[1-(4-chlorophenyl)cyclopropanecarbonyl]-4,4-dimethyl-1-oxa-7-azaspiro[4.4]nonan-2-one Chemical compound CC1(C)CC(=O)OC11CN(C(=O)C2(CC2)C=2C=CC(Cl)=CC=2)CC1 DQQQCMRHRRYHEF-UHFFFAOYSA-N 0.000 claims 1
- OLUWHORRDZKUQU-UHFFFAOYSA-N 8-[1-(4-chlorophenyl)cyclopropanecarbonyl]-2,8-diazaspiro[4.5]decan-3-one Chemical compound C1=CC(Cl)=CC=C1C1(C(=O)N2CCC3(CC(=O)NC3)CC2)CC1 OLUWHORRDZKUQU-UHFFFAOYSA-N 0.000 claims 1
- RRHGJUQNOFWUDK-UHFFFAOYSA-N Isoprene Chemical compound CC(=C)C=C RRHGJUQNOFWUDK-UHFFFAOYSA-N 0.000 claims 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- QIOZLISABUUKJY-UHFFFAOYSA-N Thiobenzamide Chemical compound NC(=S)C1=CC=CC=C1 QIOZLISABUUKJY-UHFFFAOYSA-N 0.000 claims 1
- QBDBSANFJLHUSB-UHFFFAOYSA-N [1-(4-chlorophenyl)cyclobutyl]-(3-pyridin-3-ylpyrrolidin-1-yl)methanone Chemical compound C1=CC(Cl)=CC=C1C1(C(=O)N2CC(CC2)C=2C=NC=CC=2)CCC1 QBDBSANFJLHUSB-UHFFFAOYSA-N 0.000 claims 1
- HDSJHYUMZHINRQ-UHFFFAOYSA-N [1-(4-chlorophenyl)cyclopropyl]-(1,3-dihydroisoindol-2-yl)methanone Chemical compound C1=CC(Cl)=CC=C1C1(C(=O)N2CC3=CC=CC=C3C2)CC1 HDSJHYUMZHINRQ-UHFFFAOYSA-N 0.000 claims 1
- QWTAYGITAHTASO-UHFFFAOYSA-N [1-(4-chlorophenyl)cyclopropyl]-(2,3-dihydroindol-1-yl)methanone Chemical compound C1=CC(Cl)=CC=C1C1(C(=O)N2C3=CC=CC=C3CC2)CC1 QWTAYGITAHTASO-UHFFFAOYSA-N 0.000 claims 1
- MGFIAQUDEDEXGA-UHFFFAOYSA-N [1-(4-chlorophenyl)cyclopropyl]-(2-phenylpyrrolidin-1-yl)methanone Chemical compound C1=CC(Cl)=CC=C1C1(C(=O)N2C(CCC2)C=2C=CC=CC=2)CC1 MGFIAQUDEDEXGA-UHFFFAOYSA-N 0.000 claims 1
- ZEVYIHDDQSWODK-UHFFFAOYSA-N [1-(4-chlorophenyl)cyclopropyl]-(3,3,5-trimethyl-7-azabicyclo[3.2.1]octan-7-yl)methanone Chemical compound C1C(C)(C)CC(C)(C2)CC1N2C(=O)C1(C=2C=CC(Cl)=CC=2)CC1 ZEVYIHDDQSWODK-UHFFFAOYSA-N 0.000 claims 1
- DTSBNSXEWPHUCR-UHFFFAOYSA-N [1-(4-chlorophenyl)cyclopropyl]-(3,4-dihydro-1h-isoquinolin-2-yl)methanone Chemical compound C1=CC(Cl)=CC=C1C1(C(=O)N2CC3=CC=CC=C3CC2)CC1 DTSBNSXEWPHUCR-UHFFFAOYSA-N 0.000 claims 1
- RRVFEMJNAYKVAD-UHFFFAOYSA-N [1-(4-chlorophenyl)cyclopropyl]-(3,4-dihydroxy-3-phenylpyrrolidin-1-yl)methanone Chemical compound OC1CN(C(=O)C2(CC2)C=2C=CC(Cl)=CC=2)CC1(O)C1=CC=CC=C1 RRVFEMJNAYKVAD-UHFFFAOYSA-N 0.000 claims 1
- UVZNYXVVGJCYKJ-UHFFFAOYSA-N [1-(4-chlorophenyl)cyclopropyl]-(3-hydroxy-3-phenylpyrrolidin-1-yl)methanone Chemical compound C1C(O)(C=2C=CC=CC=2)CCN1C(=O)C1(C=2C=CC(Cl)=CC=2)CC1 UVZNYXVVGJCYKJ-UHFFFAOYSA-N 0.000 claims 1
- XWABQOQSIMRBCK-UHFFFAOYSA-N [1-(4-chlorophenyl)cyclopropyl]-(3-hydroxy-3-pyridin-2-ylpyrrolidin-1-yl)methanone Chemical compound C1C(O)(C=2N=CC=CC=2)CCN1C(=O)C1(C=2C=CC(Cl)=CC=2)CC1 XWABQOQSIMRBCK-UHFFFAOYSA-N 0.000 claims 1
- SXPCXIQRLCLETJ-UHFFFAOYSA-N [1-(4-chlorophenyl)cyclopropyl]-(3-hydroxy-3-pyridin-4-ylpyrrolidin-1-yl)methanone Chemical compound C1C(O)(C=2C=CN=CC=2)CCN1C(=O)C1(C=2C=CC(Cl)=CC=2)CC1 SXPCXIQRLCLETJ-UHFFFAOYSA-N 0.000 claims 1
- DZFHRPBCHOGYHX-UHFFFAOYSA-N [1-(4-chlorophenyl)cyclopropyl]-(3-phenyl-1-oxa-2,8-diazaspiro[4.5]dec-2-en-8-yl)methanone Chemical compound C1=CC(Cl)=CC=C1C1(C(=O)N2CCC3(ON=C(C3)C=3C=CC=CC=3)CC2)CC1 DZFHRPBCHOGYHX-UHFFFAOYSA-N 0.000 claims 1
- DKSRXENEYIXSMN-UHFFFAOYSA-N [1-(4-chlorophenyl)cyclopropyl]-(3-phenylpiperidin-1-yl)methanone Chemical compound C1=CC(Cl)=CC=C1C1(C(=O)N2CC(CCC2)C=2C=CC=CC=2)CC1 DKSRXENEYIXSMN-UHFFFAOYSA-N 0.000 claims 1
- KKRCWEICXMGION-UHFFFAOYSA-N [1-(4-chlorophenyl)cyclopropyl]-(3-phenylpyrrolidin-1-yl)methanone Chemical compound C1=CC(Cl)=CC=C1C1(C(=O)N2CC(CC2)C=2C=CC=CC=2)CC1 KKRCWEICXMGION-UHFFFAOYSA-N 0.000 claims 1
- JFROAVJMZJAZNP-UHFFFAOYSA-N [1-(4-chlorophenyl)cyclopropyl]-(3-propan-2-ylpyrrolidin-1-yl)methanone Chemical compound C1C(C(C)C)CCN1C(=O)C1(C=2C=CC(Cl)=CC=2)CC1 JFROAVJMZJAZNP-UHFFFAOYSA-N 0.000 claims 1
- LMGXNFIJMLHZMK-UHFFFAOYSA-N [1-(4-chlorophenyl)cyclopropyl]-(3-pyridin-3-ylpyrrolidin-1-yl)methanone Chemical compound C1=CC(Cl)=CC=C1C1(C(=O)N2CC(CC2)C=2C=NC=CC=2)CC1 LMGXNFIJMLHZMK-UHFFFAOYSA-N 0.000 claims 1
- YSQSWUBIMQRVHG-UHFFFAOYSA-N [1-(4-chlorophenyl)cyclopropyl]-(3-pyridin-4-ylpyrrolidin-1-yl)methanone Chemical compound C1=CC(Cl)=CC=C1C1(C(=O)N2CC(CC2)C=2C=CN=CC=2)CC1 YSQSWUBIMQRVHG-UHFFFAOYSA-N 0.000 claims 1
- MFDPOIHZMVFABE-UHFFFAOYSA-N [1-(4-chlorophenyl)cyclopropyl]-(4,4-dimethyl-1-oxa-7-azaspiro[4.4]nonan-7-yl)methanone Chemical compound CC1(C)CCOC11CN(C(=O)C2(CC2)C=2C=CC(Cl)=CC=2)CC1 MFDPOIHZMVFABE-UHFFFAOYSA-N 0.000 claims 1
- LSTDKGYDDZVWLV-UHFFFAOYSA-N [1-(4-chlorophenyl)cyclopropyl]-(4-phenoxypiperidin-1-yl)methanone Chemical compound C1=CC(Cl)=CC=C1C1(C(=O)N2CCC(CC2)OC=2C=CC=CC=2)CC1 LSTDKGYDDZVWLV-UHFFFAOYSA-N 0.000 claims 1
- FFAPXILDELBXIF-UHFFFAOYSA-N [1-(4-chlorophenyl)cyclopropyl]-(4-phenylpiperidin-1-yl)methanone Chemical compound C1=CC(Cl)=CC=C1C1(C(=O)N2CCC(CC2)C=2C=CC=CC=2)CC1 FFAPXILDELBXIF-UHFFFAOYSA-N 0.000 claims 1
- NJPYIKONDPLHJZ-UHFFFAOYSA-N [1-(4-chlorophenyl)cyclopropyl]-(4-piperidin-1-ylpiperidin-1-yl)methanone Chemical compound C1=CC(Cl)=CC=C1C1(C(=O)N2CCC(CC2)N2CCCCC2)CC1 NJPYIKONDPLHJZ-UHFFFAOYSA-N 0.000 claims 1
- MXHXQJQEBCAXGE-UHFFFAOYSA-N [1-(4-chlorophenyl)cyclopropyl]-(4-pyridin-4-ylpiperidin-1-yl)methanone Chemical compound C1=CC(Cl)=CC=C1C1(C(=O)N2CCC(CC2)C=2C=CN=CC=2)CC1 MXHXQJQEBCAXGE-UHFFFAOYSA-N 0.000 claims 1
- XMQXIXRQALWNKT-UHFFFAOYSA-N [1-(4-chlorophenyl)cyclopropyl]-(5,7-dihydro-4h-thieno[2,3-c]pyridin-6-yl)methanone Chemical compound C1=CC(Cl)=CC=C1C1(C(=O)N2CC=3SC=CC=3CC2)CC1 XMQXIXRQALWNKT-UHFFFAOYSA-N 0.000 claims 1
- XDFHZQQJQXTXJH-UHFFFAOYSA-N [1-(4-chlorophenyl)cyclopropyl]-[2-(2-hydroxyethyl)piperidin-1-yl]methanone Chemical compound OCCC1CCCCN1C(=O)C1(C=2C=CC(Cl)=CC=2)CC1 XDFHZQQJQXTXJH-UHFFFAOYSA-N 0.000 claims 1
- UDAGDVKQBKNWAY-UHFFFAOYSA-N [1-(4-chlorophenyl)cyclopropyl]-[2-(hydroxymethyl)-4-phenylpyrrolidin-1-yl]methanone Chemical compound OCC1CC(C=2C=CC=CC=2)CN1C(=O)C1(C=2C=CC(Cl)=CC=2)CC1 UDAGDVKQBKNWAY-UHFFFAOYSA-N 0.000 claims 1
- CFCMBFAEYNRYMJ-UHFFFAOYSA-N [1-(4-chlorophenyl)cyclopropyl]-[3-(1-oxidopyridin-1-ium-4-yl)pyrrolidin-1-yl]methanone Chemical compound C1=C[N+]([O-])=CC=C1C1CN(C(=O)C2(CC2)C=2C=CC(Cl)=CC=2)CC1 CFCMBFAEYNRYMJ-UHFFFAOYSA-N 0.000 claims 1
- SLYMYTOHAQEAEM-UHFFFAOYSA-N [1-(4-chlorophenyl)cyclopropyl]-[3-(2-methylphenyl)pyrrolidin-1-yl]methanone Chemical compound CC1=CC=CC=C1C1CN(C(=O)C2(CC2)C=2C=CC(Cl)=CC=2)CC1 SLYMYTOHAQEAEM-UHFFFAOYSA-N 0.000 claims 1
- ZKSMCQHTGDYBOH-UHFFFAOYSA-N [1-(4-chlorophenyl)cyclopropyl]-[3-(3-chloropyridin-4-yl)-3-hydroxypyrrolidin-1-yl]methanone Chemical compound C1C(O)(C=2C(=CN=CC=2)Cl)CCN1C(=O)C1(C=2C=CC(Cl)=CC=2)CC1 ZKSMCQHTGDYBOH-UHFFFAOYSA-N 0.000 claims 1
- WATAGOMKMSEAIP-UHFFFAOYSA-N [1-(4-chlorophenyl)cyclopropyl]-[3-(3-fluoropyridin-4-yl)-3-hydroxypyrrolidin-1-yl]methanone Chemical compound C1C(O)(C=2C(=CN=CC=2)F)CCN1C(=O)C1(C=2C=CC(Cl)=CC=2)CC1 WATAGOMKMSEAIP-UHFFFAOYSA-N 0.000 claims 1
- KWJGOXWUURQAFC-UHFFFAOYSA-N [1-(4-chlorophenyl)cyclopropyl]-[3-(4-phenoxyphenyl)pyrrolidin-1-yl]methanone Chemical compound C1=CC(Cl)=CC=C1C1(C(=O)N2CC(CC2)C=2C=CC(OC=3C=CC=CC=3)=CC=2)CC1 KWJGOXWUURQAFC-UHFFFAOYSA-N 0.000 claims 1
- XTKXPLBAVFVRPS-UHFFFAOYSA-N [1-(4-chlorophenyl)cyclopropyl]-[3-(hydroxymethyl)-4-(2-hydroxyphenyl)pyrrolidin-1-yl]methanone Chemical compound OCC1CN(C(=O)C2(CC2)C=2C=CC(Cl)=CC=2)CC1C1=CC=CC=C1O XTKXPLBAVFVRPS-UHFFFAOYSA-N 0.000 claims 1
- YCVGIQQFGOBODN-UHFFFAOYSA-N [1-(4-chlorophenyl)cyclopropyl]-[3-hydroxy-3-(1,3-thiazol-2-yl)pyrrolidin-1-yl]methanone Chemical compound C1C(O)(C=2SC=CN=2)CCN1C(=O)C1(C=2C=CC(Cl)=CC=2)CC1 YCVGIQQFGOBODN-UHFFFAOYSA-N 0.000 claims 1
- NYNUTWALNBSOGE-UHFFFAOYSA-N [1-(4-chlorophenyl)cyclopropyl]-[4-(2-hydroxyethyl)piperidin-1-yl]methanone Chemical compound C1CC(CCO)CCN1C(=O)C1(C=2C=CC(Cl)=CC=2)CC1 NYNUTWALNBSOGE-UHFFFAOYSA-N 0.000 claims 1
- KNUHSPKCXJJENR-UHFFFAOYSA-N [1-(4-chlorophenyl)cyclopropyl]-[4-(4-chlorophenyl)-3,6-dihydro-2h-pyridin-1-yl]methanone Chemical compound C1=CC(Cl)=CC=C1C1=CCN(C(=O)C2(CC2)C=2C=CC(Cl)=CC=2)CC1 KNUHSPKCXJJENR-UHFFFAOYSA-N 0.000 claims 1
- YRHMNJYYUWBRRW-UHFFFAOYSA-N [1-(4-chlorophenyl)cyclopropyl]-[4-(4-fluorophenyl)piperidin-1-yl]methanone Chemical compound C1=CC(F)=CC=C1C1CCN(C(=O)C2(CC2)C=2C=CC(Cl)=CC=2)CC1 YRHMNJYYUWBRRW-UHFFFAOYSA-N 0.000 claims 1
- CFQBPTKGBSAHDD-UHFFFAOYSA-N [1-(4-chlorophenyl)cyclopropyl]-[4-(4-phenyl-1,3-thiazol-2-yl)piperidin-1-yl]methanone Chemical compound C1=CC(Cl)=CC=C1C1(C(=O)N2CCC(CC2)C=2SC=C(N=2)C=2C=CC=CC=2)CC1 CFQBPTKGBSAHDD-UHFFFAOYSA-N 0.000 claims 1
- QVMKCWFWUWVRHJ-UHFFFAOYSA-N [1-(4-chlorophenyl)cyclopropyl]-spiro[2,3-dihydro-1h-isoquinoline-4,4'-piperidine]-1'-ylmethanone Chemical compound C1=CC(Cl)=CC=C1C1(C(=O)N2CCC3(CC2)C2=CC=CC=C2CNC3)CC1 QVMKCWFWUWVRHJ-UHFFFAOYSA-N 0.000 claims 1
- CRLLLMMFQXXYCH-UHFFFAOYSA-N [1-(4-chlorophenyl)cyclopropyl]-spiro[chromene-2,4'-piperidine]-1'-ylmethanone Chemical compound C1=CC(Cl)=CC=C1C1(C(=O)N2CCC3(CC2)C=CC2=CC=CC=C2O3)CC1 CRLLLMMFQXXYCH-UHFFFAOYSA-N 0.000 claims 1
- VMVLRZURHQQPQP-UHFFFAOYSA-N [1-(4-cyclopentyloxyphenyl)cyclopropyl]-(3-pyridin-4-ylpyrrolidin-1-yl)methanone Chemical compound C1CC1(C=1C=CC(OC2CCCC2)=CC=1)C(=O)N(C1)CCC1C1=CC=NC=C1 VMVLRZURHQQPQP-UHFFFAOYSA-N 0.000 claims 1
- LECHVSQMKWEPGI-UHFFFAOYSA-N [1-(4-methylphenyl)cyclopropyl]-(3-pyridin-4-ylpyrrolidin-1-yl)methanone Chemical compound C1=CC(C)=CC=C1C1(C(=O)N2CC(CC2)C=2C=CN=CC=2)CC1 LECHVSQMKWEPGI-UHFFFAOYSA-N 0.000 claims 1
- KIMKODMKQGHDHC-UHFFFAOYSA-N [1-[4-(pyridin-2-ylmethoxy)phenyl]cyclopropyl]-(3-pyridin-4-ylpyrrolidin-1-yl)methanone Chemical compound C1CC1(C=1C=CC(OCC=2N=CC=CC=2)=CC=1)C(=O)N(C1)CCC1C1=CC=NC=C1 KIMKODMKQGHDHC-UHFFFAOYSA-N 0.000 claims 1
- JQBYRDCEWJFCFA-UHFFFAOYSA-N [1-[4-(pyridin-3-ylmethoxy)phenyl]cyclopropyl]-(3-pyridin-4-ylpyrrolidin-1-yl)methanone Chemical compound C1CC1(C=1C=CC(OCC=2C=NC=CC=2)=CC=1)C(=O)N(C1)CCC1C1=CC=NC=C1 JQBYRDCEWJFCFA-UHFFFAOYSA-N 0.000 claims 1
- ZUSWDTWYONAOPH-UHFFFAOYSA-N [2-(trifluoromethyl)phenyl]hydrazine;hydrochloride Chemical group [Cl-].[NH3+]NC1=CC=CC=C1C(F)(F)F ZUSWDTWYONAOPH-UHFFFAOYSA-N 0.000 claims 1
- AMNPXXIGUOKIPP-UHFFFAOYSA-N [4-(carbamothioylamino)phenyl]thiourea Chemical compound NC(=S)NC1=CC=C(NC(N)=S)C=C1 AMNPXXIGUOKIPP-UHFFFAOYSA-N 0.000 claims 1
- WARCRYXKINZHGQ-UHFFFAOYSA-N benzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1 WARCRYXKINZHGQ-UHFFFAOYSA-N 0.000 claims 1
- 125000000319 biphenyl-4-yl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 1
- 150000007942 carboxylates Chemical class 0.000 claims 1
- OTLZRQNOIZBCCX-UHFFFAOYSA-N cyclopropyl-[4-[5-[1-(3-phenylpyrrolidine-1-carbonyl)cyclopropyl]pyridin-2-yl]piperazin-1-yl]methanone Chemical compound C1CN(C=2N=CC(=CC=2)C2(CC2)C(=O)N2CC(CC2)C=2C=CC=CC=2)CCN1C(=O)C1CC1 OTLZRQNOIZBCCX-UHFFFAOYSA-N 0.000 claims 1
- VCAGEYKQQVTPQX-UHFFFAOYSA-N cyclopropyl-[4-[5-[1-(3-pyridin-3-ylpyrrolidine-1-carbonyl)cyclopropyl]pyridin-2-yl]piperazin-1-yl]methanone Chemical compound C1CN(C=2N=CC(=CC=2)C2(CC2)C(=O)N2CC(CC2)C=2C=NC=CC=2)CCN1C(=O)C1CC1 VCAGEYKQQVTPQX-UHFFFAOYSA-N 0.000 claims 1
- VEQYWXLWNWYKSB-UHFFFAOYSA-N ethyl 4-[3-fluoro-4-[1-(3-oxospiro[2-benzofuran-1,3'-pyrrolidine]-1'-carbonyl)cyclopropyl]phenyl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OCC)CCN1C1=CC=C(C2(CC2)C(=O)N2CC3(CC2)C2=CC=CC=C2C(=O)O3)C(F)=C1 VEQYWXLWNWYKSB-UHFFFAOYSA-N 0.000 claims 1
- MGAUCSYMENBPAP-UHFFFAOYSA-N ethyl 4-[4-[1-(3-phenylpyrrolidine-1-carbonyl)cyclopropyl]phenyl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OCC)CCN1C1=CC=C(C2(CC2)C(=O)N2CC(CC2)C=2C=CC=CC=2)C=C1 MGAUCSYMENBPAP-UHFFFAOYSA-N 0.000 claims 1
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical compound CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 claims 1
- RGNGRDXOUNVQKN-UHFFFAOYSA-N methyl 4-[4-[1-(3-phenylpyrrolidine-1-carbonyl)cyclopropyl]phenyl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OC)CCN1C1=CC=C(C2(CC2)C(=O)N2CC(CC2)C=2C=CC=CC=2)C=C1 RGNGRDXOUNVQKN-UHFFFAOYSA-N 0.000 claims 1
- LLCGHOKMOSRPKL-UHFFFAOYSA-N methyl 4-[4-[1-(3-tert-butyl-3-hydroxypyrrolidine-1-carbonyl)cyclopropyl]-3-fluorophenyl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OC)CCN1C1=CC=C(C2(CC2)C(=O)N2CC(O)(CC2)C(C)(C)C)C(F)=C1 LLCGHOKMOSRPKL-UHFFFAOYSA-N 0.000 claims 1
- 235000001968 nicotinic acid Nutrition 0.000 claims 1
- 239000011664 nicotinic acid Substances 0.000 claims 1
- 229960003512 nicotinic acid Drugs 0.000 claims 1
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 claims 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 1
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 claims 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 claims 1
- JLGPKMQLXRZYOK-UHFFFAOYSA-N tert-butyl 4-[5-[1-(3-pyridin-3-ylpyrrolidine-1-carbonyl)cyclopropyl]pyridin-2-yl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCN1C1=CC=C(C2(CC2)C(=O)N2CC(CC2)C=2C=NC=CC=2)C=N1 JLGPKMQLXRZYOK-UHFFFAOYSA-N 0.000 claims 1
- JUMOTSOHGXQRAO-UHFFFAOYSA-N tert-butyl 9-[1-(4-chlorophenyl)cyclopropanecarbonyl]-2,9-diazaspiro[4.5]decane-2-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCC21CN(C(=O)C1(CC1)C=1C=CC(Cl)=CC=1)CCC2 JUMOTSOHGXQRAO-UHFFFAOYSA-N 0.000 claims 1
- DLFVBJFMPXGRIB-UHFFFAOYSA-N thioacetamide Natural products CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 1
- 239000003862 glucocorticoid Substances 0.000 description 53
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 46
- 108090000375 Mineralocorticoid Receptors Proteins 0.000 description 23
- 102100021316 Mineralocorticoid receptor Human genes 0.000 description 23
- 229960000890 hydrocortisone Drugs 0.000 description 23
- 229940037128 systemic glucocorticoids Drugs 0.000 description 17
- 210000001519 tissue Anatomy 0.000 description 16
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 14
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 12
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 12
- 229960004544 cortisone Drugs 0.000 description 12
- 230000005764 inhibitory process Effects 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 11
- 102000004190 Enzymes Human genes 0.000 description 9
- 108090000790 Enzymes Proteins 0.000 description 9
- 241000282414 Homo sapiens Species 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 8
- 210000000577 adipose tissue Anatomy 0.000 description 7
- 239000000470 constituent Substances 0.000 description 7
- 239000003112 inhibitor Substances 0.000 description 7
- 101800000414 Corticotropin Proteins 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
- 230000009286 beneficial effect Effects 0.000 description 6
- OBZHEBDUNPOCJG-SZTGPWMUSA-N carbenoxolone Chemical compound C([C@H]1C2=CC(=O)[C@@H]34)[C@](C)(C(O)=O)CC[C@@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@H]1[C@@]3(C)CC[C@@H](OC(=O)CCC(O)=O)C1(C)C OBZHEBDUNPOCJG-SZTGPWMUSA-N 0.000 description 6
- 229960000530 carbenoxolone Drugs 0.000 description 6
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 6
- 229960000258 corticotropin Drugs 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 239000008103 glucose Substances 0.000 description 6
- 230000002440 hepatic effect Effects 0.000 description 6
- 230000004179 hypothalamic–pituitary–adrenal axis Effects 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical group N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 230000004410 intraocular pressure Effects 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- 239000000275 Adrenocorticotropic Hormone Substances 0.000 description 5
- 208000014311 Cushing syndrome Diseases 0.000 description 5
- 102000003676 Glucocorticoid Receptors Human genes 0.000 description 5
- 108090000079 Glucocorticoid Receptors Proteins 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 239000005557 antagonist Substances 0.000 description 5
- 210000000988 bone and bone Anatomy 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 230000002950 deficient Effects 0.000 description 5
- 125000005842 heteroatom Chemical group 0.000 description 5
- 239000003446 ligand Substances 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 201000009395 primary hyperaldosteronism Diseases 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- OMFXVFTZEKFJBZ-UHFFFAOYSA-N Corticosterone Natural products O=C1CCC2(C)C3C(O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 OMFXVFTZEKFJBZ-UHFFFAOYSA-N 0.000 description 4
- 108700043439 Cortisone reductase deficiency Proteins 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 230000027455 binding Effects 0.000 description 4
- 230000036772 blood pressure Effects 0.000 description 4
- OMFXVFTZEKFJBZ-HJTSIMOOSA-N corticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OMFXVFTZEKFJBZ-HJTSIMOOSA-N 0.000 description 4
- 201000004076 cortisone reductase deficiency Diseases 0.000 description 4
- 230000002939 deleterious effect Effects 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 125000002950 monocyclic group Chemical group 0.000 description 4
- 210000000963 osteoblast Anatomy 0.000 description 4
- 230000007170 pathology Effects 0.000 description 4
- 125000003367 polycyclic group Chemical group 0.000 description 4
- 201000010065 polycystic ovary syndrome Diseases 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 125000001424 substituent group Chemical group 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 238000011830 transgenic mouse model Methods 0.000 description 4
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 3
- 208000004611 Abdominal Obesity Diseases 0.000 description 3
- 102000004881 Angiotensinogen Human genes 0.000 description 3
- 108090001067 Angiotensinogen Proteins 0.000 description 3
- 102000012289 Corticotropin-Releasing Hormone Human genes 0.000 description 3
- 108010022152 Corticotropin-Releasing Hormone Proteins 0.000 description 3
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 3
- 101710088194 Dehydrogenase Proteins 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- 241000699660 Mus musculus Species 0.000 description 3
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 3
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 3
- 241000283984 Rodentia Species 0.000 description 3
- 102000010913 Type 1 Angiotensin Receptor Human genes 0.000 description 3
- 108010062481 Type 1 Angiotensin Receptor Proteins 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 239000003098 androgen Substances 0.000 description 3
- 230000008485 antagonism Effects 0.000 description 3
- 230000002238 attenuated effect Effects 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 229940041967 corticotropin-releasing hormone Drugs 0.000 description 3
- KLVRDXBAMSPYKH-RKYZNNDCSA-N corticotropin-releasing hormone (human) Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(N)=O)[C@@H](C)CC)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H]1N(CCC1)C(=O)[C@H]1N(CCC1)C(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CO)[C@@H](C)CC)C(C)C)C(C)C)C1=CNC=N1 KLVRDXBAMSPYKH-RKYZNNDCSA-N 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 230000003914 insulin secretion Effects 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 210000002997 osteoclast Anatomy 0.000 description 3
- 230000001817 pituitary effect Effects 0.000 description 3
- 125000006239 protecting group Chemical group 0.000 description 3
- 239000000376 reactant Substances 0.000 description 3
- 230000007420 reactivation Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 210000002027 skeletal muscle Anatomy 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 2
- DNISEZBAYYIQFB-PHDIDXHHSA-N (2r,3r)-2,3-diacetyloxybutanedioic acid Chemical compound CC(=O)O[C@@H](C(O)=O)[C@H](C(O)=O)OC(C)=O DNISEZBAYYIQFB-PHDIDXHHSA-N 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 2
- 108090000874 11-beta-hydroxysteroid dehydrogenases Proteins 0.000 description 2
- 102000004277 11-beta-hydroxysteroid dehydrogenases Human genes 0.000 description 2
- FUFLCEKSBBHCMO-KJQYFISQSA-N 11-dehydrocorticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 FUFLCEKSBBHCMO-KJQYFISQSA-N 0.000 description 2
- UZYQSNQJLWTICD-UHFFFAOYSA-N 2-(n-benzoylanilino)-2,2-dinitroacetic acid Chemical compound C=1C=CC=CC=1N(C(C(=O)O)([N+]([O-])=O)[N+]([O-])=O)C(=O)C1=CC=CC=C1 UZYQSNQJLWTICD-UHFFFAOYSA-N 0.000 description 2
- KMGUEILFFWDGFV-UHFFFAOYSA-N 2-benzoyl-2-benzoyloxy-3-hydroxybutanedioic acid Chemical compound C=1C=CC=CC=1C(=O)C(C(C(O)=O)O)(C(O)=O)OC(=O)C1=CC=CC=C1 KMGUEILFFWDGFV-UHFFFAOYSA-N 0.000 description 2
- 102100031126 6-phosphogluconolactonase Human genes 0.000 description 2
- 108010029731 6-phosphogluconolactonase Proteins 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000020084 Bone disease Diseases 0.000 description 2
- 206010065941 Central obesity Diseases 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 206010020112 Hirsutism Diseases 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 102000016267 Leptin Human genes 0.000 description 2
- 108010092277 Leptin Proteins 0.000 description 2
- 208000037093 Menstruation Disturbances Diseases 0.000 description 2
- 206010027339 Menstruation irregular Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 210000004404 adrenal cortex Anatomy 0.000 description 2
- 230000001919 adrenal effect Effects 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 125000005605 benzo group Chemical group 0.000 description 2
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 2
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical class C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 2
- 150000001721 carbon Chemical group 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 150000001735 carboxylic acids Chemical class 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000003920 cognitive function Effects 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000012156 elution solvent Substances 0.000 description 2
- 238000010575 fractional recrystallization Methods 0.000 description 2
- 108010002929 galactose-6-phosphate dehydrogenase Proteins 0.000 description 2
- 230000001890 gluconeogenic effect Effects 0.000 description 2
- 235000009200 high fat diet Nutrition 0.000 description 2
- 230000000971 hippocampal effect Effects 0.000 description 2
- 230000013632 homeostatic process Effects 0.000 description 2
- 201000010066 hyperandrogenism Diseases 0.000 description 2
- 210000003016 hypothalamus Anatomy 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 102000027411 intracellular receptors Human genes 0.000 description 2
- 108091008582 intracellular receptors Proteins 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 2
- 229940039781 leptin Drugs 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 210000005228 liver tissue Anatomy 0.000 description 2
- 239000001630 malic acid Substances 0.000 description 2
- 235000011090 malic acid Nutrition 0.000 description 2
- 229960002510 mandelic acid Drugs 0.000 description 2
- 231100000544 menstrual irregularity Toxicity 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 210000000885 nephron Anatomy 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000036454 renin-angiotensin system Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 210000003079 salivary gland Anatomy 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 230000000707 stereoselective effect Effects 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 238000011269 treatment regimen Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- FMCGSUUBYTWNDP-ONGXEEELSA-N (1R,2S)-2-(dimethylamino)-1-phenyl-1-propanol Chemical compound CN(C)[C@@H](C)[C@H](O)C1=CC=CC=C1 FMCGSUUBYTWNDP-ONGXEEELSA-N 0.000 description 1
- AOFUBOWZWQFQJU-SNOJBQEQSA-N (2r,3s,4s,5r)-2,5-bis(hydroxymethyl)oxolane-2,3,4-triol;(2s,3r,4s,5s,6r)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O.OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O AOFUBOWZWQFQJU-SNOJBQEQSA-N 0.000 description 1
- SYGWGHVTLUBCEM-UHFFFAOYSA-N (3alpha,5alpha,17alphaOH)-3,17,21-Trihydroxypregnane-11,20-dione Natural products C1C(O)CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC21 SYGWGHVTLUBCEM-UHFFFAOYSA-N 0.000 description 1
- CUKWUWBLQQDQAC-VEQWQPCFSA-N (3s)-3-amino-4-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s,3s)-1-[[(2s)-1-[(2s)-2-[[(1s)-1-carboxyethyl]carbamoyl]pyrrolidin-1-yl]-3-(1h-imidazol-5-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-methyl-1-ox Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 CUKWUWBLQQDQAC-VEQWQPCFSA-N 0.000 description 1
- 125000004514 1,2,4-thiadiazolyl group Chemical group 0.000 description 1
- PAAZPARNPHGIKF-UHFFFAOYSA-N 1,2-dibromoethane Chemical compound BrCCBr PAAZPARNPHGIKF-UHFFFAOYSA-N 0.000 description 1
- FTNJQNQLEGKTGD-UHFFFAOYSA-N 1,3-benzodioxole Chemical compound C1=CC=C2OCOC2=C1 FTNJQNQLEGKTGD-UHFFFAOYSA-N 0.000 description 1
- VEFLKXRACNJHOV-UHFFFAOYSA-N 1,3-dibromopropane Chemical compound BrCCCBr VEFLKXRACNJHOV-UHFFFAOYSA-N 0.000 description 1
- ULTHEAFYOOPTTB-UHFFFAOYSA-N 1,4-dibromobutane Chemical compound BrCCCCBr ULTHEAFYOOPTTB-UHFFFAOYSA-N 0.000 description 1
- RQEUFEKYXDPUSK-UHFFFAOYSA-N 1-phenylethylamine Chemical compound CC(N)C1=CC=CC=C1 RQEUFEKYXDPUSK-UHFFFAOYSA-N 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- GVYVHZKTSVDMNT-UHFFFAOYSA-N 2,3-dihydro-1,2-benzothiazole 1,1-dioxide Chemical compound C1=CC=C2S(=O)(=O)NCC2=C1 GVYVHZKTSVDMNT-UHFFFAOYSA-N 0.000 description 1
- IJXJGQCXFSSHNL-UHFFFAOYSA-N 2-amino-2-phenylethanol Chemical compound OCC(N)C1=CC=CC=C1 IJXJGQCXFSSHNL-UHFFFAOYSA-N 0.000 description 1
- WNZQDUSMALZDQF-UHFFFAOYSA-N 2-benzofuran-1(3H)-one Chemical compound C1=CC=C2C(=O)OCC2=C1 WNZQDUSMALZDQF-UHFFFAOYSA-N 0.000 description 1
- CZMRCDWAGMRECN-UHFFFAOYSA-N 2-{[3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound OCC1OC(CO)(OC2OC(CO)C(O)C(O)C2O)C(O)C1O CZMRCDWAGMRECN-UHFFFAOYSA-N 0.000 description 1
- 208000026872 Addison Disease Diseases 0.000 description 1
- 102000005862 Angiotensin II Human genes 0.000 description 1
- 101800000733 Angiotensin-2 Proteins 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 101000928755 Bos taurus 11-beta-hydroxysteroid dehydrogenase 1 Proteins 0.000 description 1
- 208000016998 Conn syndrome Diseases 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 206010048554 Endothelial dysfunction Diseases 0.000 description 1
- 102000003837 Epithelial Sodium Channels Human genes 0.000 description 1
- 108090000140 Epithelial Sodium Channels Proteins 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 208000019025 Hypokalemia Diseases 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000031773 Insulin resistance syndrome Diseases 0.000 description 1
- 108010044467 Isoenzymes Proteins 0.000 description 1
- 108010006519 Molecular Chaperones Proteins 0.000 description 1
- 102000005431 Molecular Chaperones Human genes 0.000 description 1
- FMCGSUUBYTWNDP-UHFFFAOYSA-N N-Methylephedrine Natural products CN(C)C(C)C(O)C1=CC=CC=C1 FMCGSUUBYTWNDP-UHFFFAOYSA-N 0.000 description 1
- 125000004633 N-oxo-pyridyl group Chemical group 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- 102000007399 Nuclear hormone receptor Human genes 0.000 description 1
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical class CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 108090000472 Phosphoenolpyruvate carboxykinase (ATP) Proteins 0.000 description 1
- 102100034792 Phosphoenolpyruvate carboxykinase [GTP], mitochondrial Human genes 0.000 description 1
- 208000010067 Pituitary ACTH Hypersecretion Diseases 0.000 description 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 1
- 208000020627 Pituitary-dependent Cushing syndrome Diseases 0.000 description 1
- 102100027467 Pro-opiomelanocortin Human genes 0.000 description 1
- 206010037211 Psychomotor hyperactivity Diseases 0.000 description 1
- 208000035977 Rare disease Diseases 0.000 description 1
- 102100028255 Renin Human genes 0.000 description 1
- 108090000783 Renin Proteins 0.000 description 1
- 108091027981 Response element Proteins 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- 101150082971 Sgk1 gene Proteins 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 206010041277 Sodium retention Diseases 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- SYGWGHVTLUBCEM-ZIZPXRJBSA-N Urocortisone Chemical compound C1[C@H](O)CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CC[C@@H]21 SYGWGHVTLUBCEM-ZIZPXRJBSA-N 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 208000013521 Visual disease Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 208000024447 adrenal gland neoplasm Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 description 1
- 229940126317 angiotensin II receptor antagonist Drugs 0.000 description 1
- 229950006323 angiotensin ii Drugs 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 208000005838 apparent mineralocorticoid excess syndrome Diseases 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- BNBQRQQYDMDJAH-UHFFFAOYSA-N benzodioxan Chemical compound C1=CC=C2OCCOC2=C1 BNBQRQQYDMDJAH-UHFFFAOYSA-N 0.000 description 1
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 230000003293 cardioprotective effect Effects 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 150000001886 cortisols Chemical class 0.000 description 1
- 150000001887 cortisones Chemical class 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000002188 cycloheptatrienyl group Chemical group C1(=CC=CC=CC1)* 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000003678 cyclohexadienyl group Chemical group C1(=CC=CCC1)* 0.000 description 1
- SSJXIUAHEKJCMH-UHFFFAOYSA-N cyclohexane-1,2-diamine Chemical compound NC1CCCCC1N SSJXIUAHEKJCMH-UHFFFAOYSA-N 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000006356 dehydrogenation reaction Methods 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- DLNKOYKMWOXYQA-UHFFFAOYSA-N dl-pseudophenylpropanolamine Natural products CC(N)C(O)C1=CC=CC=C1 DLNKOYKMWOXYQA-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000008694 endothelial dysfunction Effects 0.000 description 1
- 229960002179 ephedrine Drugs 0.000 description 1
- 229960001208 eplerenone Drugs 0.000 description 1
- JUKPWJGBANNWMW-VWBFHTRKSA-N eplerenone Chemical compound C([C@@H]1[C@]2(C)C[C@H]3O[C@]33[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)C(=O)OC)C[C@@]21CCC(=O)O1 JUKPWJGBANNWMW-VWBFHTRKSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 230000002461 excitatory amino acid Effects 0.000 description 1
- 239000003257 excitatory amino acid Substances 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 210000005153 frontal cortex Anatomy 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000003345 hyperglycaemic effect Effects 0.000 description 1
- 239000005555 hypertensive agent Substances 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 210000001596 intra-abdominal fat Anatomy 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000004628 isothiazolidinyl group Chemical group S1N(CCC1)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000003965 isoxazolidinyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000006371 metabolic abnormality Effects 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 208000027061 mild cognitive impairment Diseases 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000002395 mineralocorticoid Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- AGVKXDPPPSLISR-UHFFFAOYSA-N n-ethylcyclohexanamine Chemical compound CCNC1CCCCC1 AGVKXDPPPSLISR-UHFFFAOYSA-N 0.000 description 1
- 229940073569 n-methylephedrine Drugs 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003506 n-propoxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 125000005893 naphthalimidyl group Chemical group 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000000955 neuroendocrine Effects 0.000 description 1
- 230000003955 neuronal function Effects 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- 230000024121 nodulation Effects 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 description 1
- 125000005482 norpinyl group Chemical group 0.000 description 1
- 238000013116 obese mouse model Methods 0.000 description 1
- 210000002747 omentum Anatomy 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000004203 pancreatic function Effects 0.000 description 1
- 210000002963 paraventricular hypothalamic nucleus Anatomy 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- YWAKXRMUMFPDSH-UHFFFAOYSA-N pentene Chemical compound CCCC=C YWAKXRMUMFPDSH-UHFFFAOYSA-N 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 125000001792 phenanthrenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3C=CC12)* 0.000 description 1
- DLNKOYKMWOXYQA-APPZFPTMSA-N phenylpropanolamine Chemical compound C[C@@H](N)[C@H](O)C1=CC=CC=C1 DLNKOYKMWOXYQA-APPZFPTMSA-N 0.000 description 1
- 229960000395 phenylpropanolamine Drugs 0.000 description 1
- SFLGSKRGOWRGBR-UHFFFAOYSA-N phthalane Chemical compound C1=CC=C2COCC2=C1 SFLGSKRGOWRGBR-UHFFFAOYSA-N 0.000 description 1
- 125000005545 phthalimidyl group Chemical group 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 210000001127 pigmented epithelial cell Anatomy 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
- 208000024896 potassium deficiency disease Diseases 0.000 description 1
- 208000013846 primary aldosteronism Diseases 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 229960002256 spironolactone Drugs 0.000 description 1
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 201000005428 steroid-induced glaucoma Diseases 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 210000002820 sympathetic nervous system Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000005958 tetrahydrothienyl group Chemical group 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 210000001585 trabecular meshwork Anatomy 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000012301 transgenic model Methods 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- ZBZJXHCVGLJWFG-UHFFFAOYSA-N trichloromethyl(.) Chemical compound Cl[C](Cl)Cl ZBZJXHCVGLJWFG-UHFFFAOYSA-N 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 230000007497 verbal memory Effects 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 208000029257 vision disease Diseases 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 230000001755 vocal effect Effects 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Description
AMIDO COMPOUNDS AND
THEIR USE AS PHARMACEUTICALS
The present invention relates to modulators of 11-B hydroxyl steroid dehydrogenase type 1 (11BHSDI1) and/or mineralocorticoid receptor (MR), compositions thereof and methods of using the same.
Glucocorticoids are steroid hormones that regulate fat metabolism, function and distribution.
In vertebrates, glucocorticoids also have profound and diverse physiological effects on development, neurobiology, inflammation, blood pressure, metabolism and programmed cell death. In humans, the primary endogenously-produced glucocorticoid is cortisol. Cortisol is synthesized in the zona fasciculate of the adrenal cortex under the control of a short-term neuroendocrine feedback circuit called the hypothalamic-pituitary-adrenal (HPA) axis. Adrenal production of cortisol proceeds under the control of adrenocorticotrophic hormone (ACTH), a factor produced and secreted by the anterior pituitary. Production of ACTH in the anterior pituitary is itself highly regulated, driven by corticotropin releasing hormone (CRH) produced by the paraventricular nucleus of the hypothalamus.
The HPA axis maintains circulating cortisol concentrations within restricted limits, with forward drive at the diurnal maximum or during periods of stress, and is rapidly attenuated by a negative feedback loop resulting from the ability of cortisol to suppress ACTH production in the anterior pituitary and
CRH production in the hypothalamus.
Aldosterone is another hormone produced by the adrenal cortex; aldosterone regulates sodium and potassium homeostasis. Fifty years ago, a role for aldosterone excess in human disease was reported in a description of the syndrome of primary aldosteronism (Conn, (1955), J. Lab. Clin. Med. 45: 6-17). It is now clear that elevated levels of aldosterone are associated with deleterious effects on the heart and kidneys, and are a major contributing factor to morbidity and mortality in both heart failure and hypertension.
Two members of the nuclear hormone receptor superfamily, glucocorticoid receptor (GR) and mineralocorticoid receptor (MR), mediate cortisol function in vivo, while the primary intracellular receptor for aldosterone is the MR. These receptors are also referred to as ‘ligand-dependent transcription factors,” because their functionality is dependent on the receptor being bound to its ligand (for example, cortisol); upon ligand-binding these receptors directly modulate transcription via
DNA-binding zinc finger domains and transcriptional activation domains.
Historically, the major determinants of glucocorticoid action were attributed to three primary factors: 1) circulating levels of glucocorticoid (driven primarily by the HPA axis), 2) protein binding of glucocorticoids in circulation, and 3) intracellular receptor density inside target tissues. Recently, a fourth determinant of glucocorticoid function was identified: tissue-specific pre-receptor metabolism by glucocorticoid-activating and -inactivating enzymes. These 11-beta-hydroxysteroid dehydrogenase (11-B-HSD) enzymes act as pre-receptor control enzymes that modulate activation of the GR and MR by regulation of glucocorticoid hormones. To date, two distinct isozymes of 11-beta-HSD have been cloned and characterized: 11BHSD1 (also known as 11-beta-HSD type 1, 11betaHSD1, HSD11Bl1,
HDL, and HSDI11L) and 11BHSD2. 11BHSD! and 11BHSD2 catalyze the interconversion of hormonally active cortisol (corticosterone in rodents) and inactive cortisone (11- dehydrocorticosterone in rodents). 11BHSD1 is widely distributed in rat and human tissues; expression of the enzyme and corresponding mRNA have been detected in lung, testis, and most abundantly in liver and adipose tissue. 11BHSD1 catalyzes both 11-beta-dehydrogenation and the reverse 11-oxoreduction reaction, although 11BHSDI acts predominantly as a NADPH-dependent oxoreductase in intact cells and tissues, catalyzing the activation of cortiso! from inert cortisone (Low et al. (1994) J. Mol. Endocrin. 13: 167-174) and has been reported to regulate glucocorticoid access to the GR. Conversely, 113HSD2 expression is found mainly in mineralocorticoid target tissues such as kidney, placenta, colon and salivary gland, acts as an NAD-dependent dehydrogenase catalyzing the inactivation of cortisol to cortisone (Albiston et al. (1994) Mol. Cell. Endocrin. 105: R11-R17), and has been found to protect the MR from glucocorticoid excess, such as high levels of receptor-active cortisol (Blum, et al., (2003) Prog. Nucl. Acid Res. Mol. Biol. 75:173-216).
In vitro, the MR binds cortisol and aldosterone with equal affinity. The tissue specificity of aldosterone activity, however, is conferred by the expression of 11pHSD2 (Funder et al. (1988),
Science 242: 583-585). The inactivation of cortisol to cortisone by 11FHSD2 at the site of the MR enables aldosterone to bind to this receptor in vivo. The binding of aldosterone to the MR results in dissociation of the ligand-activated MR from a multiprotein complex containing chaperone proteins, translocation of the MR into the nucleus, and its binding to hormone response elements in regulatory regions of target gene promoters. Within the distal nephron of the kidney, induction of serum and glucocorticoid inducible kinase-1 (sgk-1) expression leads to the absorption of Na’ ions and water through the epithelial sodium channel, as well as potassium excretion with subsequent volume expansion and hypertension (Bhargava et al., (2001), Endo 142: 1587-1594).
In humans, elevated aldosterone concentrations are associated with endothelial dysfunction, myocardial infarction, left ventricular atrophy, and death. In attempts to modulate these ill effects, multiple intervention strategies have been adopted to control aldosterone overactivity and attenuate the resultant hypertension and its associated cardiovascular consequences. Inhibition of angiotensin- converting enzyme (ACE) and blockade of the angiotensin type 1 receptor (ATIR) are two strategies that directly impact the rennin-angiotensin-aldosterone system (RAAS). However, although ACE inhibition and ATIR antagonism initially reduce aldosterone concentrations, circulating 5S concentrations of this hormone return to baseline levels with chronic therapy (known as ‘aldosterone escape’). Importantly, co-administration of the MR antagonist Spironolactone or Eplerenone directly blocks the deleterious effects of this escape mechanism and dramatically reduces patient mortality (Pitt et al., New England J. Med. (1999), 341: 709-719; Pitt et al., New England J. Med. (2003), 348: 1309-1321). Therefore, MR antagonism may be an important treatment strategy for many patients with hypertension and cardiovascular disease, particularly those hypertensive patients at risk for target-organ damage.
Mutations in either of the genes encoding the 11-beta-HSD enzymes are associated with human pathology. For example, 11BHSD2 is expressed in aldosterone-sensitive tissues such as the distal nephron, salivary gland, and colonic mucosa where its cortisol dehydrogenase activity serves to protect the intrinsically non-selective MR from illicit occupation by cortisol (Edwards et al. (1988)
Lancet 2: 986-989). Individuals with mutations in | 1PHSD2 are deficient in this cortisol-inactivation activity and, as a result, present with a syndrome of apparent mineralocorticoid excess (also referred to as ‘SAME’) characterized by hypertension, hypokalemia, and sodium retention (Wilson et al. (1998) Proc. Natl. Acad. Sci. 95: 10200-10205). Likewise, mutations in 11BHSDI, a primary regulator of tissue-specific glucocorticoid bioavailability, and in the gene encoding a co-localized
NADPH-generating enzyme, hexose 6-phosphate dehydrogenase (H6PD), can result in cortisone reductase deficiency (CRD), in which activation of cortisone to cortisol does not occur, resulting in adrenocorticotropin-mediated androgen excess. CRD patients excrete virtually all glucocorticoids as cortisone metabolites (tetrahydrocortisone) with low or absent cortisol metabolites (tetrahydrocortisols). When challenged with oral cortisone, CRD patients exhibit abnormally low plasma cortisol concentrations. These individuals present with ACTH-mediated androgen excess (hirsutism, menstrual irregularity, hyperandrogenism), a phenotype resembling polycystic ovary syndrome (PCOS) (Draper et al. (2003) Nat. Genet. 34: 434-439).
The importance of the HPA axis in controlling glucocorticoid excursions is evident from the fact that disruption of homeostasis in the HPA axis by either excess or deficient secretion or action results in Cushing’s syndrome or Addison’s disease, respectively (Miller and Chrousos (2001)
Endocrinology and Metabolism, eds. Felig and Frohman (McGraw-Hill, New York), 4% Ed.: 387- 524). Patients with Cushing’s syndrome (a rare disease characterized by systemic glucocorticoid excess originating from the adrenal or pituitary tumors) or receiving glucocorticoid therapy develop reversible visceral fat obesity. Interestingly, the phenotype of Cushing’s syndrome patients closely resembles that of Reaven’s metabolic syndrome (also known as Syndrome X or insulin resistance syndrome) the symptoms of which include visceral obesity, glucose intolerance, insulin resistance, hypertension, type 2 diabetes and hyperlipidemia (Reaven (1993) Ann. Rev. Med. 44: 121-131).
However, the role of glucocorticoids in prevalent forms of human obesity has remained obscure because circulating glucocorticoid concentrations are not elevated in the majority of metabolic syndrome patients. In fact, glucocorticoid action on target tissue depends not only on circulating levels but also on intracellular concentration, locally enhanced action of glucocorticoids in adipose tissue and skeletal muscle has been demonstrated in metabolic syndrome. Evidence has accumulated that enzyme activity of 11BHSD1, which regenerates active glucocorticoids from inactive forms and plays a central role in regulating intracellular glucocorticoid concentration, is commonly elevated in fat depots from obese individuals. This suggests a role for local glucocorticoid reactivation in obesity and metabolic syndrome.
Given the ability of 11BHSDI to regenerate cortisol from inert circulating cortisone, considerable attention has been given to its role in the amplification of glucocorticoid function. 11BHSDI is expressed in many key GR-rich tissues, including tissues of considerable metabolic importance such as liver, adipose, and skeletal muscle, and, as such, has been postulated to aid in the tissue-specific potentiation of glucocorticoid-mediated antagonism of insulin function. Considering a) the phenotypic similarity between glucocorticoid excess (Cushing’s syndrome) and the metabolic syndrome with normal circulating glucocorticoids in the latter, as well as b) the ability of 11BHSD1 to _ generate active cortisol from inactive cortisone in a tissue-specific manner, it has been suggested that central obesity and the associated metabolic complications in syndrome X result from increased activity of 11BHSDI1 within adipose tissue, resulting in ‘Cushing’s disease of the omentum’ (Bujalska et al. (1997) Lancet 349: 1210-1213). Indeed, 11BHSDI1 has been shown to be upregulated in adipose tissue of obese rodents and humans (Livingstone et al. (2000) Endocrinology 131: 560-563; Rask et al. (2001) J. Clin. Endocrinol. Metab. 86: 1418-1421; Lindsay et al. (2003) J. Clin. Endocrinol. 75 Metab. 88: 2738-2744; Wake et al. (2003) J. Clin. Endocrinol. Metab. 88: 3983-3988).
Additional support for this notion has come from studies in mouse transgenic models.
Adipose-specific overexpression of 118HSDI under the control of the aP2 promoter in mouse produces a phenotype remarkably reminiscent of human metabolic syndrome (Masuzaki et al. (2001)
Science 294: 2166-2170; Masuzaki et al. (2003) J. Clinical Invest. 112: 83-90). Importantly, this phenotype occurs without an increase in total circulating corticosterone, but rather is driven by a local production of corticosterone within the adipose depots. The increased activity of 11BHSD1 in these mice (2-3 fold) is very similar to that observed in human obesity (Rask et al. (2001) I. Clin.
Endocrinol. Metab. 86: 1418-1421). This suggests that local 11BHSDI-mediated conversion of inert glucocorticoid to active glucocorticoid can have profound influences whole body insulin sensitivity.
Based on this data, it would be predicted that the loss of 11BHSD1 would lead to an increase in insulin sensitivity and glucose tolerance due to a tissue-specific deficiency in active glucocorticoid levels. This is, in fact, the case as shown in studies with 11BHSD1-deficient mice produced by homologous recombination (Kotelevstev et al. (1997) Proc. Natl. Acad. Sci. 94: 14924-14929; Morton et al. (2001) J. Biol. Chem. 276: 41293-41300; Morton et al. (2004) Diabetes 53: 931-938). These mice are completely devoid of 11-keto reductase activity, confirming that 11HSD1 encodes the only activity capable of generating active corticosterone from inert 11-dehydrocorticosterone. 11pHSDI1- deficient mice are resistant to diet- and stress-induced hyperglycemia, exhibit attenuated induction of hepatic gluconeogenic enzymes (PEPCK, G6P), show increased insulin sensitivity within adipose, : and have an improved lipid profile (decreased triglycerides and increased cardio-protective HDL).
Additionally, these animals show resistance to high fat diet-induced obesity. Taken together, these transgenic mouse studies confirm a role for local reactivation of glucocorticoids in controlling hepatic and peripheral insulin sensitivity, and suggest that inhibition of 11BHSD1 activity may prove beneficial in treating a number of glucocorticoid-related disorders, including obesity, insulin resistance, hyperglycemia, and hyperlipidemia.
Data in support of this hypothesis has been published. Recently, it was reported that - 15 118HSD! plays a role in the pathogenesis of central obesity and the appearance of the metabolic syndrome in humans. Increased expression of the 11BHSD! gene is associated with metabolic abnormalities in obese women and that increased expression of this gene is suspected to contribute to the increased local conversion of cortisone to cortisol in adipose tissue of obese individuals (Engeli, et al., (2004) Obes. Res. 12: 9-17).
A new class of 11BHSDI inhibitors, the arylsulfonamidothiazoles, was shown to improve hepatic insulin sensitivity and reduce blood glucose levels in hyperglycemic strains of mice (Barf et al. (2002) J. Med. Chem. 45: 3813-3815; Alberts et al Endocrinology (2003) 144: 4755-4762).
Furthermore, it was recently reported that selective inhibitors of 11BHSDI1 can ameliorate severe hyperglycemia in genetically diabetic obese mice. Thus, 11BHSDI is a promising pharmaceutical target for the treatment of the Metabolic Syndrome (Masuzaki, et al., (2003) Curr. Drug Targets
Immune Endocr. Metabol. Disord. 3: 255-62).
A. Obesity and metabolic syndrome
As described above, multiple lines of evidence suggest that inhibition of 11BHSD1 activity can be effective in combating obesity and/or aspects of the metabolic syndrome cluster, including glucose intolerance, insulin resistance, hyperglycemia, hypertension, and/or hyperlipidemia.
Glucocorticoids are known antagonists of insulin action, and reductions in local glucocorticoid levels by inhibition of intracellular cortisone to cortisol conversion should increase hepatic and/or peripheral insulin sensitivity and potentially reduce visceral adiposity. As described above, 1 1BHSD1 knockout mice are resistant to hyperglycemia, exhibit attenuated induction of key hepatic gluconeogenic enzymes, show markedly increased insulin sensitivity within adipose, and have an improved lipid profile. Additionally, these animals show resistance to high fat diet-induced obesity (Kotelevstev et al. (1997) Proc. Natl. Acad. Sci. 94: 14924-14929; Morton et al. (2001) J. Biol. Chem. 276: 41293- 41300; Morton et al. (2004) Diabetes 53: 931-938). Thus, inhibition of 11pHSDI is predicted to have multiple beneficial effects in the liver, adipose, and/or skeletal muscle, particularly related to § alleviation of component(s) of the metabolic syndrome and/or obesity.
B. Pancreatic function
Glucocorticoids are known to inhibit the glucose-stimulated secretion of insulin from pancreatic beta-cells (Billaudel and Sutter (1979) Horm. Metab. Res. | 1: 555-560). In both Cushing’s syndrome and diabetic Zucker fa/fa rats, glucose-stimulated insulin secretion is markedly reduced (Ogawa et al. (1992) J. Clin. Invest. 90: 497-504). 11BHSD! mRNA and activity has been reported in the pancreatic islet cells of ob/ob mice and inhibition of this activity with carbenoxolone, an 11BHSDI inhibitor, improves glucose-stimulated insulin release (Davani et al. (2000) J. Biol. Chem. 275: 34841-34844). Thus, inhibition of 11BHSD1 is predicted to have beneficial effects on the pancreas, including the enhancement of glucose-stimulated insulin release.
C. Cognition and dementia
Mild cognitive impairment is a common feature of aging that may be ultimately related to the progression of dementia. In both aged animals and humans, inter-individual differences in general cognitive function have been linked to variability in the long-term exposure to glucocorticoids (Lupien et al. (1998) Nat. Neurosci. 1: 69-73). Further, dysregulation of the HPA axis resulting in chronic exposure to glucocorticoid excess in certain brain subregions has been proposed to contribute to the decline of cognitive function (McEwen and Sapolsky (1995) Curr. Opin. Neurobiol. 5: 205- 216). 11BHSD1 is abundant in the brain, and is expressed in multiple subregions including the hippocampus, frontal cortex, and cerebellum (Sandeep et al. (2004) Proc. Natl. Acad. Sci. Early
Edition: 1-6). Treatment of primary hippocampal cells with the 11BHSDI inhibitor carbenoxolone protects the cells from glucocorticoid-mediated exacerbation of excitatory amino acid neurotoxicity (Rajan et al. (1996) J. Neurosci. 16: 65-70). Additionally, 11BHSDI-deficient mice are protected from glucocorticoid-associated hippocampal dysfunction that is associated with aging (Yau et al. (2001) Proc. Natl. Acad. Sci. 98: 4716-4721). In two randomized, double-blind, placebo-controlled crossover studies, administration of carbenoxolone improved verbal fluency and verbal memory (Sandeep et al. (2004) Proc. Natl. Acad. Sci. Early Edition: 1-6). Thus, inhibition of 11pHSDI is predicted to reduce exposure to glucocorticoids in the brain and protect against deleterious glucocorticoid effects on neuronal function, including cognitive impairment, dementia, and/or depression.
D. Intra-ocular pressure
Glucocorticoids can be used topically and systemically for a wide range of conditions in clinical ophthalmology. One particular complication with these treatment regimens is corticosteroid- induced glaucoma. This pathology is characterized by a significant increase in intra-ocular pressure (IOP). In its most advanced and untreated form, IOP can lead to partial visual field loss and eventually blindness. IOP is produced by the relationship between aqueous humour production and drainage. Aqueous humour production occurs in the non-pigmented epithelial cells (NPE) and its drainage is through the cells of the trabecular meshwork. 1 1BHSD1 has been localized to NPE cells (Stokes et al. (2000) Invest. Ophthalmol. Vis. Sci. 41: 1629-1683; Rauz et al. (2001) Invest.
Ophthalmol. Vis. Sei. 42: 2037-2042) and its function is likely relevant to the amplification of glucocorticoid activity within these cells. This notion has been confirmed by the observation that free cortisol concentration greatly exceeds that of cortisone in the aqueous humour (14:1 ratio). The functional significance of 11BHSDI in the eye has been evaluated using the inhibitor carbenoxolone in healthy volunteers (Rauz et al. (2001) Invest. Ophthalmol. Vis. Sci. 42: 2037-2042). After seven days of carbenoxolone treatment, 10P was reduced by 18%. Thus, inhibition of 11BHSDI in the eye is predicted to reduce local glucocorticoid concentrations and IOP, producing beneficial effects in the management of glaucoma and other visual disorders.
E. Hypertension
Adipocyte-derived hypertensive substances such as leptin and angiotensinogen have been proposed to be involved in the pathogenesis of obesity-related hypertension (Matsuzawa et al. (1999)
Ann. N.Y. Acad. Sci. 892: 146-154; Wajchenberg (2000) Endocr. Rev. 21: 697-738). Leptin, which is secreted in excess in aP2-11BHSD]1 transgenic mice (Masuzaki et al. (2003) J. Clinical Invest. 112: 83-90), can activate various sympathetic nervous system pathways, including those that regulate blood pressure (Matsuzawa et al. (1999) Ann. N.Y. Acad. Sci. 892: 146-154). Additionally, the renin- angiotensin system (RAS) has been shown to be a major determinant of blood pressure (Walker et al. (1979) Hypertension 1: 287-291). Angiotensinogen, which is produced in liver and adipose tissue, is the key substrate for renin and drives RAS activation. Plasma angiotensinogen levels are markedly elevated in aP2-11BHSDI transgenic mice, as are angiotensin II and aldosterone (Masuzaki et al. (2003) J. Clinical Invest. 112: 83-90). These forces likely drive the elevated blood pressure observed in aP2-11BHSDI transgenic mice. Treatment of these mice with low doses of an angiotensin II receptor antagonist abolishes this hypertension (Masuzaki et al. (2003) J. Clinical Invest. 112: 83-90).
This data illustrates the importance of local glucocorticoid reactivation in adipose tissue and liver, and suggests that hypertension may be caused or exacerbated by 11BHSDI activity. Thus, inhibition of 11BHSDI and reduction in adipose and/or hepatic glucocorticoid levels is predicted to have beneficial effects on hypertension and hypertension-related cardiovascular disorders.
F. Bone disease
Glucocorticoids can have adverse effects on skeletal tissues. Continued exposure to even moderate glucocorticoid doses can result in osteoporosis (Cannalis (1996) J. Clin. Endocrinol. Metab. 81: 3441-3447) and increased risk for fractures. Experiments in vitro confirm the deleterious effects of glucocorticoids on both bone-resorbing cells (also known as osteoclasts) and bone forming cells (osteoblasts). 11BHSDI has been shown to be present in cultures of human primary osteoblasts as well as cells from adult bone, likely a mixture of osteoclasts and osteoblasts (Cooper et al. (2000)
Bone 27: 375-381), and the 11BHSDI inhibitor carbenoxolone has been shown to attenuate the negative effects of glucocorticoids on bone nodule formation (Bellows et al. (1998) Bone 23: 119- 125). Thus, inhibition of 11pHSDI1 is predicted to decrease the local glucocorticoid concentration within osteoblasts and osteoclasts, producing beneficial effects in various forms of bone disease, including osteoporosis.
Small molecule inhibitors of 11BHSDI1 are currently being developed to treat or prevent 11BHSDI1-related diseases such as those described above. For example, certain amide-based inhibitors are reported in WO 2004/089470, WO 2004/089896, WO 2004/056745, and WO 2004/065351.
Antagonists of 11BHSD1 have been evaluated in human clinical trials (Kurukulasuriya , et al., (2003) Curr. Med. Chem. 10: 123-53).
In light of the experimental data indicating a role for 11pHSDI1 in glucocorticoid-related disorders, metabolic syndrome, hypertension, obesity, insulin resistance, hyperglycemia, hyperlipidemia, type 2 diabetes, androgen excess (hirsutism, menstrual irregularity, hyperandrogenism) and polycystic ovary syndrome (PCOS), therapeutic agents aimed at augmentation or suppression of these metabolic pathways, by modulating glucocorticoid signal transduction at the level of 11BHSD]1 are desirable.
Furthermore, because the MR binds to aldosterone (its natural ligand) and cortisol with equal affinities, compounds that are designed to interact with the active site of 11BHSD1 (which binds to cortisone/cortisol) may also interact with the MR and act as antagonists. Because the MR is implicated in heart failure, hypertension, and related pathologies including atherosclerosis, arteriosclerosis, coronary artery disease, thrombosis, angina, peripheral vascular disease, vascular wall damage, and stroke, MR antagonists are desirable and may also be useful in treating complex cardiovascular, renal, and inflammatory pathologies including disorders of lipid metabolism including dyslipidemia or hyperlipoproteinaemia, diabetic dyslipidemia, mixed dyslipidemia, hypercholesterolemia, hypertriglyceridemia, as well as those associated with type 1 diabetes, type 2 diabetes, obesity, metabolic syndrome, and insulin resistance, and general aldosterone-related target- organ damage.
As evidenced herein, there is a continuing need for new and improved drugs that target 11BHSD1 and/or MR. The compounds, compositions and methods described herein help meet this and other needs.
The present invention provides, inter alia, compounds of Formulas I 11, III, IV, Va, Vb, VI,
VII, and VIII: 3 v |) L] rR" RZ R R' R2 > (W'-X'-Y'-Z') \ "
Cy “Rr Cy 0] 0
I 11 1 2
R R (xray R! R? G'
N_~ r N 2
Cy Cy G 0 6) 111 |AY
Q2 ALY LU
EE Ql (W-X"-Y -2")s wr [CGE
N (W"'-X"-Y"-2"),
Cy q 0
Va (W-X-Y'-Z)y =e XC
X NS Ww LX “Y"-Z");
R’ R2 [ Q? (W'-X"-Y"-Z")¢
N
Cy q 0]
Vb 1—-Q2 WwW xX" Y" z" xr Qt 9 WXYZ)
Qt
R! R? [ 4 V3
N U4 c A mm NN WXYZ, y q 0]
Vi rR! R? A'~q2
N (XYZ
PN ZN gt (W-X"-Y"-Z"),
VII
R! R? Q'~q2
N
0 A vir or pharmaceutically acceptable salts or prodrugs thereof, wherein constituent members are defined herein,
The present invention further provides compositions comprising compounds of the invention and a pharmaceutically acceptable carrier.
The present invention further provides methods of modulating 1 1BHSD1 or MR by contacting the 118HSD1 or MR with a compound of the invention.
The present invention further provides methods of treating diseases assocated with activity or expression of 11BHSD1 or MR.
The present invention further perovids use of the compounds and compositions herein in therapy.
The present invention further provides use of the compounds and compositions here for the preparation of a medicament for use in therapy. - DETAILED DESCRIPTION
The present invention provides, inter alia, compounds of Formula I:
R! R2 Re oN Re o or pharmaceutically acceptable salts or prodrugs thereof, wherein:
Cy is aryl, heteroaryl, cycloalkyl or heterocycloalkyl, each optionally substituted by 1,2, 3, 4 or5 -W-X-Y-Z;
R' and R? together with the C atom to which they are attached form a 3-, 4-, 5-, 6- or 7- membered cycloalkyl group or a 3-, 4-, 5-, 6- or 7-membered heterocycloalky! group, each optionally substituted by 1,2 0r3 R%
R? and R? together with the N atom to which they are attached form a 4-15 membered heterocycloalkyl group optionally substituted by 1, 2, 3, or 4 -W'-X"-Y’-Z’;
R’ is halo, C4 alkyl, Cos alkenyl, Cos alkynyl, C,.4 haloalkyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, CN, NO, OR, SR?, C(O)R", C(O)NR°RY, C(O)OR’, OC(O)R", OC(O)NRR’,
NR°RY, NR°C(O)R’, NR°C(O)OR’, S(O)R®, S(O)NR°RY, S(O)R", or S(O),NRR,
W, W’ and W’ are each, independently, absent, C5 alkylenyl, C,¢alkenylenyl, Cas alkynylenyl, O, S, NR’, CO, CS, COO, CONR’, OCONR’, SO, SO, SONR®, or NR°CONR', wherein said C14 alkylenyl, C6 alkenylenyl, Cas alkynylenyl are each optionally substituted by 1, 2 or 3 halo,
OH, C4 alkoxy, C4 haloalkoxy, amino, C4 alkylamino or Cy dialkylamino;
X, X* and X’* are each, independently, absent, C,salkylenyl, Cg alkenylenyl, Cas alkynylenyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, cycloalkylalkyl, heteroarylalkyl, heterocycloalkylalkyl, arylalkenyl, cycloalkylalkenyl, heteroarylalkenyl, heterocycloalkylalkenyl, arylalkynyl, cycloalkylalkynyl, heteroarylalkynyl, heterocycloalkylalkynyl, each of which is optionally substituted by one or more halo, CN, NO,, OH, C,.salkoxy, C).4 haloalkoxy, amino, C4 alkylamino or Cp dialkylamino;
Y, Y’ and Y”’ are each, independently, absent, Ci.¢ alkylenyl, Cys alkenylenyl, Ca alkynylenyl, O, S, NR*, CO, CS, COO, CONR®, OCONR®, SO, SO, SONR®, or NRECONR, wherein said C,¢alkylenyl, C,¢alkenylenyl, Cys alkynylenyl are each optionally substituted by 1,2 or 3 halo,
OH, C,.4 alkoxy, Ci.4 haloalkoxy, amino, C4 alkylamino or C,.¢ dialkylamino;
Z, Z’ and Z"’ are each, independently, H, halo, CN, NO,, OH, C,.4 alkoxy, C,., haloalkoxy, amino, C4 alkylamino or C,.s dialkylamino, C,. alkyl, Cy alkenyl, Cy alkynyl, aryl, cycloalkyl, heteroaryl or heterocycloalkyl, wherein said Cy. alkyl, Cs. alkenyl, Cy. alkynyl, aryl, cycloalkyl, heteroaryl or heterocycloalky! is optionally substituted by 1, 2 or 3 halo, Cy.¢ alkyl, Cz.¢ alkenyl, Cy alkynyl, C,., haloalkyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, CN, NO,, OR’, SR? C(O)R",
C(O)NRR', C(O)OR?, OC(O)R®, OC(O)NRR?, NR°R’, NR°C(O)RY, NR°C(O)OR?, S(O)R”,
S(O)NR°RY, S(O);R®, or S(O);NR°R’; wherein two —W-X-Y-Z attached to the same atom optionally form a 3-20 membered cycloalkyl or heterocycloalkyl group optionally substituted by 1,2 or 3 “WXYZ wherein two —W’-X’-Y’-Z’ attached to the same atom optionally form a 3-20 membered cycloalkyl or heterocycloalkyl group optionally substituted by 1,2 or 3 WXYZ wherein —=W-X-Y-Z is other than H; wherein —W’-X’-Y’-Z’ is other than H;
wherein —=W”’-X’’-Y**-Z’" is other than H;
R? is H, Cy. alkyl, C,.¢ haloalkyl, Cy alkenyl, (C1. alkoxy)-Ci.c alkyl, Cos alkynyl, aryl, cycloalkyl, heteroaryl or heterocycloalkyl;
R® is H, C1. alkyl, C,.¢ haloalkyl, Ca. alkenyl, Cy. alkynyl, aryl, cycloalkyl, heteroaryl or heterocycloalkyl;
RC and RY are each, independently, H, Cis alkyl, C, haloalkyl, Ca.6 alkenyl, Cy alkynyl, aryl, cycloalkyl, arylalkyl, or cycloalkylalkyl; or RC and R® together with the N atom to which they are attached form a 4-,5-,6-or7- membered heterocycloalkyl group; and
RE and Rf are each, independently, H, Cis alkyl, Cis haloalkyl, C..¢ alkenyl, Ca.¢ alkynyl, aryl, cycloalkyl, arylalkyl, or cycloalkylalkyl; or R® and Rf together with the N atom to which they are attached form a 4-, 5-, 6- or 7- membered heterocycloalkyl group.
In some embodiments, when R® and R* together with the N-atom to which they are attached form piperidinyl, the piperidinyl is unsubstituted or substituted by other than: 0 v—
Ne $ >
RTC
F wherein:
V is CH,CH,, CH=CH, or CHO; and
R is H, halo or Cs alkyl.
In some embodiments, when R? and R* together with the N-atom to which they are attached form piperazinyl, the Cy is substituted by at least one -W-X-Y-Z.
In some embodiments, Cy is aryl or heteroaryl, each optionally substituted by 1,2,3,40r5 —
W-X-Y-Z.
In some embodiments, Cy is aryl optionally substituted by 1, 2, 3, 4 or 5 -W-X-Y-Z.
In some embodiments, Cy is aryl optionally substituted by 1, 2 or 3 halo, Cy.4 alkyl, C4 alkoxy, C;.4 haloalkyl, or C, 4 haloalkoxy.
In some embodiments, Cy is phenyl optionally substituted by 1, 2 or 3 halo, Ciaalkyl, Cia alkoxy, Cys haloalkyl, or C4 haloalkoxy.
In some embodiments, R' and R? together with the C atom to which they are attached form a 3-,4-, 5-, 6- or 7-membered cycloalkyl group.
In some embodiments, R' and R? together with the C atom to which they are attached forma cyclopropyl group.
In some embodiments, R® and R* together with the N atom to which they are attached form a 4-7 membered heterocycloalkyl group optionally substituted by 1, 2,3, 0r 4 WXYZ.
In some embodiments, R® and R* together with the N atom to which they are attached form a piperidiny] or pyrrolidinyl group, each optionally substituted by 1,2, 3, or 4 -W-X-Y-2’.
In some embodiments, R® and R* together with the N atom to which they are attached form a piperidinyl or pyrrolidiny! group, each substituted by 2,3, or 4 _W’-X'-Y'-Z’; wherein two —W’-X’- v’-Z’ are attached to the same atom and optionally form a 3-20 membered cycloalkyl or heterocycloalkyl group optionally substituted by 1,2 or 3 -W*-X""-Y’-Z".
In some embodiments, —W-X-Y-Z is halo, cyano, C,.4 cyanoalkyl, nitro, Cy.galkyl, Cas alkenyl, Cy.g haloalkyl, Ci. alkylthio, C.4 haloalkylthio, C,.s alkoxy, Cz.s alkenyloxy, Ci. haloalkoxy,
OH, (C,4alkoxy)-C;.4alkyl, amino, C.4alkylamino, Cys dialkylamino, OC(O)NR°R®, NRC(O)RY,
NR‘C(O)OR’, NR°S(O),R®, C(O)OR®, C(O)R*, C(O)NR®NR'R’, S(O)R’, SR, C(O)NRRY,
C(S)NR°R!, aryloxy, heteroaryloxy, cycloalkyloxy, cycloalkenyloxy, heterocycloalkyloxy, arylalkyloxy, heteroarylalkyloxy, cycloalkylalkyloxy, heterocycloalkylalkyloxy, heteroaryloxyalkyl, aryloxyalkyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, arylalkenyl, arylalkynyl, heteroarylalkyl, heteroarylalkenyl , heteroarylalkynyl, cycloalkylalkyl, or heterocycloalkylalkyl; wherein each of said Cz alkyl, Cys alkenyl, C5 haloalkyl, C4 alkylthio, Ci haloalkylthio,
C,.s alkoxy, aryloxy, heteroaryloxy, arylalkyloxy, heteroarylalkyloxy, heteroaryloxyalkyl, aryloxy, heteroaryloxy, cycloalkyloxy, cycloalkenyloxy, heterocycloalkyloxy, arylalkyloxy, heteroarylalkyloxy, cycloalkylalkyloxy, heteracycloalkylalkyloxy, heteroaryloxyalkyl, aryloxyalkyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, arylalkenyl, arylalkynyl, heteroarylalkyl, heteroarylalkenyl , heteroarylalkynyl, cycloalkylalkyl, or heterocycloalkylalkyl is optionally substituted by 1, 2, or 3 halo, cyano, nitro, hydroxyl-(C,.¢ alkyl), aminoalkyl, dialkylaminoalkyl, Ci alkyl, Cj.s haloalkyl, C4 cyanoalkyl, Cis alkoxy, Ci.4 haloalkoxy, OH, OR?, (C4 alkoxy)-C;4 alkyl, amino, C4 alkylamino, C,5 dialkylamino, C(O)NR°R?, C(O)OR?, C(O)R’, (cyclocalkylalkyl)-C(O)-,
NR°C(O)R?, NR°C(O)OR’, NR°S(O),R’, C(S)NRR?, S(0).R’, SR’, (C14 alkyl)sulfonyl, arylsulfonyl, aryl optionally substituted by halo, heteroaryl, cycloalkylalkyl, cycloalkyl, or heterocycloalkyl.
In some embodiments, ~-W-X-Y-Z is halo, cyano, Cy. cyanoalkyl, nitro, Cis alkyl, Cis alkenyl, C,.5 haloalkyl, C,.jo alkoxy, C,4haloalkoxy, OH, Cs alkoxyalkyl, amino, C4 alkylamino, C,. dialkylamino, OC(O)NR°R’, NR°C(O)R?, NR°C(O)OR’, aryloxy, heteroaryloxy, arylalkyloxy, heteroarylalkyloxy, heteroaryloxyalkyl, aryloxyalkyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, arylalkenyl, arylalkynyl, heteroarylalkyl, heteroarylalkenyl , heteroarylalkynyl, cycloalkylalkyl, or heterocycloalkylalkyl; wherein each of said Cs alkyl, Cy.salkenyl, Cs haloalkyl, C,.3 alkoxy, aryloxy, heteroaryloxy, arylalkyloxy, heteroarylalkyloxy, heteroaryloxyalkyl, aryloxyalkyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, arylalkenyl, arylalkynyl, heteroarylalkyl, heteroarylalkenyl , heteroarylalkynyl, cycloalkylalkyl, or heterocycloalkylalky! is optionally substituted by 1, 2, or 3 halo, cyano, nitro, hydroxyl{Ci.¢ alkyl), aminoalkyl, dialkylaminoalkyl, Ci.4 alkyl, Cis haloalkyl, Ci. alkoxy, Ci haloalkoxy, OH, Ci.s alkoxyalkyl, amino, C,4alkylamino, C,.3 dialkylamino, C(O)NR'R’,
C(O)OR® , NR°C(O)R?, NR°S(O)RY, (C\.salkyl)sulfonyl, arylsulfonyl, aryl, heteroaryl, cycloalkyl, or heterocycloalkyl. 12. The compound of claim 1 wherein —-W-X-Y-Z is halo, cyano, Cis cyanoalkyl, nitro,
C4nitroalky), Ci4alkyl, Ci4 haloalkyl, C\.4alkoxy, C;.4haloalkoxy, OH, (C,.; alkoxy)-Ci4 alkyl, amino, Cy. alkylamino, Cag dialkylamino, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, or heterocycloalkylalkyl.
In some embodiments, —-W-X-Y-Z is halo, C;.4 alkyl, or C,_4alkoxy.
In some embodiments, -W’-X’-Y’-Z’ is halo, OH, cyano, CHO, COOH, C(0)O~« C4 alkyD),
C(O) C4 alkyl), SO»( Ci alkyl), Cy.s alkyl, Cis alkoxy or -L-R’, wherein said C4 alkyl or Ci4 alkoxy is optionally substituted by one or more halo, OH, COOH or C(0)O-( C4 alkyl);
In some embodiments, ~-W’-X’-Y’-Z’ is halo; Cis alkyl; Cis haloalkyl; OH; C,4 alkoxy; Ci.4 haloalkoxy; hydroxyalkyl; alkoxyalkyl; aryl; heteroaryl, aryl substituted by halo, Cis alkyl, Cia alkoxy, aryl, heteroaryl, or aryloxy; or heteroaryl substituted by halo, C, 4 alkyl, C4 alkoxy, aryl, or © heteroaryl.
In some embodiments, —~W’-X’-Y’-Z’ are attached to the same atom and optionally form a 3- membered cycloalky! or heterocycioalkyl group optionally substituted by 1,2 or 3 “WX Y-
Zz’. . 20 In some embodiments, —-W”-X”-Y”-Z” is halo, cyano, Cy4 cyanoalkyl, nitro, C4 nitroalkyl,
Ci alkyl, C;.4 haloalkyl, C4 alkoxy, Ci. haloalkoxy, OH, (C.4alkoxy)-C,4 alkyl, amino, Cia alkylamino, C, dialkylamino, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, or heterocycloalkylalkyl.
In some embodiments: —W'-X’-Y"-Z’ is halo, OH, cyano, CHO, COOH, C(O)O~( Cy.salkyl), C(O)-( C14 alkyl), SO,- ( CisalkyD), C4 alkyl, C14 alkoxy or —L-R’, wherein said C4 alkyl or C4 alkoxy is optionally substituted by one or more halo, OH, COOH or C(0)O-( Cy.« alkyl);
L is absent, O, CH,, NHSO,, N{C(0)-( Cis alkyD)]; and
R’ is aryl or heteroaryl, each is optionally substituted by 1, 2, or 3 halo, OH, cyano, CHO,
COOH, C(0)O~( C14 alkyl), C(O) Ci.4 alkyl), SO2-( C14 alkyl), SO:-NH( Cy.salky), Ciaalkyl, Cis alkoxy, Cy haoalkyl, Cys hydroxyalkyl, aryl, heteroaryl or aryloxy.
In some embodiments, the compounds of the invention have Formula II:
R!' RZ [x WXYZ,
N <
Cy 0] 11 including pharmaceutically acceptable salts or prodrugs thereof, wherein constituent variables are defined herein above, and gis 0, 1, 2,3 or 4.
In some embodiments, Cy is aryl or heteroaryl, each optionally substituted by 1, 2,3,40r5 —
W-X-Y-Z.
In some embodiments, q is 1,2,3 or 4.
In some embodiments, q is 2, 3 or 4.
In some embodiments, two —W’-X’-Y’-Z’ attached to the same atom form a 3-20 membered cycloalkyl or heterocycloalky! group optionally substituted by 1, 2 or 3 -W*-X"*-Y"’-Z>".
The present invention further provides compounds of Formula III:
R! R? 1's WXN-Z) oN 0) m or pharmaceutically acceptable salts or prodrugs thereof, wherein constituent variables are defined hereinabove; and ris0,1,2,3 0r4.
In some embodiments, when U is CHa, then —W’-X’-Y’-Z’ forms a group other than: 0 v— 3
CY
RT
HF wherein:
V is CH,CH,, CH=CH, or CH,0; and
Ris H, halo or Cs alkyl.
In some embodiments, when U is NH, Cy is substituted by at least one —W-X-Y-Z.
In some embodiments, ris 1,2, 3 or 4.
In some embodiments, ris 2, 3 or 4.
In some embodiments, U is CH,.
In some embodiments, two —W*-X’-Y’-Z’ attached to the same atom form a 3-20 membered cycloalkyl! or heterocycloalky! group optionally substituted by 1,2 or 3 ~W>-X">-Y**-Z"’.
The present invention further provides compounds of Formula IV: (W'-X'-Y'-2)y
R! R? he oN 0) 1\Y or pharmaceutically acceptable salts or prodrugs thereof, wherein constituent variables are defined hereinabove:
G' and G? together with the carbon atom to which they are attached form a 3-20 membered cycloalkyl! or heterocycloalkyl group optional substituted by 1,2 or 3 ~W-X"-Y-Z”,; and vis 0, 1 or 2.
In some embodiments, v is 0.
In some embodiments, v is 1.
In some embodiments, G' and G? together with the carbon atom to which they are attached form a 9-14 membered cycloalkyl or heterocycloalkyl group optional substituted by 1,2 or 3 -W*’-
XYZ, :
In some embodiments, —W”-X”-Y”-Z” is halo, cyano, C,.4 cyanoalkyl, nitro, Cy nitroalkyl,
C14 alkyl, C4 haloalkyl, C,4 alkoxy, C,4haloalkoxy, OH, (C,4alkoxy)-Cy.4 alkyl, amino, C4 alkylamino, C.s dialkylamino, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalky]l, cycloalkylalkyl, or heterocycloalkylalkyl
The present invention further provides compounds of Formula Va or Vb: (WXYZ), Qt=@ (WXYZ)
N (WXYZ), oO
Va (XA Zh rps
RR? i Qt WXYZ) " ih) oN 0
Vb or pharmaceutically acceptable salts or prodrugs thereof, wherein contstituent variables are defined herein above: ring B is a fused 5 or 6-membered aryl or heteroaryl group;
Q' is 0, S, NH, CH,, CO, CS, SO, SO, OCH,, SCH,, NHCH,, CH,CH,, CH=CH, COCH;,
CONH, COO, SOCH,, SONH, SO,CHy, or SO,NH,;
Q?is 0, S$, NH, CH,, CO, CS, SO, SO,, OCH,, SCH,, NHCH,, CH;CH, CH=CH, COCH,,
CONH, COO, SOCH;, SONH, SO;CH, or SO,NH; qisQorl; vis 0,1 or2; ris0,1or2; sis 0, 1 or2; and the sum of rand s is 0, 1 or 2.
In some embodiments, Q' and Q? are selected to form a 1-, 2-, or 3- atom spacer. In further embodiments, Q' and Q” when bonded together form a spacer group having other than an O-O or O-S ring-forming bond.
In some embodiments, Q' is 0, 8, NH, CH; or CO, wherein each of said NH and CH; is optionally substituted by WXYZ".
Tn some embodiments, Q' is O, NH, CH, or CO, wherein each of said NH and CH, is optionally substituted by “Wr X-Y”-Z7,
In some embodiments, Q” is O, S, NH, CH,, CO, or SO, wherein each of said NH and CH; is optionally substituted by ~-W”-X>-Y”-Z".
In some embodiments, one of Q' and Q’ is O and the other is CO or CONH, wherein said
CONH is optionally substituted by —-W"-X"-Y"-Z".
In some embodiments, one of Q' and Q? is CO and the other is O, NH, or CH,, and wherein 95 each of said NH and CH, is optionally substituted by ~-W”-X"-Y”-Z”.
In some embodiments, one of Q' and Q? is CH, and the other is O, S, NH, or CH, and wherein each of said NH and CH, is optionally substituted by ~W"-X"-Y"-Z".
In some embodiments, one of Q' and Q’is CO.
In some embodiments, the compound has Formula Va wherein one of Q' and Q?is CO and the other is O, NH, or CH,, and wherein each of said NH and CH, is optionally substituted by —W”- xX -Y”-Z”,
In some embodiments, the compound has Formula Va wherein one of Q' and Q’is CH, and the other is O, S, NH, or CH,, and wherein each of said NH and CH; is optionally substituted by —W"-
X»-Y”-27,
In some embodiments, the compound has Formula Vb wherein one of Q' and Q* is CO.
In some embodiments, the compound has Formula Va.
In some embodiments, the compound has Formula Vb.
In some embodiments, ring B is phenyl or pyridyl.
In some embodiments, ring B is phenyl.
In some embodiments, r is 0.
In some embodiments, ris 0 or 1.
In some embodiments, s is 0 or 1.
The present invention further provides compounds of F ormula VI:
WXYZ) qQ! 7 (W'-X"-Y"-Z")s
X J
R! R? f Ye
A N = wey zy,
Cy q 0
VI pharmaceutically acceptable salt forms and prodrugs thereof, wherein constituent variables are defined hereinabove, and Q*and Q* are each, independently, CH or N. :
In some embodiments, Q’ is CH optionally substituted by “WXYZ.
In some embodiments, Q’ is N.
In some embodiments, Q* is CH optionally substituted by “W»-X>-Y”-Z27.
In some embodiments, Q* is N.
In some embodiments, Q° is CH and Q* is CH, each optionally substituted by -W2-X7-Y”-2”
In some embodiments, Q’ is CH and Q'is N, wherein said Q’ is optionally substituted by —
W2-X>-Y”-Z7.
In some embodiments, Q is N and Q* is CH optionally substituted by -W7-X"-Y-Z",
In some embodiments, Q' is O, NH, CH, or CO, wherein each of said NH and CH; is optionally substituted by ~-W”-X"-Y"-Z".
In some embodiments, Q is O, S, NH, CHa, CO, or SO, wherein each of said NH and CH, is optionally substituted by —W”-X”-Y”-Z”".
In some embodiments, one of Q' and Q? is CO and the other is O, NH, or CH,, wherein each of said NH and CH, is optionally substituted by —-W”-X"-Y”-Z” .
In some embodiments, one of Q' and Q? is CH, and the other is O, S, NH, or CH,, wherein each of said NH and CH, is optionally substituted by —W”-X"-Y"-Z”.
In some embodiments, one of Q' and Q? is O and the other is CO or CONH, wherein said
CONH is optionally substituted by —W”-X"-Y”-Z".
In some embodiments, risQ or 1.
In some embodiments, sis O or 1.
The present invention further provides compounds of Formula VII:
R! R? Aq
N (WXYZ)
AN ZN ge (W'-X"-Y"-Z");
VII, pharmaceutically acceptable salts and prodrugs thereof, wherein constituent variables are defined hereinabove.
The present invention further provides compounds of having Formula VII:
R! R? Q'~q2
N ahte; : VIII; pharmaceutically acceptable salts and prodrugs thereof, wherein constituent variables are defined hereinabove.
In some embodiments, Q' is O, NH, CH, or CO, wherein each of said NH and CH, is optionally substituted by “WXYZ.
In some embodiments, Q° is O, S, NH, CH,, CO, or SO, wherein each of said NH and CH, is optionally substituted by —W”-X"-Y”-Z".
In some embodiments, one of Q' and Q* is CO and the other is O, NH, or CH,, wherein each of said NH and CH, is optionally substituted by —W”-X*-Y”-Z” .
In some embodiments, one of Q' and Q? is CH; and the other is O, 5, NH, or CH,, wherein each of said NH and CH, is optionally substituted by —W”-X"-Y>-Z"
In some embodiments, one of Q' and Q’ is O and the other is CO or CONH, wherein said
CONH is optionally substituted by —-W”-X"-Y"-Z”.
In some embodiments, Q° is CH optionally substituted by “WXYZ.
In some embodiments, Q* is N.
In some embodiments, Q* is CH optionally substituted by WXYZ.
In some embodiments, Q* is N.
In some embodiments, ris 0 or 1.
In some embodiments, s is 0 or 1.
At various places in the present specification, substituents of compounds of the invention are disclosed in groups or in ranges. Itis specifically intended that the invention include each and every individual subcombination of the members of such groups and ranges. For example, the term “Cre alkyl” is specifically intended to individually disclose methyl, ethyl, Cs alkyl, C4 alkyl, Cs alkyl, and Cealkyl
For compounds of the invention in which a variable appears more than once, each variable can be a different moiety selected from the Markush group defining the variable. For example, where a structure is described having two R groups that are simultaneously present on the same compound; the two R groups can represent different moieties selected from the Markush group defined for R. In another example, when an optionally multiple substituent is designated in the form:
Re o/ then it is understood that substituent R can occur s number of times on the ring, and R can be a different moiety at each occurrence. Further, in the above example, should the variable Q be defined to include hydrogens, such as when Q is said to be CHa, NH, etc., any floating substituent such as R in the above example, can replace a hydrogen of the Q variable as well as a hydrogen in any other non- variable component of the ring.
It is further intended that the compounds of the invention are stable. As used herein “stable” refers to a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and preferably capable of formulation into an efficacious therapeutic agent.
Tt is further appreciated that certain features of the invention, which are, for clarity, described in the context of separate embodiments, can also be provided in combination in a single embodiment.
Conversely, various features of the invention which are, for brevity, described in the context of a single embodiment, can also be provided separately or in any suitable subcombination.
As used herein, the term “alkyl” is meant to refer to a saturated hydrocarbon group which is straight-chained or branched. Example alkyl groups include methyl (Me), ethyl (Et), propyl (e.g., n- propyl and isopropyl), butyl (eg., n-butyl, isobutyl, t-butyl), pentyl (e.g. n-pentyl, isopentyl, neopentyl), and the like. An alkyl group can contain from 1 to about 20, from 2 to about 20, from | to about 10, from 1 to about 8, from | to about 6, from 1 to about 4, or from 1 to about 3 carbon atoms.
The term “alkylenyl” refers to a divalent alkyl linking group.
As used herein, “alkenyl” refers to an alkyl group having one or more double carbon-carbon bonds. Example alkenyl groups include ethenyl, propenyl, cyclohexenyl, and the like. The term “alkenylenyl” refers to a divalent linking alkenyl group. An example C, alkenylenyl is -CH=.
As used herein, “alkynyl” refers to an alkyl group having one or more triple carbon-carbon bonds. Example alkynyl groups include ethynyl, propynyl, and the like. The term “alkynylenyl” refers to a divalent linking alkynyl group.
As used herein, “haloalkyl” refers to an alkyl group having one or more halogen substituents.
Example haloalkyl groups include CFs, C;Fs, CHF, CCl3, CHCl, C,Cls, and the like.
As used herein, “aryl” refers to monocyclic or polycyclic (e.g, having 2, 3 or 4 fused rings) aromatic hydrocarbons such as, for example, phenyl, naphthyl, anthracenyl, phenanthrenyl, indanyl, indenyl, and the like. In some embodiments, aryl groups have from 6 to about 20 carbon atoms.
As used herein, “cycloalkyl” refers to non-aromatic cyclic hydrocarbons including cyclized alkyl, alkenyl, and alkynyl groups. Cycloalky! groups can include mono- or polycyclic (e.g., having 2, 3 or 4 fused rings) ring systems as well as 2-ring, 3-ring, 4-ring spiro system (e.g., having 8 to 20 ring-forming atoms). Example cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclopentenyl, cyclohexenyl, cyclohexadienyl, cycloheptatrienyl, norbornyl, norpinyl, norcarnyl, adamantyl, and the like. Also included in the definition of cycloalkyl are moieties that have one or more aromatic rings fused (i.e., having a bond in common with) to the cycloalkyl ring, for example, benzo, pryido or thieno derivatives of pentane, pentene, hexane, and the like.
Carbon atoms of the cycloalky! group can be optionally oxidized, e. g. bear an oxo or sulfildo group to form CO or CS.
As used herein, “heteroaryl” groups refer to an aromatic heterocycle having at least one heteroatom ring member such as sulfur, oxygen, or nitrogen. Heteroaryl groups include monocyclic and polycyclic (e.g., having 2, 3 or 4 fused rings) systems. Examples of heteroaryl groups include without limitation, pyridyl, N-oxopyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazinyl, furyl, quinolyl, isoquinolyl, thienyl, imidazolyl, thiazolyl, indolyl, pyrryl, oxazolyl, benzofuryl, benzothienyl, benzthiazolyl, isoxazolyl, pyrazolyl, triazolyl, tetrazolyl, indazolyl, 1,2,4-thiadiazolyl, isothiazolyl, benzothienyl, purinyl, carbazolyl, benzimidazolyl, indolinyl, and the like. In some embodiments, the heteroaryl group has from 1 to about 20 carbon atoms, and in further embodiments from about 3 to about 20 carbon atoms. In some embodiments, the heteroaryl group contains 3 to about 14, 3 to about 7, or 5 to 6 ring-forming atoms. In some embodiments, the heteroaryl group has 1 to about 4, 1 to about 3, or 1 to 2 heteroatoms.
As used herein, “heterocycloalkyl” refers to non-aromatic heterocycles including cyclized alkyl, alkenyl, and alkyny! groups where one or more of the ring-forming carbon atoms is replaced by a heteroatom such as an O, N, or S atom. Also included in the definition of heterocycloalkyl are moieties that have one or more aromatic rings fused (i.e., having a bond in common with) to the nonaromatic heterocyclic ring, for example phthalimidyl, naphthalimidyl, and benzo derivatives of heterocycles such as indolene and isoindolene groups. Heterocycloalky! groups can be mono- or polycyclic (e.g., having 2, 3, 4 or more fused rings or having a 2-ring, 3-ring, 4-ring spiro system (e.g., having 8 to 20 ring-forming atoms)). Heteroatoms or carbon atoms of the heterocycloalkyl group can be optionally oxidized, e. g., bearing one or two oxo or sulfildo groups to form SO, SO,
CO, NO, etc. In some embodiments, the heterocycloalkyl group has from 1 to about 20 carbon atoms, and in further embodiments from about 3 to about 20 carbon atoms. In some embodiments, the heterocycloalkyl group contains 3 to about 14, 3 to about 7, or 5 to 6 ring-forming atoms. In some embodiments, the heterocycloalkyl group has 1 to about 4, | to about 3, or 1 to 2 heteroatoms. In some embodiments, the heterocycloalkyl group contains 0 to 3 double bonds. In some embodiments, the heterocycloalky! group contains 0 to 2 triple bonds. Example “heterocycloalkyl” groups include morpholino, thiomorpholino, piperazinyl, tetrahydrofuranyl, tetrahydrothienyl, ~~ 2,3- dihydrobenzofuryl, 1,3-benzodioxole, benzo-1,4-dioxane, piperidinyl, pyrrolidinyl, isoxazolidinyl, isothiazolidinyl, pyrazolidinyl, oxazolidinyl, thiazolidinyl, imidazolidinyl, as well as radicals of 3H- isobenzofuran-1-one, 1,3-dihydro-isobenzofuran, 2,3-dihydro-benzo[d]isothiazole 1,1-dioxide, and the like.
As used herein, “halo” or “halogen” includes fluoro, chloro, bromo, and iodo.
As used herein, “alkoxy” refers to an -O-alkyl group. Example alkoxy groups include methoxy, ethoxy, propoxy {(e.g., n-propoxy and isopropoxy), t-butoxy, and the like.
As used here, “haloalkoxy” refers to an ~O-haloalkyl group. An example haloalkoxy group is
OCF;.
As used herein, “arylalkyl!” refers to alkyl substituted by ary! and “cycloalkylalkyl” refers to. alkyl substituted by cycloalkyl. An example arylalkyl group is benzyl.
As used herein, “amino” refers to NH,. -
As used herein, “alkylamino” refers to an amino group substituted by an alkyl group.
As used herein, “dialkylamino” refers to an amino group substituted by two alkyl groups.
The compounds described herein can be asymmetric (e.g. having one or more stereocenters).
All stereoisomers, such as enantiomers and diastereomers, are intended unless otherwise indicated.
Compounds of the present invention that contain asymmetrically substituted carbon atoms can be isolated in optically active or racemic forms. Methods on how to prepare optically active forms from optically active starting materials are known in the art, such as by resolution of racemic mixtures or by stereoselective synthesis. Many geometric isomers of olefins, C=N double bonds, and the like can also be present in the compounds described herein, and all such stable isomers are contemplated in the present invention. Cis and trans geometric isomers of the compounds of the present invention are described and may be isolated as a mixture of isomers or as separated isomeric forms.
Resolution of racemic mixtures of compounds can be carried out by any of numerous methods known in the art. An example method includes fractional recrystallizaion using a “chiral resolving acid” which is an optically active, salt-forming organic acid. Suitable resolving agents for fractional recrystallization methods are, for example, optically active acids, such as the D and L forms of tartaric acid, diacetyltartaric acid, dibenzoyltartaric acid, mandelic acid, malic acid, lactic acid or the various optically active camphorsulfonic acids such as B-camphorsulfonic acid. Other resolving agents suitable for fractional crystallization methods include stereoisomerically pure forms of a- methylbenzylamine (e.g., S and R forms, or diastereomerically pure forms), 2-phenylglycinol,
norephedrine, ephedrine, N-methylephedrine, cyclohexylethylamine, 1,2-diaminocyclohexane, and the like.
Resolution of racemic mixtures can also be carried out by elution on a column packed with an optically active resolving agent (e.g. dinitrobenzoylphenylglycine). Suitable elution solvent composition can be determined by one skilled in the art.
Compounds of the invention also include tautomeric forms, such as keto-enol tautomers.
Compounds of the invention can also include all isotopes of atoms occurring in the intermediates or final compounds. Isotopes include those atoms having the same atomic number but different mass numbers. For example, isotopes of hydrogen include tritium and deuterium.
The phrase "pharmaceutically acceptable" is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgement, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
The present invention also includes pharmaceutically acceptable salts of the compounds described herein. As used herein, "pharmaceutically acceptable salts” refers to derivatives of the disclosed compounds wherein the parent compound is modified by converting an existing acid or base moiety to its salt form. Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like. The pharmaceutically acceptable salts of the present invention include the conventional non-toxic salts or the quaternary ammonium salts of the parent compound formed, for example, from non-toxic inorganic or organic acids. The pharmaceutically acceptable salts of the present invention can be synthesized from the parent compound which contains a basic or acidic moiety by conventional chemical methods. Generally, such salts can be prepared by reacting 95 the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two; generally, nonaqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are preferred. Lists of suitable salts are found in Remington's Pharmaceutical Sciences, 17th ed., Mack Publishing Company, Easton, Pa., 1985, p. 1418 and Journal of Pharmaceutical Science, 66, 2 (1977), each of which is incorporated herein by reference in its entirety.
The present invention also includes prodrugs of the compounds described herein. As used herein, “prodrugs” refer to any covalently bonded carriers which release the active parent drug when administered to a mammalian subject. Prodrugs can be prepared by modifying functional groups present in the compounds in such a way that the modifications are cleaved, either in routine manipulation or in vivo, to the parent compounds. Prodrugs include compounds wherein hydroxyl, amino, sulfhydryl, or carboxyl groups are bonded to any group that, when administered to a mammalian subject, cleaves to form a free hydroxyl, amino, sulfhydryl, or carboxyl group respectively. Examples of prodrugs include, but are not limited to, acetate, formate and benzoate derivatives of alcohol and amine functional groups in the compounds of the invention. Preparation and use of prodrugs is discussed in T. Higuchi and V. Stella, "Pro-drugs as Novel Delivery Systems,"
Vol. 14 of the A.C.S. Symposium Series, and in Bioreversible Carriers in Drug Design, ed. Edward B. Roche, American Pharmaceutical Association and Pergamon Press, 1987, both of which are hereby incorporated by reference in their entirety.
Synthesis
The novel compounds of the present invention can be prepared in a variety of ways known to one skilled in the art of organic synthesis. The compounds of the present invention can be synthesized using the methods as hereinafter described below, together with synthetic methods known in the art of synthetic organic chemistry or variations thereon as appreciated by those skilled in the art.
The compounds of this invention can be prepared from readily available starting materials using the following general methods and procedures. It will be appreciated that where typical or preferred process conditions (i.e., reaction temperatures, times, mole ratios of reactants, solvents, pressures, etc.) are given; other process conditions can also be used unless otherwise stated. Optimum reaction conditions may vary with the particular reactants or solvent used, but such conditions can be determined by one skilled in the art by routine optimization procedures.
The processes described herein can be monitored according to any suitable method known in the art. For example, product formation can be monitored by spectroscopic means, such as nuclear magnetic resonance spectroscopy (e.g. 'H or °C) infrared spectroscopy, spectrophotometry (e.g.
UV-visible), or mass spectrometry, or by chromatography such as high performance liquid chromatograpy (HPLC) or thin layer chromatography.
Preparation of compounds can involve the protection and deprotection of various chemical groups. The need for protection and deprotection, and the selection of appropriate protecting groups can be readily determined by one skilled in the art. The chemistry of protecting groups can be found, for example, in Greene, et al., Protective Groups in Organic Synthesis, 2d. Ed., Wiley & Sons, 1991, which is incorporated herein by reference in its entirety.
The reactions of the processes described herein can be carried out in suitable solvents which can be readily selected by one of skill in the art of organic synthesis. Suitable solvents can be substantially nonreactive with the starting materials (reactants), the intermediates, or products at the temperatures at which the reactions are carried out, i.e., temperatures which can range from the solvent's freezing temperature to the solvent's boiling temperature. A given reaction can be carried out in one solvent or a mixture of more than one solvent. Depending on the particular reaction step, suitable solvents for a particular reaction step can be selected.
The compounds described herein can be asymmetric (e.g. having one or more stereocenters). All stereoisomers, such as enantiomers and diastereomers, are intended unless otherwise indicated. Compounds of the present invention that contain asymmetrically substituted carbon atoms can be isolated in optically active or racemic forms. Methods on how to prepare optically active forms from optically active starting materials are known in the art, such as by resolution of racemic mixtures or by stereoselective synthesis.
Resolution of racemic mixtures of compounds can be carried out by any of numerous methods known in the art. An example method includes fractional recrystallizaion using a “chiral resolving acid” which is an optically active, salt-forming organic acid. Suitable resolving agents for fractional recrystallization methods are, for example, optically active acids, such as the D and L forms of tartaric acid, diacetyltartaric acid, dibenzoyltartaric acid, mandelic acid, malic acid, lactic acid or the various optically active camphorsulfonic acids. Resolution of racemic mixtures can also be carried out by clution on a column packed with an optically active resolving agent (e.g, dinitrobenzoylphenylglycine). Suitable elution solvent composition can be determined by one skilled in the art.
The compounds of the invention can be prepared, for example, using the reaction pathways and techniques as described below.
A series of cycloalkylcarboxmides of formula 2 can be prepared by the method outlined in
Scheme 1. The carboxylic acids 1 can be coupled to an amine using coupling reagents such as BOP to provide the desired product 2.
Scheme 1
AVA R3R*NH NS i
BOP, iProNEt, CHCl 0 0) 1 2
A series of cycloalkylcarboxylic acids formula 3 can be prepared by the method outlined in
Scheme 2. Mono-alkylation of alpha-substituted methyl 4 with an alkylenedihalide such as ethylene bromide, 1,3-dibromopropane, and 1,4-dibromobutane provides mono-alkylated product 5, followed by treatment with either 1) sodium hydride in DMSO or DMF or 2) LDA in THF provides the cycloalkylcarboxylic acid esters 6. Hydrolysis of 6 gives the corresponding acid 3.
Claims (44)
1. A compound of Formula I: R! R? RY oN N- R* 0) 1 or pharmaceutically acceptable salt or prodrug thereof, wherein: Cy is aryl, heteroaryl, cycloalkyl or heterocycloalkyl, each optionally substituted by 1, 2, 3, 4 or5 -W-X-Y-Z; "R' and R? together with the C atom to which they are attached form a 3-, 4-, 5-,6-or 7- membered cycloalkyl group or a 3-, 4-, 5-, 6- or 7.membered heterocycloalky! group, each optionally substituted by 1,2 or 3 R%; R’ and R* together with the N atom to which they are attached form a 4-15 membered heterocycloalkyl group optionally substituted by 1, 2,3, 0r4-W*-X'-Y’-Z’; R’ is halo, C6 alkyl, C,.¢ alkenyl, C». alkynyl, Cy haloalkyl, aryl, cycloalkyl, heteroary], heterocycloalkyl, CN, NO,, OR’, SR®, C(O)R®, C(O)NR'R’, C(O)OR’, OC(O)R®, OC(O)NR'R®, NRR?, NR'C(O)R?, NR°C(O)OR?, S(O)R®, S(O)NR'R?, S(0)R", or S(O):NR'R%; W, W’ and W*’ are each, independently, absent, Cy. alkylenyl, Cy alkenylenyl, Cz alkynylenyt, O, S, NR®, CO, CS, COO, CONR®, OCONR?®, SO, SO,, SONR’, or NR°CONR/, wherein said Cy alkylenyl, Cys alkenylenyl, Cy alkynylenyl are each optionally substituted by 1, 2 or 3 halo, ‘OH, C,.4 alkoxy, C,.q haloalkoxy, amino, C,.4 alkylamino or Ca dialkylamino; X, X* and X'* are each, independently, absent, Cg alkylenyl, Cag alkenylenyl, Cag alkynylenyl, aryl, cycloalkyl, heteroaryl, heteracycloalkyl, arylalkyl, cycloalkylalkyl, heteroarylalkyl, heterocycloalkylalkyl, arylalkenyl, cycloalkylalkenyl, heteroarylalkenyl, heterocycloalkylalkenyl, arylalkynyl, cycloalkylalkynyl, heteroarylalkynyl, heterocycloalkylalkynyl, each of which is optionally substituted by one or more halo, CN, NO,, OH, C,.salkoxy, C,_, haloalkoxy, amino, C,.4 alkylamino or Cy dialkylamino; Y, Y’ and Y*’ are each, independently, absent, C, alkylenyl, Ca.6 alkenylenyl, Cy.6 alkynyleny!, O, S, NR¢, CO, CS, COO, CONR®, OCONRS, SO, SO,, SONR’, or NR°CONR, wherein said C.alkylenyl, Cy. alkenylenyl, Co alkynylenyl are each optionally substituted by 1, 2 or 3 halo, OH, C,.4alkoxy, C4 haloalkoxy, amino, C,_4 alkylamino or C,gdialkylamino; Z,Z’ and Z*’ are each, independently, H, halo, CN, NO,, OH, C4 alkoxy, Ci. haloalkoxy, amino, C4 alkylamino or Cy.z dialkylamino, Cy.c alkyl, Cac alkenyl, Caos alkynyl, aryl, cycloalkyl, heteroaryl or heterocycloalkyl, wherein said C;salkyl, Cs alkenyl, Cy6 alkynyl, aryl, cycloalkyl, heteroaryl or heterocycloalkyl is optionally substituted by 1, 2 or 3 halo, Cy. alkyl, Cy. alkenyl, C,.6 alkynyl, C,.4 haloalkyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, CN, NO, OR?, SR?, C(O)R”,
C(O)NRR¢, C(O)OR?, OC(O)R”, OC(O)NR°RY, NR°R¢, NR°C(O)R’, NR"C(O)OR’, S(O)R®, S(O)NRR’, S(O),R®, or S(O):NRR’;
wherein two —W-X-Y-Z attached to the same atom optionally form a 3-20 membered cycloalkyl or heterocycloalkyl group optionally substituted by 1,2 or 3 WXYZ wherein two —W?-X’-Y’-Z’ attached to the same atom optionally form a 3-20 membered cycloalky! or heterocycloalkyl group optionally substituted by 1,2 or 3 “WXYZ wherein —W-X-Y-Z is other than H; wherein —W’-X’-Y’-2’ is other than H; wherein —W?**-X?’-Y*'-Z"" is other than H; R? is H, C6 alkyl, Cy. haloalkyl, C,.¢ alkenyl, (C.¢ alkoxy)-Cy.¢ alkyl, Cy6 alkynyl, aryl, cycloalkyl, heteroaryl or heterocycloalkyl; RY is H, C, alkyl, Cy. haloalkyl, C;6 alkenyl, Cae alkynyl, aryl, cycloalkyl, heteroary! or heterocycloalkyl; RE and RY are each, independently, H, C,.c alkyl, Cis haloalkyl, Cs. alkenyl, Cy. alkynyl, aryl, cycloalkyl, arylalkyl, or cycloalkylalkyl; : or R® and R" together with the N atom to which they are attached form a 4-, 5-, 6- or 7- membered heterocycloalkyl group; and R® and Rf are each, independently, H, Cy alkyl, Cys haloalkyl, C,¢ alkenyl, Cas alkynyl, aryl, cycloalkyl, arylalkyl, or cycloalkylalkyl; : or R® and R' together with the N atom to which they are attached form a 4-, 5-, 6- or 7- membered heterocycloalkyl group; with the provisos: a) when R® and R? together with the N-atom to which they are attached form piperidinyl, said piperidinyl is unsubstituted or substituted by other than: 0 v— 3 > RC wherein: V is CH,CH,, CH=CH, or CH;O; and R is H, halo or C,.salkyl; and b) when R® and R* together with the N-atom to which they are attached form piperazinyl, said Cy is substituted by at least one —W-X-Y-Z.
2. The compound of claim 1 wherein Cy is aryl or heteroaryl, each optionally substituted by 1, 2,3,40t5 ~W-X-Y-Z.
3. The compound of claim 1 wherein Cy is aryl optionally substituted by 1,2,3,4 or 5 -W-X- Y-Z
4. The compound of claim 1 wherein Cy is aryl optionally substituted by 1,2 or 3 halo, Cis alkyl, C4 alkoxy, Ci4 haloalkyl, or Cy. haloalkoxy.
5. The compound of claim 1 wherein Cy is phenyl optionally substituted by 1,2 or 3 halo, Cia alkyl, C,.4 alkoxy, Cj.4 haloalkyl, or Cy.4 haloalkoxy.
6. The compound of claim 1 wherein R' and R? together with the C atom to which they are attached form a 3-, 4-, 5-, 6- or 7-membered cycloalkyl group.
7. The compound of claim 1 wherein R' and R? together with the C atom to which they are attached form a cyclopropyl group.
8. The compound of claim 1 wherein R? and R* together with the N atom to which they are attached form a 4-7 membered heterocycloalkyl group optionally substituted by 1, 2, 3,or4 -W-X’- Y'-Z'.
9. The compound of claim 1 wherein R? and R? together with the N atom to which they are attached form a piperidinyl or pyrrolidinyl group optionally substituted by 1, 2,3, 0r4-W-X-Y'-Z’.
10. The compound of claim 1 wherein R?® and R* together with the N atom to which they are attached form a piperidinyl or pyrrolidinyl group substituted by 2, 3, or 4 ~-W-X’-Y*-Z’; wherein two
~W’.-X’-Y’-Z’ are attached to the same atom and optionally form a 3-20 membered cycloalkyl or heterocycloalky! group optionally substituted by 1,2 or 3 “WXYZ
11. The compound of claim 1 wherein —~W-X-Y-Z is halo, cyano, Cy. cyanoalkyl, nitro, Cg alkyl,
C,.s alkenyl, Cg haloalkyl, Cy. alkylthio, C,.4 haloalkylthio, C,.s alkoxy, C;.¢alkenyloxy, Ci haloalkoxy, OH, (C1.4 alkoxy)-C).4 alkyl, amino, C,4 alkylamino, C,.¢ dialkylamino, OC(O)NR°RY, NR°C(O)R?, NR°C(O)OR?, NR°S(0),R?, C(O)OR?, C(O)R* , C(O)NR’NR'R’, S(O);R", SRY, C(O)NR°RY, C(S)NR°R!, aryloxy, heteroaryloxy, cycloalkyloxy, cycloalkenyloxy, heterocycloalkyloxy, arylalkyloxy, heteroarylalkyloxy, cycloalkylalkyloxy, heterocycloalkylalkyloxy, heteroaryloxyalkyl, aryloxyalkyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, arylalkeny!,
arylalkyny), heteroarylalkyl, heteroarylalkenyl , heteroarylalkynyl, cycloalkylalkyl, or heterocycloalkylalkyl; wherein each of said Cy.salkyl, Cog alkenyl, C,.shaloalkyl, Ci.4 alkylthio, Cy.¢ haloalkylthio,
C,.s alkoxy, aryloxy, heteroaryloxy, arylalkyloxy, heteroarylalkyloxy, heteroaryloxyalkyl, aryloxy, heteroaryloxy, cycloalkyloxy, cycloalkenyloxy, heterocycloalkyloxy, arylalkyloxy, heteroarylalkyloxy, cycloalkylalkyloxy, heterocycloalkylalkyloxy, heteroaryloxyalkyl, aryloxyalkyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, arylalkenyl, arylalkynyl, heteroarylalkyl, heteroarylalkenyl , heteroarylalkynyl, cycloalkylalkyl, or heterocycloalkylalkyl is optionally substituted by 1, 2, or 3 halo, cyano, nitro, hydroxyl(C1.5 alkyl), aminoalkyl, dialkylaminoalkyl, C4 alkyl, C,.4 haloalkyl, C4 cyanoalkyl, Ci. alkoxy, Cy haloalkoxy, OH, OR? (Ci alkoxy)-C,4 alkyl, amino, C, alkylamino, C,.¢ dialkylamino, C(O)NR°RY, C(O)OR?, C(O)R’, (cyclocalkylalkyl)-C(O)-, NR°C(O)R, NR“C(O)OR?, NR*S(O);R’, C(S)NR°RY, S(0);RY, SR, (C1. alkyl)sulfonyl, arylsulfonyl, ary! optionally substituted by halo, heteroaryl, cycloalkylalkyl, cycloalkyl, or heterocycloalkyl.
12. The compound of claim 1 wherein ~-W-X-Y-Z is halo, cyano, C4 cyanoalkyl, nitro, Cys alkyl,
C,.s alkenyl, C, ghaloalkyl, Cy.;0 alkoxy, Ci. haloalkoxy, OH, Cs alkoxyalkyl, amino, C,.4 alkylamino, Cys diatkylamino, OC(O)NR°R?, NR“C(O)R’, NR°C(O)OR’, aryloxy, heteroaryloxy, arylalkyloxy, heteroarylalkyloxy, heteroaryloxyalkyl, aryloxyalkyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, arylalkenyl, arylalkynyl, heteroarylalkyl, heteroarylalkenyl , heteroarylalkynyl, cycloalkylalkyl, or heterocycloalkylalkyl, wherein each of said Cs alkyl, Cy.salkenyl, C,ghaloalkyl, Cys alkoxy, aryloxy, heteroaryloxy, arylalkyloxy, heteroarylalkyloxy, heteroaryloxyalkyl, aryloxyalkyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, arylalkenyl, arylalkynyl, heteroarylalkyl, heteroarylalkenyl , heteroarylalkynyl, cycloalkylalkyl, or heterocycloalkylalkyl is optionally substituted by 1,2, or 3 halo, cyano, nitro, hydroxyl-(C,.s alkyl), aminoalkyl, dialkylaminoalkyl, C, 4 alkyl, C4 haloalkyl, C,4 alkoxy, Cy.4 haloalkoxy, OH, Cig alkoxyalkyl, amino, C4 alkylamino, C,.g dialkylamino, C(O)NR°R!, C(O)OR* , NR°C(O)R?, NR°S(O):R?, (C14 alkyDsulfonyl, arylsulfonyl, aryl, heteroaryl, cycloalkyl, or heterocycloalkyl.
13. The compound of claim 1 wherein —-W-X-Y-Z is halo, cyano, C4 cyanoalkyl, nitro, C;.4 nitroalkyl, Cy. alkyl, C,.q haloalkyl, Cys alkoxy, Cy. haloalkoxy, OH, (Ci alkoxy)-Ci.4alkyl, amino,
Ci. alkylamino, C,.5 dialkylamino, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, or heterocycloalkylalkyl.
14. The compound of claim 1 wherein -W-X-Y-Z is halo, C4 alkyl, or C,., alkoxy.
15. The compound of claim 1 wherein: 20S
—W-X’-Y*-Z’ is halo, OH, cyano, CHO, COOH, C(0)O-( Ci alkyD, C(O) Cy4 alkyl), SO»- ( Cy alkyl), Cys alkyl, Ci alkoxy or —L-R’, wherein said C4 alkyl or Ci alkoxy is optionally substituted by one or more halo, OH, COOH or C(0)O~( Cis alkyl); L is absent, O, CH,, NHSO,, N[C(0O)-( C,.4alkyl)]; and R’ is aryl or heteroaryl, each is optionally substituted by 1, 2, or 3 halo, OH, cyano, CHO, COOH, C(0)O-( C14 alkyl), C(O) C14 alkyl), SO-( Ci alkyl), SO,-NH( Cr. alkyl), Ciaalkyl, Cia alkoxy, Ci haoalkyl, C14 hydroxyalkyl, aryl, heteroaryl or aryloxy.
16. The compound of claim 1 wherein _W'-X’-Y’-Z’ is halo; C,.s alkyl; C,4 haloalkyl; OH; C,. alkoxy; C,.4 haloalkoxy; hydroxyalkyl; alkoxyalkyl; aryl; heteroaryl; ary! substituted by halo, C4 alkyl, C14 alkoxy, aryl, heteroaryl, or aryloxy; or heteroaryl substituted by halo, Cy alkyl, C4 alkoxy, aryl, or heteroaryl.
17. The compound of claim 1 wherein two —W'-X’-Y’-Z' are attached to the same atom and optionally form a 3-20 membered cycloalkyl or heterocycloalky! group optionally substituted by 1, 2 or3 -W»-X-Y.Z”,
18. The compound of claim 1 wherein —-W”-X”-Y”-Z” is halo, cyano, C4 cyanoalkyl, nitro, Ci.4 nitroalkyl, C,4 alkyl, Cy. haloalkyl, C4 alkoxy, C).« haloalkoxy, OH, (Ci alkoxy)-Ci.4 alkyl, amino,
Ci. alkylamino, C, 3 dialkylamino, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, or heterocycloalkylalkyl.
19. A compound of claim 1 having Formula II: R! RZ? [WX 2)q Xe N < Cy 0] 11 or pharmaceutically acceptable salt or prodrug thereof, wherein: Cy is aryl, heteroaryl, cycloalkyl or heterocycloalkyl, each optionally substituted by 1, 2,3, 4 or5 -W-X-Y-Z; . R' and R? together with the C atom to which they are attached form a 3-, 4-, 5-,6-or7- membered cycloalkyl group or a 3-, 4-, 5-, 6- or 7-membered heterocycloalkyl group, each optionally substituted by 1, 2 or 3 R’; R? is halo, Cy. alkyl, Cos alkenyl, Cs. alkynyl, C1 haloalkyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, CN, NO,, OR? SR®, C(O)R®, C(O)NRR?, C(O)OR?, OC(O)R®, OC(O)NR'RY, NRERY, NR°C(O)R?, NR°C(O)OR?, S(O)R®, S(O)NR°R®, S(0):R”, or S(0):NRR’;
W, W’ and W*’ are each, independently, absent, Cy. alkylenyl, Cis alkenylenyl, Cy alkynylenyl, O, S, NR®, CO, CS, COO, CONR?, OCONR¢, SO, SO, SONR’, or NR°CONR', wherein said C,.salkylenyl, Cys alkenylenyl, Cy¢ alkynylenyl are each optionally substituted by 1,2 or 3 halo, OH, C4 alkoxy, Cy. haloalkoxy, amino, Ci. alkylamino or Cs dialkylamino; X, X’ and X'’ are each, independently, absent, Cy.g alkylenyl, Cy.g alkenylenyl, Cy. alkynylenyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, cycloalkylalkyl, heteroarylalkyl, heterocycloalkylalkyl, arylalkenyl, cycloalkylalkenyl, heteroarylalkenyl, heterocycloalkylalkenyl, arylalkynyl, cycloalkylalkynyl, heteroarylalkynyl, heterocycloalkylalkynyl, each of which is optionally substituted by one or more halo, CN, NO,, OH, C4 alkoxy, C4 haloalkoxy, amino, C4 alkylamino or Cys dialkylamino; Y, Y* and Y** are each, independently, absent, C,.salkylenyl, Cys alkenylenyl, Cz6 alkynylenyl, O, S, NR®, CO, CS, COO, CONR®, OCONRS, SO, SO,, SONR®, or NRSCONR', wherein said Cys alkylenyl, C».¢ alkenylenyl, Cy. alkynylenyl are each optionally substituted by 1, 2 or 3 halo, OH, C4 alkoxy, C,.4 haloalkoxy, amino, C, alkylamino or C,.gdialkylamino;
7.7’ and Z’ are each, independently, H, halo, oxo, sulfido, CN, NO,, OH, C,. alkoxy, Ci4 haloalkoxy, amino, Cy. alkylamino or Cygdialkylamino, C.¢alkyl, Cr alkenyl, Ca alkynyl, aryl, cycloalkyl, heteroaryl or heterocycloalkyl, wherein said Cy. alkyl, Cy alkenyl, Cy alkynyl, aryl, cycloalkyl, heteroaryl or heterocycloalkyl is optionally substituted by 1, 2 or 3 halo, C,.¢ alkyl, Cas
. alkenyl, Cy. alkynyl, C, 4 haloalkyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, CN, NO,, OR? SR®, C(O)R®, C(O)NR°R®, C(O)OR®, OC(O)R®, OC(O)NR'R’, NR°R¢, NR°C(O)R!, NR°C(O)OR?, S(O)R®, S(O)NRR?, S(0)R”, or S(O),NRR; wherein two —W-X-Y-Z attached to the same atom optionally form a 3-20 membered cycloalkyl or heterocycloalkyl group optionally substituted by 1, 2 or 3 WXYZ wherein two —~-W’-X’-Y’-Z’ attached to the same atom optionally form a 3-20 membered cycloalkyl or heterocycloalky! group optionally substituted by 1,2 or 3 WXYZ wherein —-W-X-Y-Z is other than H; wherein —W’-X'-Y’-Z’ is other than H; wherein =W?’-X’.Y’’-Z”’ is other than H; R® is H, Cy. alkyl, C\.¢ haloalkyl, C,. alkenyl, (Cy.¢ alkoxy)-C. alkyl, Cy alkynyl, aryl, cycloalkyl, heteroaryl or heterocycloalkyl; R® is H, C,.s alkyl, C,. haloalkyl, Cy. alkenyl, Cy. alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl; R® and RY are each, independently, H, C, alkyl, C,.¢ haloalkyl, Cs alkenyl, C,.¢ alkynyl, aryl, cycloalkyl, arylalkyl, or cycloalkylalkyl; or R® and RY together with the N atom to which they are attached form a 4-, 5-, 6- or 7- membered heterocycloalkyl group;
RE and Rf are each, independently, H, Cy alkyl, C,.¢ haloalkyl, Cas alkenyl, Cs. alkynyl, aryl, cycloalkyl, arylalkyl, or cycloalkylalkyl; : or R® and Rf together with the N atom to which they are attached form a 4-, 5-, 6-or 7- membered heterocycloalky! group; and qis0,1,2,30r4.
20. A compound of claim 1 having Formula III: RF (YL wor, oN 0] 1m or pharmaceutically acceptable salt or prodrug thereof, wherein: Cy is aryl, heteroaryl, cycloalkyl! or heterocycloalkyl, each optionally substituted by 1, 2, 3, 4 or 5 —-W-X-Y-Z; UisNH,CHyor 0; R' and R? together with the C atom to which they are attached form a 3-, 4-, 5-, 6-or 7- membered cycloalkyl group or a 3-, 4-, 5-, 6- or 7-membered heterocycloalkyl group, each optionally substituted by 1, 2 or 3 R; R’ is halo, Cy alkyl, C,.¢ alkenyl, Ca alkynyl, Cy4 haloalkyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, CN, NO, OR’, SR? C(O)R®, C(O)NRR, C(O)OR®, OC(O)R®, OC(O)NR'R®, NR°R?, NR°C(O)RY, NR°C(O)OR?, S(O)R?, S(O)NRR!, S(O);:R", or S(O);NR°R%; W, W’ and W*’ are each, independently, absent, Cy alkylenyl, Cy alkenylenyl, Cy alkynylenyl, O, S, NR, CO, CS, COO, CONR‘, OCONR?®, SO, SO, SONR®, or NR°CONR', wherein said C,.s alkylenyl, Css alkenylenyl, C,.¢alkynylenyl are each optionally substituted by 1, 2 or 3 halo, OH, C, alkoxy, C,., haloalkoxy, amino, C,_4 alkylamino or Cy ¢ dialkylamino; X, X’ and X’’ are each, independently, absent, Cys alkylenyl, C.salkenylenyl, Cy.5 alkynylenyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, cycloalkylalkyl, heteroarylaikyl, heterocycloalkylalkyl, arylalkenyl, cycloalkylalkenyl, heteroarylalkenyl, heterocycloalkylalkenyl, arylalkynyl, cycloalkylalkynyl, heteroarylalkynyl, heterocycloalkylalkynyl, each of which is optionally substituted by one or more halo, CN, NO,, OH, C,4alkoxy, Ci. haloalkoxy, amino, C4 alkylamino or C,¢ dialkylamino; Y, Y’ and Y”’ are each, independently, absent, Cys alkylenyl, Ca alkenylenyl, Co6 alkynylenyl, O, S, NR", CO, CS, COO, CONR®, OCONR’, SO, SO,, SONR’, or NR°CONR, whercin said C, salkylenyl, C,¢alkenylenyl, C,.¢ alkynylenyl are each optionally substituted by 1,2 or 3 halo, OH, C4 alkoxy, C,4 haloalkoxy, amino, C4 alkylamino or C,.3 dialkylamino;
7,2’ and 2° are each, independently, H, halo, oxo, sulfido, CN, NO,, OH, C4 alkoxy, C,.4 haloalkoxy, amino, C4 alkylamino or Cy dialkylamino, Cy. alkyl, C2 alkenyl, Cos alkynyl, aryl, cycloalkyl, heteroaryl or heterocycloalkyl, wherein said C4 alkyl, Cac alkenyl, Cy alkynyl, aryl, cycloalkyl, heteroaryl or heterocycloalkyl is optionally substituted by 1,2 or 3 halo, C,¢ alkyl, Ca. alkenyl, Cy.6 alkynyl, Cys haloalkyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, CN, NO, OR’, SR?, C(O)R?, C(O)NR°RY, C(O)OR’, OC(O)R", OC(O)NR'R’, NRRY, NR°C(O)R?, NR°C(O)OR?, S(O)R", S(O)NR°R, S(O).R", or S(O);NR°RY; _ wherein two —W-X-Y-Z attached to the same atom optionally form a 3-20 membered cycloalkyl or heterocycloalkyl group optionally substituted by 1,2 or 3 “WXYZ wherein two —W’-X’-Y’-Z attached to the same atom optionally form a 3-20 membered cycloalkyl or heterocycloalkyl group optionally substituted by 1, 2 or 3 -W-X*'-Y’-2"’; wherein —-W-X-Y-Z is other than H; wherein ~W?*-X’-Y’-Z’ is other than H; wherein—W?’-X’’-Y”’-Z’’ is other than H; Ris H, C, alkyl, Cys haloalky], Cy alkenyl, (Cs alkoxy)-C,.¢ alkyl, Cy alkynyl, aryl, cycloalkyl, heteroaryl! or heterocycloalkyl; Ris H, C, alkyl, C,.¢ haloalkyl, C, alkenyl, C,. alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl; R and R are each, independently, H, Ci alkyl, Cys haloalkyl, C,.6 alkenyl, Cas alkynyl, aryl, cycloalkyl, arylalkyl, or cycloalkylalkyl; or R® and R® together with the N atom to which they are attached form a 4-, 5-, 6- or 7- membered heterocycloalkyl group; R* and Rf are each, independently, H, C, alkyl, C,.¢ haloalkyl, Cy alkenyl, Cy. alkynyl, aryl, cycloalkyl, arylalkyl, or cycloalkylalkyl; or R® and Rf together with the N atom to which they are attached form a 4-, 5-, 6- or 7- membered heterocycloalkyl group; and : ris0,1,2,30r4; with the provisos: a) when U is CH,, then —W’*-X’-Y’-Z’ forms a group other than: 0 v— 3 > RUC =z wherein: V is CH,CH,, CH=CH, or CH,0; and
R is H, halo or C,.s alkyl; and b) when U is NH, said Cy is substituted by at least one -W-X-Y-Z.
21. A compound of claim | having Formula IV: (W'-X'-Y'-2"), R! R2 0% oe O Iv or pharmaceutically acceptable salt or prodrug thereof, wherein: Cy is aryl, heteroaryl, cycloalkyl or heterocycloalkyl, each optionally substituted by 1,2, 3, 4 or5 -W-X-Y-Z, R' and R? together with the C atom to which they are attached form a 3-, 4-,5-,6-or 7- membered cycloalkyl group or a 3-, 4-, 5-, 6- or 7-membered heterocycloalky! group, each optionally ’ substituted by 1, 2 or 3 Rr G' and G? together with the carbon atom to which they are attached form a 3-20 membered cycloalky! or heterocycloalkyl group optional substituted by 1,2 or 3 WXYZ R? is halo, Cys alkyl, Ca. alkenyl, Cy alkynyl, Cy haloalkyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, CN, NO,, OR?, SR®, C(O)R®, C(O)NR'R’, C(O)OR*, OC(O)R", OC(O)NR°RY, NR°RY, NRC(O)R®, NR°C(O)OR?, S(O)R?, S(O)NR°RY, S(O);R®, or S(0),NRRY; W, W’and W”’ are each, independently, absent, C.salkylenyl, Ci. alkenylenyl, Ca alkynylenyl, O, S, NR, CO, COO, CONRS, SO, SO, SONR’, or NR°CONR’, wherein said Cy. alkylenyl, C,.alkenylenyl, C4 alkynylenyl are each optionally substituted by 1, 2 or 3 halo, OH, C,., alkoxy, Cy.4 haloalkoxy, amino, C4 alkylamino or C;4 dialkylamino; X, X* and X* are each, independently, absent, C; gs alkylenyl, C, galkenylenyl, Cy. alkynylenyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, cycloalkylalkyl, heteroarylalkyl, heterocycloalkylalkyl, arylalkenyl, cycloalkylalkenyl, heteroarylalkenyl, heterocycloalkylalkenyl, arylalkynyl, cycloalkylalkynyl, heteroarylalkynyl, heterocycloalkylalkynyl, each of which is optionally substituted by one or more halo, CN, NO,, OH, Cs alkoxy, C4 haloalkoxy, amino, C4 alkylamino or Cy gdialkylamino; Y, Y’ and Y?? are each, independently, absent, C,.¢alkylenyl, Cy alkenylenyl, Cz. alkynylenyl, O, S, NR, CO, CS, COO, CONR®, OCONR?, SO, SO,, SONR?, or NR°CONR, wherein said Cy alkylenyl, Cs alkenylenyl, C,salkynylenyl are each optionally substituted by 1, 2 or 3 halo, OH, Cs alkoxy, C,.4 haloalkoxy, amino, C 4 alkylamino or C, dialkylamino; Z, 27’ and 2”’ are each, independently, H, halo, oxo, sulfido, CN, NO,, OH, C,.4alkoxy, Ci haloalkoxy, amino, C,.4 alkylamino or Cy dialkylamino, Cs alkyl, C6 alkenyl, C;.s alkynyl, aryl,
cycloalkyl, heteroaryl or heterocycloalkyl, wherein said Cysalkyl, Cy. alkenyl, C,.¢ alkynyl, aryl, cycloalkyl, heteroaryl or heterocycloalkyl is optionally substituted by 1, 2 or 3 halo, Cy alkyl, Ca. alkenyl, Cys alkynyl, Ci4 haloalkyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, CN, NO,, OR’, SR®, C(O)R®, C(O)NR°R?, C(O)OR?, OC(O)R®, OC(O)NRR', NR'R’, NRC(O)R?, NR°C(O)OR’, S(O)R®, S(O)NR°R’, S(O):R”, or S(O),NRRY, wherein two ~W-X-Y-Z attached to the same atom optionally form a 3-20 membered cycloalky! or heterocycloalkyl group optionally substituted by 1, 2 or 3 WXYZ wherein —W-X-Y-Z is other than H; wherein —W?’’-X*’-Y*’-Z" is other than H; R® is H, Cy alkyl, C). haloalkyl, C,.¢ alkenyl, (Ci alkoxy)-Cy.¢ alkyl, Cy alkynyl, aryl, cycloalkyl, heteroaryl or heterocycloalkyl; R® is H, C, alkyl, C,. haloalkyl, Co alkenyl, Cp alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl; R® and R? are each, independently, H, Cy. alkyl, C,.¢ haloalkyl, C,.¢ alkenyl, Cy alkynyl, aryl, cycloalkyl, arylalkyl, or cycloalkylalkyl; or R°and R* together with the N atom to which they are attached form a 4-, 5-, 6- or 7- ‘membered heterocycloalkyl group; R® and RF are each, independently, H, Cys alkyl, Cy. haloalkyl, Cy alkenyl, Cs. alkynyl, aryl, cycloalkyl, arylalkyl, or cycloalkylalkyl; or R® and R' together with the N atom to which they are attached form a 4-, 5-,6-0r7- membered heterocycloalkyl group; and vis 0, lor2.
22. A compound of claim 1 having Formula Va or Vb: (WXYZ), qQ! ~Q¢_ (W'-X"-Y"-Z") po Te N (WXYZ), oN a o Va TEEN Drea Rl R? (J (WXYZ), N PN q 0]
Vb or pharmaceutically acceptable salt or prodrug thereof, wherein: ring B is a fused 5 or 6-membered aryl or heteroaryl group; Q'is 0, S, NH, CH,, CO, CS, SO, SO,, OCH, SCH,, NHCH,, CH,CH,, CH=CH, COCH;, CONH, COO, SOCH,, SONH, SO,CH;,, or SO,NH;
Q*is 0, S, NH, CH,, CO, CS, SO, SO, OCH, SCH,, NHCH,, CH,CH,, CH=CH, COCH,, CONH, COO, SOCH,, SONH, SO,CH,, or SO;NH;
Cy is aryl, heteroaryl, cycloalkyl or heterocycloalkyl, each optionally substituted by 1,2, 3,4 or5 -W-X-Y-Z,
R! and R? together with the C atom to which they are attached form a 3-, 4-, 5-,6-o0r7- membered cycloalkyl group or a 3-, 4-, 5-, 6- or 7-membered heterocycloalkyl group, each optionally substituted by 1,2 or 3 R%;
R? is halo, C,.¢ alkyl, Ca. alkenyl, Ca. alkynyl, Ci haloalkyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, CN, NO, OR?, SR®, C(O)R", C(O)NRR?, C(O)OR?, OC(O)R®, OC(O)NR'R’, NR°R®, NR°C(O)R®, NR°C(O)OR’, S(O)R®, S(O)NR'R’, S(0).R’, or S(0),NR°R’;
W, W’ and W”’ are each, independently, absent, Cy alkylenyl, C,.¢ alkenylenyl, Ca alkynylenyl, O, 8, NR*, CO, CS, COO, CONR, OCONRS, SO, SO,, SONR®, or NR°CONR', wherein said Ci alkylenyl, Cys alkenylenyl, Cas alkynylenyl are each optionally substituted by 1,2 or 3 halo, OH, C,.4 alkoxy, C,4haloalkoxy, amino, C4 alkylamino or Cys diatkylamino;
X, X’ and X’’ are each, independently, absent, Cys alkylenyl, Ca.¢ atkenylenyl, Cys alkynylenyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, cycloalkylalkyl, heteroarylalkyl, heterocycloalkylalkyl, arylalkenyl, cycloalkylalkenyl, heteroarylalkenyl, heterocycloalkylalkenyl, arylalkynyl, cycloalkylalkynyl, heteroarylalkynyl, heterocycloalkylalkynyl, each of which is optionally substituted by one or more halo, CN, NO, OH, C,.4 alkoxy, C,.4 haloalkoxy, amino, C4 alkylamino or C,.g dialkylamino;
Y,Y’ and Y’ are each, independently, absent, Cy.¢ alkylenyl, C,¢ alkenylenyl, Cy alkynylenyl, O, S, NR, CO, CS, COO, CONR®, OCONRS, SO, SO,, SONR®, or NR°CONR', wherein said C..¢ alkylenyl, Cys alkenylenyl, Cy. alkynylenyl are each optionally substituted by 1, 2 or 3 halo, OH, C,. alkoxy, C,.4 haloalkoxy, amino, C4 alkylamino or Cy dialkylamino;
Z,Z’ and 2”’ are each, independently, H, halo, oxo, sulfido, CN, NO, OH, C,4alkoxy, C4 haloalkoxy, amino, Cy.4 alkylamino or Cys dialkylamino, Cys alkyl, Cz.6 alkenyl, Cp. alkynyl, aryl, cycloalkyl, heteroaryl or heterocycloalkyl, wherein said Cy alkyl, Ca alkenyl, Cp. alkynyl, aryl, cycloalkyl, heteroaryl or heterocycloalkyl is optionally substituted by 1,2 or 3 halo, Cy.¢ alkyl, Cy6 alkenyl, Ca.6 alkynyl, Cy haloalkyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, CN, NO,, OR’, SR?, C(O)R®, C(O)NR'R!, C(O)OR®, OC(O)R®, OC(ONR'R’, NR°RY, NR"C(O)R’, NR‘C(O)OR", S(O)R®, S(O)NRR?, S(O),R®, or S(0),NRR’;
wherein two —~W-X-Y-Z attached to the same atom optionally form a 3-20 membered cycloalkyl or heterocycloalkyl group optionally substituted by 1,2 or 3-WrX-Y-2 wherein —W-X-Y-Z is other than H; wherein —-W’-X’*-Y’*-Z"" is other than H; R® is H, C,. alkyl, C;.¢ haloalkyl, Cz alkenyl, (Cis alkoxy)-C. alkyl, Ca alkynyl, aryl, cycloalkyl, heteroaryl or heterocycloalkyl; R® is H, C,.¢ alkyl, C,.¢ haloalkyl, Cy. alkenyl, Co. alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl; RE and RY are each, independently, H, C, 4 alkyl, Ci. haloalkyl, Cy. alkenyl, Cy alkynyl, aryl, cycloalkyl, arylalkyl, or cycloalkylalkyl; or R® and R® together with the N atom to which they are attached form a 4-, 5-, 6- or 7- membered heterocycloalkyl group; R® and Rf are each, independently, H, Cy. alkyl, Ci.¢ haloalkyl, Cy. alkenyl, Ca. alkynyl, aryl, cycloalkyl, arylalkyl, or cycloalkylalkyl; or R® and Rf together with the N atom to which they are attached form a 4-, 5-, 6- or 7- membered heterocycloalkyl group; / qisOorl; vis0,1o0r2; ris0,1or2; sis 0, 1 or 2; and the sum ofrandsis 0, ! or2. :
23. A compound of claim 1 having Formula VI: (W-X-Y'-Z'), QQ (WXYZ), 4 R! R2 < / 3, oN = Swexevz) q 0) Vi wherein Q*and Q* are each, independently, CH or N.
24. A compound of claim 1 having Formula VII:
R' R? '~q2 N T— (WXYZ) oN = Q? (W"-X"-Y"-Z"); VIL — 25. A compound of claim 1 having Formula VIII: R! R? Q'~q2 N PN “2 0 \ VIII
26. A compound of claim 1 selected from: 1-((1-(4-Chloropheny!) cyclopropyl) carbonyl)pyrrolidin-3-ol; 1-[(1-Phenylcyclopropyl) carbonyl] pyrrolidin-3-ol; 1-[(1-Phenylcyclopropy!) carbonyl] pyrrolidin-3-ol; 1-{[1-(4-Chlorophenyl)cyclopropyl] carbonyl}-2-phenylpyrrolidine; 1'-{[14-Chlorophenyl)cyclopropyl] carbonyl}-2,3-dihydrospiro[indene-1,4"-piperidine]; 1-{[1-(4-Chlorophenyl)cyclopropyl] carbonyl}-3-phenylpiperidine; 1-{[1-(4-Chlorophenyl)cyclopropyl] carbonyl}-4-phenylpiperidine-4-carbonitri le; 1-{[1-(4-Chlorophenyl)cyclopropyl] carbonyl}-4-phenoxypiperidine; 1'-{[1-(4-chlorophenyl)cyclopropyl] carbonyl}-1 -methylspiro[indole-3,4"-piperidin]-2(1 H)- one; 1-{[1-(4-Chlorophenyl)cyclopropy!] carbonyl}-4-phenylpiperidin-4-ol; Methyl 3-(1-{[1-(4-chlorophenyl) cyclopropyllcarbonyl} piperidin-4-yl)benzoate; 4-Benzyl-1-{[1-(4-chlorophenyl) cyclopropyl]carbonyl} piperidin-4-ol; 4-(4-tert-Buty|-1,3-thiazol-2-y1)-1-{[1-(4-chlorophenyl)cyclopropyl] carbonyl} piperidine; Methyl 4-(1-{[1-(4-chlorophenyl) cyclopropyllcarbonyl} piperidin-4-yl)benzoate, tert-Butyl 1'-{[1-(4-chlorophenyl) cyclopropyljcarbonyl}spiro[indole-3,4'-piperidine]-1(2H)- carboxylate; 1'-{[1-(4-Chlorophenyl)cyclopropyl] carbonyl}-2,3-dihydro-1H-spiro [isoquinoline-4,4'- piperidine]; 8-{[1-(4-Chlorophenyl)cyclopropyl] carbonyl}-3-phenyl-1-oxa-2,8-diazaspiro[4.5]dec-2-ene;
1-{[1-(4-Chlorophenyl)cyclopropyl] carbonyi}-4-[3 (trifluoromethyl) phenyl] piperidine; 1-{[1-(4-Chlorophenyl)cyclopropyl] carbonyl}-4-(4-phenyl-1 ,3-thiazol-2-yl)piperidine;
: tert-Butyl 7-{[1-(4-chlorophenyl) cyclopropyl]carbonyl}-2,7-diazaspiro [4.5]decane-2- carboxylate; tert-Butyl 1'-{[1-(4-chlorophenyl) cyclopropyt]carbonyl}-1H-spiro [isoquinoline-4,4'- piperidine]-2(3H)-carboxylate; tert-Butyl 7-{[1-(4-chlorophenyl Yeyclopropyljcarbonyl}-2,7-diazaspiro [3.5]nonane-2- . carboxylate; 4-(1-{[1-(4-Chlorophenyl)cyclopropyl] carbonyl} pyrrolidin-3-yl)pyridine; 4-(1-{[144-Chlorophenyl) cyclopropyljcarbonyl} pyrrolidin-3-yl)pyridine; 4-(1-{[1 (4-Chlorophenyl) cyclopropyl]carbony!}pyrrolidin-3-yl)pyridine; 1-{[1-(4-Chlorophenyl) cyclopropyl] carbonyl}-3-phenylpyrrolidine; 2-(1-{[1-(4-Chlorophenyl)cyclopropy!] carbonyl} pyrrolidin-3-yl)pyrazine; 3-(1-{[1-(4-Chlorophenyl)cyclopropyl] carbonyl} pyrrolidin-3-yl)pyridine; 1-{[1-(4-Chloropheny!) cyclopropyl]carbonyl}-3-phenylpyrrolidine; 3-(3-Chlorophenyl)-1-{[1 -(4-chlorophenyl)cyclopropyllcarbonyl} pyrrolidine; 1-{[1<(4-Chlorophenyl)cyclopropyl] carbonyl}-3-[3-(triflucromethyl) phenyl]pyrrolidine; 2-(1-{[1-(4-Chlorophenyl)cyclopropyl] carbonyl}pyrrolidin-3-yDpyridine; 1-{[1-(4-Chlorophenyl)cyclopropyl] carbonyl}-3 -phenylpyrrolidin-3-ol; 1-{[1-(4-Chlorophenyl)cyclopropyl]} carbonyl}-3 -(2-naphthyl)pyrrolidine; 3-Benzyl-1-{[1-(4-chlorophenyl) cyclopropyljcarbonyl} pyrrolidine; 1-{[1-(4-Chlorophenyl)cyclopropyl] carbonyl}-3 -(phenylsulfonyl)pyrrolidine, 2-{[1-(4-Chlorophenyl)cyclopropyl] carbonyl}-5-(4-fluorophenyl)-2,5- diazabicyclo{2.2.1]heptane; 1-{[1-(4-Chlorophenyl)cyclopropyl] carbonyl} -3-(4-phenoxyphenyl) pyrrolidine; Methyl 1-{[1-(4-chlorophenyl) cyclopropyl]carbonyl}-4-phenyl pyrrolidine-3-carboxylate; 1-{[1-(4-Chlorophenyl)cyclopropyl] carbonyl}-3-(4-methoxypheny! )pyrrolidine; 1-((1-(4-Chlorophenyl)cyclopropyl carbonyl)-3-(4-trifluoropheny!) pyrrolidine; 3-(4-Chlorophenyl)-1-{[1-(4-chlorophenyl)cyclopropyljcarbonyl} pyrrolidine; 4-(1-{[1-(2,4-Dichlorophenyl) cyclopropyl]carbonyl} pyrrolidin-3-yDpyridine; 4-(1-{[1-(4-Methoxyphenyl) cyclopropyl] carbonyl} pyrrolidin-3-yl)pyridine; 4-(1-{[1-(4-Methylphenyl)cyclopropyl] carbonyl} pyrrolidin-3-yl)pyridine; 1-{[1-(4-Chlorophenyl)cyclopropyl] carbonyl}-4-phenylpiperidine; 3-{[1-(4-Chlorophenyl)cyclopropyl] carbonyl}-1,2,3,4,4a,5,6,1 0b-octa- hydrobenzo|[f]isoquinoline; 2-{[1-(4-Chlorophenyl)cyclopropyl] carbonyl}-2,3,3a,4,5,9b-hexahydro-1H- benzofelisoindole;
2-{[1-(4-Chlorophenyl)cyclopropyl] carbonyl}-1 2.3,3a,8,8a-hexahydroindeno(1,2-c]pyrrole; 1'-{[1-(4-Chlorophenylcyclopropyl] carbonyl}-1 ,3-dihydrospiro[indene-2,4"-piperidine]; 3-{[1-(4-Chlorophenyl)cyclopropyl] carbonyl} -2,3,4,4a,5,6-hexahydro-1 H-pyrazino(1,2- ajquinoline; 2-{[t -(4-Chlorophenyl)cyclopropyl] carbonyl}-1,2,3,4,1 0,10a-hexahydro pyrazino[1,2- alindole; 1'-{[1 -(4-Chlorophenyl)cyclopropyl] carbonyl }spiro[chromene-2,4'-piperidine];
: 1'-{[1-(4-Chlorophenyl)cyclopropyl] carbonyl }-3H-spiro[2-benzofuran-1 ,4'-piperidine}; 1'-{[1-(4-Chlorophenyl)cyclopropyl] carbonyl! yspiro[indole-3,4"-piperidin]-2(1 H)-one; 8-{[1-(4-Chlorophenyl)cyclopropyl] carbonyl}-2,8-diazaspiro[4.5]decan-3-one; 2-{[1-(4-Chlorophenyl)cyclopropyl] carbonyl}-1,2,3,4-tetrahydro isoquinoline; 6-{[1-(4-Chlorophenyl)cyclopropyl] carbonyl}-4,5,6,7-tetrahydrothieno [2,3-c]pyridine; 1-{[1-(4-Chlorophenyl)cyclopropyl] carbonyl}indoline; 2-{[1-(4-Chlorophenyl)cyclopropyl] carbonyl}isoindoline;
8-{[1 -(4-Chlorophenyl)cyciopropyi] carbonyl}-1-phenyl-1,3,8-triazaspiro [4.5]decan-4-one; 4-Benzylidene-1-{[1-(4-chlorophenyl) cyclopropyl]carbonyl} piperidine; 1'-{[1-(4-Chlorophenyl)cyclopropyl] carbonyl} -1,4'-bipiperidine; 4-(1-{[1(4-Chlorophenyl)cyclopropyl] carbonyl} piperidin-4-yl)pyridine; 1-{[1-(4-Chlorophenyl)cyclopropyl] carbonyi}-3 -(4-fluorophenyl) pyrrolidine; 1-{[1(4-Chlorophenyl)cyclopropyl] carbony 1}-3-(3-fluorophenyl) pyrrolidine; N-~(1-{{1-(4-Chlorophenyl) cyclopropy [Jcarbonyl}piperidin-4-yl)-N-phenylpropanamide; 2-{[1-(4-Chlarophenyl)cyclopropyl] carbonyl} octahydropyrrolo[1,2-a]pyrazine; 4-{[1-(4-Chloropheny!)cyclopropyl] carbonyl} piperazine-1 -carbaldehyde; 4-{[1-(4-Chlorophenyl)cyclopropyl] carbonyl}-2-methyl-1-phenyl iperazine; 1-{[1 (4-Chlorophenyl)cyclopropy!] carbonyl}-4-(pyridin-4-ylmethyl) piperazine; 1-{[1<(4-Chlorophenyl)cyclopropyl] carbonyl}-4-(2-thienylsulfonyl) piperazine; 2-(1-{[1-(4-Chlorophenyl)cyclopropyl] carbonyl} piperidin-2-yl)ethanol, 2-(1-{[1-(4-Chlorophenyl)cyclopropyl] carbonyl} piperidin-4-yl)ethanol; 1-{[1-(4-Chlorophenyl)cyclopropyl] carbonyl}-4-(4-fluorophenyl) piperidine; 4-(4-Chlorophenyl)-1-{[1-(4-chlorophenyl)cyclopropyl]carbonyl}-1,2,3 ,6-tetrahydropyridine; (1-{[1-(4-Chlorophenyl)cyclopropyl] carbonyl} piperidin-2-y!)methanol; 2-(1-{[1-(4-Chloropheny!)cyclopropyl] carbonyl} pyrrolidin-2 -yDethanol; (1-{[1-(4-Chlorophenyl) cyclopropy!]carbonyl}pyrrolidin-2-yhmethanol; (1-{[1-(4-Chloropheny}) cyclopropyljcarbonyl}pyrrolidin-2-yl)methanol; 1'-{[1-(4-Chlorophenyl)cyclopropyl] carbony!}spiro[1,2-benzisothiazole-3,3-pyrrolidine] 1,1-dioxide;
1-{[1 -(4-Chlorophenyi)cyclopropyl] carbonyl} -3H-spiro[2-benzofuran-1 ,3"-pyrrolidin]-3- : one; 1'-({1-[4-(Pyridin-2-yloxy) phenylicyclopropyl}carbonyl)-3 H-spiro{2-benzofuran-1,3'- pyrrolidin]-3-one; 1'-{[1-(4-Chlorophenyl)cyclobutyl] carbonyl} -3H-spiro[2-benzofuran-1 ,3-pyrrolidin]-3-one; 1'-{[1-(4-Methylphenyl)cyclopropyl] carbonyl}-3H-spiro[2-benzofuran-1,3"-pyrrolidin]-3- one; _ 1'-{[1 -(4-Methoxyphenyl)cyclopropyl) carbonyl} -3H-spiro[2-benzofuran-1 ,3"-pyrrolidin]-3- one; oo 1'-{[1«(2,4-Dichlorophenyl) cyclopropy!]carbonyl} -3H-spiro[2-benzofuran-1 ,3-pyrrolidin}-3- one; : 1'-{[1-(4-Chiorophenyl)cyclopropyl] carbonyl }-3H-spiro[2-benzofuran-1 ,3'-pyrrolidine]; 1'-{[1-(4-Chlorophenyl)cyclopropyl] carbonyl}-7H-spiro{furo[3,4-b]pyridine-5,3'-pyrrolidin]- 7-one; 1'-{[1-(4-Chloropheny!)cyclopropyl] carbonyl}-3 H-spiro[furo[3,4-c]pyridine-1,3"-pyrrolidin]- 3-one; 1'-{[1-(4-Chlorophenyl)cyclopropyl] carbonyl}-1H-spiro[furo(3 ,4-c]pyridine-3,3"-pyrrolidin]- 1-one; 1'-{[1<4-Chlorophenyl)cyclopropyl] carbonyl} spiro[indole-3,3'-pyrrolidin]-2(1H)-one; 1'-({ 1-[4-(1H-Pyrazol-1-yl)phenyl] cyclopropyl} carbonyl)-3 H-spiro[furo[3,4-c}pyridine-1,3"- pyrrolidin]-3-one; 1'-({1-[4-(Difluoromethoxy) phenyljcyclopropyl}carbonyl)-3H-spiro[furo[3,4-c] pyridine- 1,3"-pyrrolidin]-3-one; 1'-{[1-(6-Phenylpyridin-3-yl)cyclopropyl]carbonyl}-3 H-spiro[2-benzofuran-1,3"-pyrrolidin]- 3-one; 1'-{[1-(6-Phenylpyridin-3-yl) cyclopropyl]carbonyl}-3H-spiro[furo[3,4-c] pyridine-1,3'- pyrrolidin}-3-one; 1'-{{1«(4-Pyrrolidin-1-ylphenyl) cyclopropyl]carbonyl}-3H-spiro[ furo[3,4-c]pyridine-1,3'- pyrrolidin}-3-one; 1'-{[1-(4-Pyrrolidin-1-ylphenyl) cyclopropyl]carbonyl}-3H-spiro[2-benzofuran-1,3'- pyrrolidin]-3-one; and 1'-{[146-Pyrrolidin-1-ylpyridin-3-yl)cyclopropyljcarbonyl} -3H-spiro[furo[3,4-c]pyridine- 1,3"-pyrrolidin]-3-one, or pharmaceutically acceptable salt thereof.
27. A compound of claim 1 selected from: 1-{[1-(6-Pyrrolidin-1-ylpyridin-3-yl)cyclopropyl]carbonyl}-3H-spiro[2-benzofuran-1,3'- pyrrolidin]-3-one;
1'-({1-[4-(2-Oxo0-1 3-oxazolidin-3-yl)phenyl]cyclopropyl}carbonyl)-3H-spiro[2-benzofuran- 1,3'-pyrrolidin}-3-one; 1'-({1-[4-(2-Oxopyrrolidin-1 -yl)phenylJcyclopropyl}carbonyl)-3H-spiro[2-benzofuran-1 »3- pyrrolidin]-3-one; 1'-({1 -[4-(2-Phenylethoxy)phenyl] cyclopropyi}carbonyl)-3H-spiro[furo[3,4-c] pyridine-1,3'- pyrrolidin]-3-one; 1'-[(1-{4-[(1-Methylcyclopropyl) methoxy]phenyl}cyclopropyl)-carbony 1]-3H-spiro[furo(3,4- _ ¢}pyridine-1,3"-pyrrolidin]-3-one; 1'-{(1 -{4-[(2-Fluorobenzyl)oxy) phenyl} cyclopropyl)carbonyl]-3H-spiroffuro[3,4-c] pyridine- 1,3'-pyrrolidin]-3-one; 1'-({1-[4-(Quinolin-2-ylmethoxy) phenyljcyclopropyl}carbonyl)-3H-spirof furo[3 A- c]pyridine-1,3'-pyrrolidin]-3-one; 1'-[(1-{4-[(3-Fluorobenzyl)oxy} phenyl} cyclopropyl)carbonyl}-3H-spiro[furof3 ,4-c]pyridine- 1,3'-pyrrolidin]-3-one; 1'<({1-[4-(1 ,3-Benzothiazol-2-ylmethoxy)phenyl]cyclopropyl}- carbonyl)-3H-spiro[furo[3,4- c]pyridine-1,3'-pyrrolidin]-3-one; 1'-{[1-(4-{[3,5-Bis(trifluoromethy!) benzyljoxy} phenyl)-cyclopropyl] carbonyl}-3H- spiro[furo[3,4-c]pyridine-1,3'-pyrrolidin]-3-one; ) 1'-[(1-{4-[2-(4-Fluorophenyl)ethoxy] phenyl}cyclopropyl)-carbonyl}-3H-spiro furo(3,4- c]pyridine-1,3'-pyrrolidin]-3-one; 4-[(4-{1-[(3-Oxo0-1'H,3H-spiro [furo[3,4-c]pyridine-1,3"-pyrrolidin]-1'-y [Ycarbonyl] cyclopropyl} phenoxy)methyl]benzonitrile; 1'-{[1-(4-Phenoxyphenyl)cyclopropyl] carbonyl}-3H-spiro[furo[3,4-c]pyridine-1,3'- pyrrolidin]-3-one; 1'-({1-[{4-(Pyridin-4-ylmethoxy) phenyl]cyclopropy!}-carbonyl)-3H-spiro[2-benzofuran-1 »3'- pyrrolidin]-3-one; 1'-({ 1 -[4-(Pyridin-2-ylmethoxy) phenyl]cyclopropyl}-carbonyl)-3H-spiro[2-benzofuran-1 3 pyrrolidin]-3-one; 1'-{[1-(4-Pyridin-4-yIpheny!) cyclopropyl]carbonyl }-3H-spiro[2-benzofuran-1,3'-pyrrolidin]- 3-one; 1'-{[1-(4-Cyclopropylphenyl) cyclopropyljcarbonyl}-3H-spiro[2-benzofuran-1 ,3'-pyrrolidin]- 3-one; 1'-{[1-(2-Fluoro-4-pyridin-2-ylphenyl)cyclopropyl]-carbonyl} -3H-spiro{2-benzofuran-1,3'- pyrrolidin}-3-one; 1'-[(1-{4-[(E)-2-(4-Methylphenyl)vinyl]phenyl} -cyclopropyl)carbony!}-3 H-spiro[2- benzofuran-1,3"-pyrrolidin]-3-one;
1-({1 -[4-(2-Pyridin-2-ylethoxy)phenyl]cyclopropyl}-carbonyl)-3H-spiro[2-benzofuran-1 ,3- pyrrolidin]-3-one; 1'-({1-[4-(2-Pyridin-2-ylethoxy) phenyl]cyclopropy!}carbonyl)-3H-spiro[furo(3 ,4-c]pyridine- 1,3'-pyrrolidin]-3-one; 1'-[(1-{4-[(E)-2-Pyridin-4-ylvinyl]phenyl} cyclopropyl)-carbonyl]-3H-spiro[2-benzofuran- 1,3'-pyrrolidin]-3-one; 1'-({1 -[4-(3,5-Dimethylisoxazol-4-yl)phenyl]cyclopropyl} carbonyl)-3H-spiro[2-benzofuran- } 1,3'-pyrrolidin]-3-one; 1'-({1 [4 1-Methyl-1H-pyrazol-4-yl)phenyljcyclopropyl} carbonyl)-3H-spiro[2-benzofuran- 1,3"-pyrrolidin]-3-one; 1'-({1-[4'-(Methylsulfonyl) biphenyl-4-yl]cyclopropyl}carbonyl)-3H-spiro[2-benzofuran-1 3 pyrrolidin}-3-one; 1'-({1-[4-(3-Methyl-1H-pyrazol-1-yl)phenyl]cyclopropyl} carbonyl)-3H-spiroffuro[3,4- c}pyridine-1,3"-pyrrolidin]-3-one; 1'-[(1-{4-[3-(Trifluoromethyl)-1H-pyrazol-1 -yl]phenyl} cyclopropyl) carbonyl]-3H- spiro[fure[3,4-c]pyridine-1,3'-pyrrolidin]-3-one; 1'-({1-[4-(4-Methyl-1H-pyrazol-1-yl)phenyl]cyclopropy!} carbonyl)-3H-spiro [furo[3,4- c]pyridine-1,3"-pyrrolidin}-3-one; 1'-({1-[4-(2H-Indazol-2-yl)phenyl] cyclopropyl} carbonyl)-3H-spiro[furo [3,4-c]pyridine-1,3- pyrrolidin]-3-one; 1'<({1-[4-(1H-Benzimidazol-1-yl)phenyl]cyclopropyl}carbonyl)-3H-spiro[furo[3,4- c]pyridine-1,3"-pyrrolidin}-3-one; 1'~({1-[4-(2-Methyl-1H-imidazol-1-yl)phenyl]cyclopropyl}carbonyl)-3H-spiro [furo[3,4- c]pyridine-1,3"-pyrrolidin}-3-one; 1'({1-[4-(10-1,2,4-Triazol-1-yl)phenyl]cyclopropyl}carbonyl)-3 H-spiro[2-benzofuran-1,3'- pyrrolidin]-3-one; 1'({1-[4-(1-Hydroxycyclopentyl) phenyljcyclopropyl} carbonyl)-3H-spiro[2-benzofuran-1,3'- pyrrolidin]-3-one; 1'-{[1-(4-Cyclopentylphenyl) cyclopropyl]carbony!} -3H-spiro[furo[3,4-c]pyridine-1,3'- pyrrolidin}-3-one; 1'<({ 1-[4-(1-Hydroxycyclopentyl) phenyl]cyclopropyl}carbony 1)-3H-spiro[furof3,4- c]pyridine-1,3"-pyrrolidin]-3-one; 1'-({1-[4-(1-Hydroxycyclobutyl) phenyl]cyclopropyl}carbonyl)-3H-spiro[2-benzofuran-1,3'- pyrrolidin}-3-one; 1'-({1-{4-(1-Hydroxycyclobuty!) phenyl]cyclopropyl}carbonyl)-3H-spiro[furo[3,4-c]pyridine- 1,3'-pyrrolidin]-3-one;
1'-({1-[4-(Tetrahydro-2H-pyran-4-y Iphenyl]cyclopropyl} carbonyl)-3H-spiro[furo [3.4- c]pyridine-1,3'"-pyrrolidin}-3-one; 1'-{{1-(4-Cyclobutylphenyl) cyclopropy!Jcarbonyl}-3H-spiro[furo[3,4-c]pyridine-1 3 pyrrolidin]-3-one; 1'-({! -[4-(4-Hydroxytetrahydro-2H-pyran-4-yl)phenyl] cyclopropy!}carbonyl)-3H-spiro(2- benzofuran-1,3"-pyrrolidin}-3-one; 1'-({1-[4-(4-Hydroxytetrahydro-2H-pyran-4-yi)phenyl] cyclopropyl} carbonyl)-3H- _ spiro[furo[3,4-c]pyridine-1 ,3'-pyrrolidin]-3-one; 1'-({1-[4-(2-Amino-1,3 -thiazol-4-yl)phenyljcyclopropyl}carbonyl)-3H-spiro[2-benzofuran- - 1,3'-pyrrolidin]-3-one; 1'-({1-[4«(2-Methyl-1 3-thiazol-4-yl)phenyl]cyclopropy|}carbonyl)-3H-spiro[2-benzofuran- 1,3'-pyrrolidin}-3-one; 1'-({1-[4~(2-Ethyl-1 ,3-thiazol-4-yl)phenyl]cyclopropyl} carbonyl)-3H-spiro [2-benzofuran- 1,3'-pyrrolidin}-3-one, 1'-({1-[4«2-Amino-1 ,3-thiazol-4-yl)phenyl]cyclopropyl}carbonyl)-3H-spiro[furo[3,4- ¢]pyridine-1,3'-pyrrolidin]-3-one; 1'-({1-[4-(2-Methyl-1,3-thiazol-4-yl)phenyljcyclopropyl} carbony!)-3H-spiro{furo[3,4- c]pyridine-1,3'-pyrrolidin}-3-one; 1'-({1-[4-(1 ,3-Thiazol-4-yl)phenyl]cyclopropy!}carbonyl)-3H-spiro[2-benzofuran-1,3"- pyrrolidin}-3-one; 4-(1-¢ [1-(4-Chlorophenyl)-3-(methoxymethoxy)cyclobutyl]carbonyl} pyrrolidin-3- yDpyridine; 3-(3-Chloropheny!)-1-{[1-(4-chlorophenyl)-3-(methoxymethoxy} cyclobutyl] carbonyl}pyrrolidine; 1'-{[trans-1-(4-Chlorophenyl)-3-hydroxycyclobutyl]Jcarbonyl} -3H-spiro[2-benzofuran-1,3'- pyrrolidin}-3-one; 1'-{[cis-1-(4-Chlorophenyi)-3-fluorocyclobutyl]carbony!} -3H-spiro[2-benzofuran-1,3'- pyrrolidin}-3-one; 1'-{[cis-1-(4-Chloropheny!)-3-fluorocyciobutyl]carbony!}-3 H-spiro[2-benzofuran-1,3'- pyrrolidine]; 1'-{[cis-1-(4-Chloropheny!)-3-fluorocyclobutyl]carbonyl}-3 H-spiro[furo[3,4-c]pyridine-1,3'- pyrrolidin]-3-one; 1'-{[cis-1-(4-Chlorophenyl)-3-fluorocyclobutyljcarbonyl} -7H-spiro[ furo[3,4-bjpyridine-5,3'"- pyrrolidin]-7-one; 3-(1-{[1-(4-Chlorophenyl)cyclobutyl] carbonyl} pyrrolidin-3-yl)pyridine; I'-{[1-(4-Chlorophenyl)cyclobutyl] carbony!}-7H-spiro[furo[3,4-b]pyridine-5,3"-pyrrolidin}- 7-one;
1'-({1-[4-(1H-Indazol-i-yl)phenyl] cyclobutyl}carbonyl)-3H-spiro[furo [3,4-c)pyridine-1,3'"- pyrrolidin]-3-one; 1'-[(1-{4-[3-(Trifluoromethyl)-1 H-pyrazol-1-yl]pheny!}cyclobutyl) carbonyl}-3H- spiro[furo(3,4-c]pyridine-1 ,3'-pyrrolidin]-3-one; 1'-({1-[4-(1 H-Benzimidazol-1 -ylyphenyljcyclobutyl} carbonyl)-3H-spiroffuro[3,4-c]pyrid ine- 1,3'-pyrrolidin}-3-one; 1'-({1-[4-(2-Ox0-1,3 -oxazolidin-3-yl)phenyl]cyclobuty!}carbonyl)-3 H-spiro{2-benzofuran- 1,3'-pyrrolidin]-3-one; 1'-[(1-Pyridin-4-ylcyclobutyl) carbonyl]-3 H-spiro[2-benzofuran-1,3'-pyrrolidin}-3-one; B 1'-{[1-(4-Pyridin-4-ylphenyl) cyclobutyl]carbonyl}-3H-spiro[2-benzofuran-1,3"-pyrrolidin)-3- one; N,N-Dimethyl-4-[5-(1-{[3-0x0-1'H,3 H-spiro[2-benzofuran-1,3"-pyrrolidin]-1 '-yljcarbonyl} cyclopropyl)pyridin-2-yl]piperazine-1 -carboxamide; 1'-[(1-{6-[4-(Methylsulfonyl) piperazin-1-yl]pyridin-3-yl}cyclopropy!)carbonyl}-3H-spiro[2- benzofuran-1,3'-pyrrolidin]-3-one; 1'-[(1-{6-[4-(2-Fluoropheny!)piperazin-1-yl]pyridin-3 -yl}cyclopropyl)carbonyl]-3H-spiro[2- benzofuran-1,3'-pyrrolidin]-3-one; 1'-({1-[6-(3,3-Difluoropyrrolidin-1-yl)pyridin-3 -yl]cyclopropyl}carbonyl)-3H-spiro[2- benzofuran-1,3'-pyrrolidin]-3-one; 1'-[(1-{6-[3-Hydroxypyrrolidin-1-yl]pyridin-3 -yl}cyclopropyl)carbonyl]-3H-spiro[2- benzofuran-1,3'-pyrrolidin]-3-one; N-{1-[5-(1-{[3-Oxo0-1'H,3H-spiro[2-benzofuran-1 ,3'-pyrrolidin]-1'- yl]carbonyl} cyclopropyl)pyridin-2-yl]pyrrolidin-3-yl} acetamide; 1'-({1-[6-(1 ,3-Dihydro-2H-isoindol-2-yl)pyridin-3-yl]cyclo-propyl} carbonyl)-3H-spiro[2- benzofuran-1,3'-pyrrolidin]-3-one; 1'-({1-[6-(3,4-Dihydro-isoquinolin-2(1 H)-yl)pyridin-3-yl]cyclopropyl}carbonyl)-3H-spiro{2- benzofuran-1,3'-pyrrolidin]-3-one; 1’-{[ 1 (6-Morpholin-4-ylpyridin-3-yl)cyclopropyljcarbonyl}-3 H-spiro[2-benzofuran-1,3°- pyrrolidin]-3-one; 1'-({1-[6-(4-Hydroxypiperidin-1-yl)pyridin-3-yllcyclopropy!} carbonyl)-3H-spiro[2- benzofuran-1,3'-pyrrolidin}-3-one; N-{4-[5-(1-{[3-Oxo-1'H,3H-spirof2-benzofuran-1 ,3-pyrrolidin]-1'- . yl]carbonyl}cyclopropyl)pyridin-2-yl]phenyl} acetamide; 1'-({1-[6-(2-Fluorophenyl) pyridin-3-ylJcyclopropyl} carbonyl)-3H-spiro[2-benzofuran-1,3'- pyrrolidin]-3-one; 1'-({1-[6-(1-Benzothien-3-yl)pyridin-3-yl]cyclopropyl} carbonyl)-3H-spiro[2-benzofuran-1,3"- pyrrolidin]-3-one;
1'-{[1-(2,3"-Bipyridin-S-yl)cyclopropyljcarbonyl }-3H-spiro[2-benzofuran-1,3"-pyrrolidin}-3- one; 1'-({1-[6-(1 -Methyl-1H-indo}-5-yl)pyridine-3-yl]cyclopropy!} carbonyl)-3H-spiro[2- benzofuran-1,3’-pyrrolidin]-3-one; 1°-[(1-{6-[3-(Trifluoromethoxy)phenyl]pyridine-3 -yl}cyclopropyl)carbonyl]-3H-spiro[2- benzofuran-1,3’-pyrrolidin]-3-one; 1°-({ 1-[6-(3-Thienyl)pyridine-3-yljcyclopropyl}carbonyl)-3H-spiro[2-benzofuran-1 3 pyrrolidin]-3-one; 1 »[(1-{6-[3-(Trifluoromethyl)phenyl]pyridine-3-yl}cyclopropyl)carbonyl]-3H-spiro[2- benzofuran-1,3’-pyrrolidin}-3-one; 1’-({1-[6-(1 -Methy!-1H-pyrazol-4-yl)pyridine-3-yl]cyclopropyl}carbonyl)-3 H-spiro[2- benzofuran-1,3’-pyrrolidin]-3-one; 1'-{[1-(6-Chloropyridin-3 -ylcyclopropyl]carbonyl}-3H-spiro[2-benzofuran-1 ,3'-pyrrolidin)- 3-one; 1'({ 1-{6-(Benzyloxy)pyridin-3-yljcyclopropyl}carbonyl)-3H-spiro[2-benzofuran- 1,3"- pyrrolidin]-3-one; 1'-[(1-Quinolin-3 -ylcyclopropyl)carbonyl]-3H-spiro[2-benzofuran-1 ,3'-pyrrolidin}-3-one; 1'-({1-[6-(1-Methy!-1H-pyrazol-4-yl)pyridin-3 -yl]cyclopropyl}carbonyl)-3H-spiro[ furo(3,4- c]pyridine-1,3"-pyrrolidin]-3-one; 1'«({1-[6-(Benzyloxy)pyridin-3-ylJcyclopropyl }carbonyl)-3H-spiro[ uro[3,4-c]pyridine-1,3"- pyrrolidin]-3-one; 1'-{[1-(6-Chloropyridin-3-yl)cyclopropyl)carbonyl}-3H-spiro{furo[3 ,4-c]pyridine-1,3'- pyrrolidin]-3-one; 1'-({1-[6-(3,4-Dihydroisoquinolin-2(1 H)-yl)pyridin-3 -ylleyclopropyl}carbonyl)-3H- spiro[furo[3,4-c]pyridine-1,3'-pyrrolidin]-3-one; 1'-({1-[6-(1 ,3-Dihydro-2H-isoindol-2-yl)pyridin-3-yl]cyclopropy!} carbonyl)-3H- spiro[furo{3,4-c}pyridine-1,3'-pyrrolidin]-3-one; 1'-({1-[6-(3,3-Diflucropyrrolidin-1-yl)pyridin-3-yl]cyclopropyl}carbonyl)-3H-spiro[ furo[ 3,4- ¢]pyridine-1,3'-pyrrolidinj-3-one; Isobutyl 4-(5-{1-[(3-ox0-1'H,3H-spiro[furo[3,4-c]pyridine-1,3"-pyrrolidin]-1'- yl)carbonyl]cyclopropyl} pyridin-2-yi)piperazine-1-carboxylate; 2-[4-(5-{1-[(3-Oxo0-1'H,3H-spiro[furo[3,4-c]pyridine-1,3'-pyrrolidin]-1'- yl)carbonyl]cyclopropyl} pyridin-2-yl)piperazin-1-yl]benzonitrile; 1'-[(1-{6-[4-(4-Fluorophenyl) piperazin-1-yl]pyridin-3-yl}cyclopropyl)carbonyl]-3H- spiro[furo[3,4-c]pyridine-1,3'-pyrrolidin]-3-one; 1'-[(1-{6-[3-(Trifluoromethyl)phenyl] pyridin-3-yl}cyclopropyl)carbonyl]-3H-spiro[furo(3,4- c)pyridine-1,3'-pyrrolidin}-3-one;
1'-[(1-{6-[3-(Trifluoromethoxy) phenyljpyridin-3-yl}cyclopropyl) carbonyl]-3H- spiro[furo[3,4-c]pyridine-1 ,3'-pyrrolidin]-3-one; 4-(5-{1-[(3-Oxo-1 'H,3H-spiro[furo[3,4-c]pyridine-1 ,3"-pyrrolidin}-1'-yl)carbonyl] cyclopropyl} pyridin-2-yl)benzonitrile; 1'-({1-[6-(3 -Chloro-4-fluoropheny!)pyridin-3-yljcyclopropy!} carbonyl)-3H-spiro[furo[3,4- c)pyridine-1,3"-pyrrolidin}-3-one; 1'-[(1-{6-[4-(Methoxymethyl) phenyl]pyridin-3-yl}cyclopropy!) carbonyl}-3H-spiro[furo[3,4- _ ¢]pyridine-1,3"-pyrrolidin]-3-one; N-[3-(5-{1-[(3-Ox0-1 'H,3H-spiro[ furo{3,4-c]pyridine-} ,3'-pyrrolidin}-1'-yl)carbonyl] cyclopropyl} pyridin-2-yl)phenyl]acetamide; and 4-(5-{1-[(3-Oxo-1'H,3H-spiro[furo[3,4-c]pyridine-1 ,3"-pyrrolidin]-1'-yl)carbonyl] cyclopropyl} pyridin-2-yl)benzamide, or pharmaceutically acceptable salt thereof.
28.. A compound of claim | selected from: 1-[(1-{6-[4(Methylsulfonyl)phenyl] pyridin-3-yl}cyclopropyl)carbonyl]-3H-spiro [furo[3,4- c)pyridine-1,3'-pyrrolidin}-3-one; 1-({1-[6-(1-Methyl-1H-indol-5-yl)pyridin-3 -ylJcyclopropyl}carbonyl)-3H-spiro[furo[3,4- c]pyridine-1,3'-pyrrolidin]-3-one; 1-({1-[6-(1-Benzothien-5-yl)pyridin-3 -yllcyclopropyl}carbonyl)-3H-spiro[ furo[3,4- c]pyridine-1,3"-pyrrolidin]-3-one; 1'-{[1-(6-Quinolin-3 -ylpyridin-3-yl)cyclopropyl]carbonyl}-3H-spiro[furo[3,4-c] pyridine-1,3'- pyrrolidin]-3-one; 1'-({1-[6-(3-Thienyl)pyridin-3-yl] cyclopropyl} carbonyl)-3H-spiro[furo[3 ,4-clpyridine-1,3'- pyrrolidin}-3-one; 1'-({1-[4-(2-Oxo0-2,3-dihydro-1H-indol-1-yl)phenyl]cyclopropyl} carbonyl)-3H- spiro[furo[3,4-c]pyridine-1,3'"-pyrrolidin]-3-one; 1'-({1-[4-(3-Methyl-2-0x0-2,3-dihydro-1H-benzimidazol-1-yl)phenyl]cyclopropyl} carbonyl)-3H-spiro[furo{3,4-c]pyridine-1,3"-pyrrolidin}-3-one; 4-{14{(3-Oxo-1"H,3H-spiro[furo[3,4-c]pyridine-1,3'-pyrrolidin]-1 "-yl)carbonyl] cyclopropyl} benzonitrile; 4-{1-[(3-Oxo-1"H,3H-spiro[furo[3,4-c]pyridine-1,3'-pyrrolidin]-1"-yl)carbonyl] cyclopropyl} benzenecarbothioamide; 1'-[(1-{4-[1-(Methylsulfonyl)-1,2,3 ,6-tetrahydropyridin-4-yl}pheny!}cyclopropyl)carbonyl]- 3H-spiro[furo{3,4-c]pyridine-1,3'-pyrrolidin]-3-one; 1'-[(1-{4-[(E)-2-Pyridin-4-ylvinyl] phenyl} cyclopropyl)carbonyl]-3H-spiro[furo[3,4- c]pyridine-1,3'-pyrrolidin}-3-one;
1'-[(1-{4-[Cyclopentyl(fluoro)methyl] phenyl} cyclopropyl)carbonyl}-3H-spiro[furo(3,4- c]pyridine-1,3-pyrrolidin]-3-one; 1'-({1 {4-(Tetrahydro-2H-pyran-4-yloxy)phenyl]cyclopropy!} carbony!)-3H-spiro {furo[3,4- clpyridine-1,3-pyrrolidin}-3-one; tert-Butyl (4-{1-[(3-oxo0-1 'H,3H-spiro[furo[3,4-c]pyridine-1 ,3"-pyrrolidin]-1'-yl)carbonyl] cyclopropyl} phenoxy)acetate; “-{1-[3 -Oxo-1'H,3H-spiro[furo[3,4-c]pyridine-1 ,3"-pyrrolidin]-1'-yl)carbonyl] cyclopropyl} _ phenoxy)acetonitrile; 1-[(1-{4-[(5-Methylisoxazol-3-yl)methoxy]phenyl} cyclopropyl)carbony!]-3H-spiro[furo[3,4- ¢]pyridine-1,3"-pyrrolidin]-3-one; 1'-({1-[4«(Cyclopentylmethoxy) phenyl]cyclopropy!}carbonyl)-3H-spiro [furo[3,4-c]pyridine- 1,3'-pyrrolidin}-3-ong; : 1'<({1-[4«(Quinolin-3-ylmethoxy) phenyl]cyclopropyl} carbony!)-3H-spiro [furo[3,4- ¢]pyridine-1,3'-pyrrolidin]-3-one; 1'-({1-[4Quinolin-4-ylmethoxy) phenyl]cyclopropyl} carbony!)-3H-spiro[furo(3,4- c¢]pyridine-1,3'-pyrrolidin}-3-one; 1'-({1-[4-(Quinolin-6-ylmethoxy) phenyljcyclopropyl} carbonyl)-3H-spiro[furo[3,4- c]pyridine-1,3"-pyrrolidin}-3-one; 1'-( {1-[4-(Pyridin-3-ylmethoxy) phenyl]cyclopropyl}carbonyl)-3H-spiro{furof3,4-c]pyridine- 1,3'-pyrrolidin]-3-one; 6-(Trifluoromethyl)-1'-({1 -[4-(trifluoromethy!)phenyl]cyclopropyl}carbonyl)-3H- spiro furo[3,4-c]pyridine-1,3'-pyrrolidin]-3-one; 1'«({ 1-[4~(Trifluoromethoxy)phenyl] cyclopropyl} carbonyl)-6-(trifluoromethyl)-3H- spiro[furo[3,4-c]pyridine-1,3'-pyrrolidin]-3-one; 1'-{[1-(2,4-Difluorophenyl) cyclopropyljcarbonyl}-6-(triflucromethyl)-3H-spiro[furo(3,4- c]pyridine-1,3"-pyrrolidin]-3-one; 1'-{[1-(1 ,3-Benzothiazol-2-yl)cyclopropyl]carbonyl}-6-(trifluoromethyl)-3 H-spiro[furo[3,4- ¢]pyridine-1,3'-pyrrolidin]-3-one; 1'-{[1-(4-Chlorophenyl)cyclopropyl] carbonyl}-6-(trifluoromethyl)-3H-spiro[furo[3,4- c}pyridine-1,3'-pyrrolidin]-3-one; 4-Fluoro-1'-[(1 -quinolin-4-ylcyclopropyl)carbonyl}-3H-spiro[furo[3,4-c]pyridine-1,3'- pyrrolidin}-3-one; 1"-{[1-(4-Chlorophenyl)cyclopropyl] carbonyl}-4-fluoro-3H-spiro{furo[3 A-clpyridine-1,3'- pyrrolidin]-3-one; 7-Fluoro-1'-[(1-{4-[(trifluoromethyl) thio]phenyl} cyclopropyl)carbonyl]-3H-spiro[furo{3,4- cJpyridine-1,3"-pyrrolidin]-3-one;
1'- ([1-(4-Bromophenyl)cyclopropyl] carbonyl} -7-fluoro-3H-spiroffuro[3,4-c]pyridine-1 3 pyrrolidin]-3-one; 1'-{[1-(1,3-Benzothiazol-2-y Deyclopropylicarbonyl} -3H-spiro[furo{3,4-c]pyridine-1,3'- pyrrolidin]-3-one; r-{t-(l ,3-Benzothiazol-2-yl)cyclopropyl]carbony!} -6-chloro-3H-spiro[furo[3,4-c]pyridine- 1,3'-pyrrolidin]-3-one; 6-Chloro-1'-({1-[4-(trifluoromethoxy) phenyl]cyclopropyl}carbonyl)-3H-spiro[ furof3,4- c]pyridine-1,3'-pyrrolidin]-3-one; 6-Chloro-1'-{[ 1-(2-fluoropheny!) cyclopropyljcarbonyl}-3H-spiro( furo[3 ,A-c]pyridine-1,3'- pyrrolidin}-3-one, 1'-({1-[4-(4-Chlorophenyl)-1,3 -thiazol-2-yl]cyclopropy!} carbonyl)-3H-spiro {furo[3.4- c]pyridine-1,3'-pyrrolidin]-3-one; 4-(1-{[3-Oxo-1'H,3H-spiro[2-benzofuran-1 ,3'-pyrrolidin]-1'-yl]carbonyl} cyclopropyl)benzonitrile; 1'-{[1-(3-(Hydroxymethyl)phenyl) cyclopropyljcarbonyl} -3H-spiro[2-benzofuran-1,3'- pyrrolidin]-3-one; : 1'-{[1-(4-Bromophenyl) cyclopropy!]carbonyl}-3H-spiro[2-benzofuran-1,3 '-pyrrolidin]-3- : one; 1'-({1-[4-(Pyrrolidin-1-ylcarbonyl)phenyljcyclopropy!} carbony!)-3H-spiro[2-benzofuran- 1,3'-pyrrolidin}-3-one; 4-(1-{[3-Oxo-1'H,3H-spiro[2-benzofuran-1,3"-pyrrolidin]-1'-yl]carbonyl} cyclopropyl) benzohydrazide; N-Methyl-4-(1-{[3-oxo-1'H,3H-spiro[2-benzofuran-1,3"-pyrrolidin}-1'- yljcarbony!}cyclopropyl)benzamide; 4-(1-{[3-Oxo-1'H,3H-spiro[2-benzofuran-1,3"-pyrrolidin]-1 ‘.yljcarbony!} cyclopropyl) benzenecarbothioamide; : 1'-[(1-{4-[2-(Trifluoromethyl)-1H-imidazol-4-yl]phenyl} cyclopropyl) carbonyl]-3H-spiro[2- benzofuran-1,3'-pyrrolidin]-3-one; 1'-({1-[4-(1-Methyl-1H-pyrazol-3-yl)phenyl]cyclopropyl} carbonyl)-3H-spiro[2-benzofuran- 1,3'-pyrrolidin}-3-one ; N-Cyclopropyl-4'-(1-{[3-oxo0-1'H,3H-spiro[2-benzofuran-1,3'-pyrrolidin]-1 "-yl]carbonyl} cyclopropyl)biphenyl-4-carboxamide; 1'-[(1-{4-[5-(Trifluoromethyl)-1H-1,2 4-triazol-3-yl)phenyl} cyclopropy!)carbonyl}-3H- spiro[2-benzofuran-1,3"-pyrrolidin]-3-one; : 1'-({1-[4-(1-Methyl-1H-tetrazol-5-yl)phenyl]cyclopropyl} carbonyl)-3H-spiro[2-benzofuran- 1,3'-pyrrolidin}-3-one;
1'-({1-[4-(2-Amino-1 ,3-oxazol-4-yl)phenyl]cyclopropyl}carbonyl)-3 H-spiro[2-benzofuran- 1,3"-pyrrolidin}-3-one; 1'-{[1<(4-Pyrimidin-5-ylphenyl) cyclopropyl]carbonyl}-3H-spiro{2-benzofuran-1 ,3- pyrrolidin]-3-one; 1'-({1 _[4-(6-Fluorapyridin-3-yl)phenyljcyclopropyl}carbonyl)-3H-spiro[2-benzofuran-1 3- pyrrolidin}-3-one; 1'-({1-[4-(6-Pyrrolidin-1 -ylpyridin-3-yl)phenyl]cyclopropyl} carbonyl)-3H-spiro[2- _ benzofuran-1,3'-pyrrolidinj-3-one; : N-Cyclopropyl-5-{4-(1-{[3 -ox0-1'H,3H-spiro[2-benzofuran-1 ,3'-pyrrolidin]-1 "_yl]carbonyl} cyclopropyl)phenyl] pyridine-2-carboxamide; N-Methyl-5-[4-(1-{[3-0x0-] 'H,3H-spiro[2-benzofuran-1 3-pyrrolidin}- 1'-yljcarbonyl} cyclopropyl)phenyl] pyridine-2-carboxamide; 1'-({1-[4-(Methylsulfonyl)pheny!] cyclopropyl} carbonyl)-3H-spiro[2-benzofuran-1,3"- - pyrrolidin]-3-one; 1'-[(1-{4-[(Trifluoromethyl)thio] phenyl} cyclopropyl)carbonyi]-3H-spiro[2-benzofuran-1 ,3- pyrrolidin]-3-one; 1'-{[1-(4-Chloro-2-fluorophenyl) cyclopropyl]carbonyl} -3H-spiro[2-benzofuran-1,3'- pyrrolidin]-3-one; 1'-({ 1-[4-(2-Oxopyridin-1(2H)-yl)phenyljcyclopropyl}carbonyl)-3H-spiro[2-benzofuran-1,3'- pyrrolidin]-3-one; Methyl 4-[4-(1-{[3-ox0-1'H,3H-spiro[2-benzofuran-1 ,3-pyrrolidin]-1'- yl]carbonyl}cyclopropyl)phenyl] piperazine-1 -carboxylate; 1'-[(1- {4-[4-(Methylsulfonyl)-2-oxopiperazin-1-yl] phenyl}cyclopropyl) carbonyl]-3H- spiro[2-benzofuran-1,3'-pyrrolidin]-3-one; 7-Fluoro-1'-[(1- {4-[3-(trifluoromethyl)-1H-pyrazal-1-yl]phenyl} cyclopropyl)carbonyl}-3H- spiro[2-benzofuran-1,3'-pyrrolidin]-3-one; N-[4-(1-{[3-Oxo-1'H,3H-spiro[2-benzofuran-1 ,3"-pyrrolidin}-1'- yl]carbonyl}cyclopropyl)phenyl]cyclopropanecarboxamide; N-[4-(1-{[3-Oxo0-1'H,3H-spiro[2-benzofuran-1 ,3"-pyrrolidin}-1'- yl]carbonyl}cyclopropyl)phenyl]benzenesulfonamide; Methyl] allyl[4-(1-{[3-0x0-1'H,3H-spiro[2-benzofuran-1,3'-pyrrolidin]-1'- yl]carbonyl}cyclopropyl)phenyl] carbamate; 1'-({1-{4-(1H-1,2,4-Triazol-1 -yl)phenyl]cyclopropyl} carbonyl)-3H-spiro[2-benzofuran-1,3'- pyrrolidin]-3-one; 1'-[(1-Quinolin-6-ylcyclopropyl)carbonyl}-3H-spiro[ 2-benzofuran-1,3"-pyrrolidin]-3-one; 1'-[(1-Pyridin-4-ylcyclopropyl) carbonyl]-3H-spiro[2-benzofuran-1,3"-pyrrolidin]-3-one; 1'-[(1-Quinolin-4-ylcyclopropyl) carbonyl]-3H-spiro[2-benzofuran-1,3'-pyrrolidin]-3-one;
1-[(1 -Quinolin-2-ylcyclopropyl)carbonyt]-3H-spiro[2-benzofuran-1 ,3"-pyrrolidin]-3-one¢; 1'-{(1-Pyridin-2-ylcyclopropyl) carbonyl] -3H-spiro[2-benzofuran-1,3"-pyrrol idin]-3-one; 1-{[1-(1,3 -Benzothiazol-2-yl)cyclopropyl]carbonyl}-3H-spiro[2-benzofuran- ,3'-pyrrolidin]-
3-one; 2-(1-{[1-(4-Chlorophenyl)cyclopropyl] carbonyl} pyrrolidine-3-y!)-1,3-thiazole; 1'-{[1-(4-Methylphenyl)cyclopropyl] carbonyl} spiro[pyrido[3,4-d][1 ,3]oxazine-4,3'- pyrrolidin}-2(1H)-one trifluoroacetate; 1-{[1-(4-Chlorophenyl)cyclopropyl] carbonyl} -3-pyridin-4-ylpyrrolidin-3-ol; 1-{[1 -(4-Chlorophenyl)cyclopropyl] carbonyl}-3-(3 fluoropyridin-4-yl)pyrrolidin-3-ol; 1-{[1-(4-Chlorophenyl)cyclopropyl] carbonyl}-3-(2-flucrophenyl) pyrrolidin-3 -ol; 1-{[1-(4-Chlorophenyl)cyclopropy!] carbonyl}-3-[2-(hydroxymethyl) phenyl]pyrrolidin-3-ol; 1-{[1-(4-Chlorophenyl)cyclopropyl] carbonyl} -3 -pyridin-2-ylpyrrolidin-3-ol; 1'-({1-[4-(Pyrrolidin-1 -ylmethylyphenyl]cyclopropyl}carbonyl)-3H-spiro[2-benzofuran- 1,3 pyrrolidin]-3-one; [4-(1-{[3-Oxo-1'H,3H-spiro[2-benzofuran-1 ,3"-pyrrolidin]-1'-yl]carbonyl} cyclopropyl) phenyl] cyclopropyl acetic acid; 6-Chloro-1'<({1-[4-(Trifluoromethyl)phenyl]cyclopropyl} carbonyl)-3H-spiro[furof3,4- . ¢]pyridine-1,3"-pyrrolidin]-3-one; 6-Chloro-1'-{[1-(4-methylphenyl) cyclopropyl]carbonyl}-3H-spirof furo[3,4-c]pyridine-1,3'- pyrrolidin]-3-one; 1'-({1-{4-(3-Thienyl)phenyl] cyclopropyl}carbonyl)-3 H-spiro{2-benzofuran-1,3'-pyrrolidin}- 3-one; 1-{[1(4-Chlorophenyl)cyclopropyl] carbonyl}-3-(1 ,3-thiazol-2-yl)pyrrolidin-3-ol; 1'-{[1-(2-Naphthyl)cyclopropyl] carbonyl}-3H-spiro[furo [3,4-c]pyridine-1,3"-pyrrolidin]-3- one; 1'-({1-[4-(Pyridin-4-ylmethoxy) phenyl]cyclopropy!}carbonyl)-3H-spiro[furo[3,4-c]pyridine- 1,3'-pyrrolidin]-3-one; 2-{[1-(4-Chloropheny!) cyclopropyl]carbonyl}octahydro-1H-isoindole; 1'-{[1-(4-Chlorophenyl)cyclopropyl] carbonyl} spiro[isochromene-3,3'-pyrrolidin}-1(4H)-one; Ne(tert-Butyl)-2-(1-{[1-(4-chlorophenyl)cyclopropyl]carbonyl} -3-hydroxypyrrolidin-3- yl)benzenesulfonamide; 2-[(1-{[1 -{4-Chlorophenyl) cyclopropyl]carbonyl}-3-hydroxypymolidin-3 -y)methyl]nicotinic acid; 1-{[1-(4-Chlorophenyl)cyclopropyl] carbonyl}-3-phenylpyrrolidine-3,4-diol; I'-{[1 -(2-Fluoro-4-pyridin-4-ylphenyl)cyclopropyl]carbonyl}-3H-spiro[2-benzofuran-1,3'- pyrrolidin]-3-one;
5-Methoxy-1'-{[1-(4-methylphenyl) cyclopropy {carbonyl} -3H-spiro{2-benzofuran-1,3'- pyrrolidin]-3-one; I'-{[1-(4-Methylphenyl)cyclopropyl] carbonyl} -3-ox0-3H-spiro[2-benzofuran-1,3"- pyrrolidine]-5-carbonitrile; 1'-({1-[3"-(Hydroxymethyl) biphenyl-4-yl]cyclopropyl}carbonyl)-3H-spiro[2-benzofuran-1,3'- pyrrolidin]-3-one; 1'(§ 1-[2'-(Methylthio)biphenyl-4-yl]cyclopropyl} carbonyi)-3 H-spiro[2-benzofuran-1,3'- pyrrolidin]-3-one; 1-{[1-(1,3 -Benzothiazol-2-yl)cyclopropyl]carbony!}-7H-spiro[furo[3,4-b]pyridine-5,3" pyrrolidin]-7-one; 1°-{[1-(2-Naphthyl)cyclopropyl] carbonyl}-7H-spirof furo{3,4-blpyridine-5,3 >-pyrrolidin}-7- one; 1'-({1-[4-(Difluoromethoxy)phenyl] cyclopropyl} carbonyl)-7H-spiro[furo[3 ,4-b]pyridine- 5,3'-pyrrolidin}-7-one; 1'-{[1-(4-{{4-(Trifluoromethoxy) benzyl]oxy}phenyl)cyclopropyljcarbonyl}-3H- spiro[furo[3,4-c]pyridine-1,3’-pyrrolidin}-3-one; and 17-[(1-{4-[1-(4-Bromopheny!)ethoxy] phenyl} cyclopropyl)carbonyl]-3H-spiro[furo[3,4- c]pyridine-1,3’-pyrrolidin]-3-one, or pharmaceutically acceptable salt thereof.
29, A compound of claim 1 selected from: 1'-{[1 -(4-Pyridin-3-yliphenyl) cyclopropyl]carbonyl}-3H-spiro[furo[3,4-¢] pyridine-1,3"- pyrrolidin]-3-one; [4-(4-{1-[(3-Oxo-1'H,3H-spiro{furo [3,4-c]pyridine-1,3"-pyrrolidin]-1'-yl)carbonyl] cyclopropyl} phenyl)-1,3-thiazol-2-yl]acetonitrile; 1'-({1-[4-(2-Pyridin-3-yl-1,3-thiazol-4-yl)phenyljcyclopropyl} carbonyl)-3H-spiro[furo[3,4- c]pyridine-1,3'-pyrrolidin]-3-one; 1'-({1-[4-(1-Propionyl-1,2,3,6-tetrahydropyridin-4-yl)phenyl]cyclopropyl} carbonyl)-3H- spiro[furo[3,4-c]pyridine-1,3'-pyrrolidin}-3-one; Ethyl 4-{4-(1-{[3-ox0-1'H,3H-spiro[furo[3,4-c]pyridine-1,3'-pyrrolidin]-1"-yl]carbony!} cyclopropyl)phenyl]}-3,6-dihydropyridine-1(2H)-carboxylate; 4-[(E)-2-(4-{1-[(3-Oxo0-1'H,3H-spiro[furo[3,4-c]pyridine-1,3"-pyrrolidin]-1'-yl)carbonyl] cyclopropyl} phenyl)vinyljbenzonitrile; 1'={{1<2-Fluoro-4-pyridin-4-ylphenyl)cyclopropyl]carbonyl}-3H-spiro[furo[3,4-c]pyridine- 1,3'-pyrrolidin]-3-one; 1'-[(1-{2-Fluoro-4-{3-(triflucromethyl)- 1 H-pyrazol-1-yl]phenyl} cyclopropyl)carbonyl}-3H- spiro[furo{3,4-c]pyridine-1,3"-pyrrolidin}-3-one;
1'-({1-[4-(2H-Indazol-2-yl)phenyl] cyclopropy}carbonyl)-3H-spiro {furo(3 ,A-c]pyridine-1,3'- ‘pyrrolidin]-3-one; 1'-({1-[4-(3,3-Difluoropyrrolidin-1 -yl)pheny!]cyclopropy!}carbonyl)-3 H-spiro[furo[3,4- ¢]pyridine-1,3"-pyrrolidin}-3-one; 1'-({1-[2-Fluoro-4-(2-oxopyrrolidin-1 -yl)phenyt]cyclopropyl}carbonyi)-3 H-spiro[furo[3,4- c]pyridine-1,3-pyrrolidin]-3-one; '({1 -[4-(2-Oxopyrrolidin-1-yl)phenyl]cyclopropyl} carbonyl)-3H-spiro[furo[3,4-c]pyridine- 1,3"-pyrrolidin]-3-one; 1'«({1-[4-(2-Ox0-1,3 -oxazolidin-3-yl)phenyl]cyclopropyl } carbonyl)-3H-spiro[furo{3 ,4- c]pyridine-1,3'-pyrrolidin}-3-one; 1'-[(1-{4-[4-Isopropyl-2-oxo-1 ,3-oxazolidin-3-yl]phenyl} cyclopropy!)carbonyl])-3H-spiro olidin}-3-one; 1'-({1-[4-(2-Oxoimidazolidin-1 -yl)phenyl]cyclopropyl} carbonyl)-3 H-spiro[furo[3,4- c]pyridine-1,3"-pyrrolidin}-3-one; 1'-({1-[4-(2-Oxoimidazolidin-1-y l)phenylicyclopropyl!} carbonyl)-3H-spiro[2-benzofuran- 1,3'-pyrrolidin]-3-one; 1'-[(1-{4-[4-Tsopropy}-2-0xo-1,3-0xazolidin-3-y!] phenyl} cyclopropy!)carbony!}-3H-spiro[2- benzofuran-1,3'-pyrrolidin]-3-one; 1'-({1-[2-Fluoro-4-(2-oxopyrrolidin-1-yl)phenyl} cyclopropyl} carbonyl)-3H-spiro[2- benzofuran-1,3'-pyrrolidin]-3-one; 1'-({1-[2-Fluoro-4-(2-oxo-1,3-0xazolidin-3-yl)phenyl] cyclopropyl}carbonyl)-3H-spiro[2- benzofuran-1,3'-pyrrolidin]-3-one; Methyl 3-0x0-4-[4-(1-{[3-0x0-1'H,3H-spiro[2-benzofuran-1,3 ‘-pyrrolidin]-1'-yl]carbony!} cyclopropyl)phenyllpiperazine-1-carboxylate; 1'-[(1-{6-[4-(Cyclopropyl carbonyl)piperazin-1 -yl]pyridin-3-yl}cyclopropyl) carbonyl]-3H- spiro[2-benzofuran-1,3"-pyrrolidin]-3-one; 1'-[(1-{6-[4-(Pyridin-4-yloxy)piperidin-1 -yl]pyridin-3-y1}cyclopropyl)carbonyl]-3H-spiro[2- benzofuran-1,3-pyrrolidin]-3-one; I'{(1 -{6-[3-(Pyridin-4-yloxy)pyrrolidin-1-yl}pyridin-3-yl} cyclopropyl) carbonyl]-3H- spiro{2-benzofuran-1,3"-pyrrolidin}-3-one; 1'-({1-[4-(6-Methoxypyridin-3-yl)phenyl]cyclopropy!}carbonyl)-3H-spiro [2-benzofuran-1,3'- pyrrolidin]-3-one; [4'-(1-{[3-Oxo0-1'H,3H-spiro[2-benzofuran-1,3'-pyrrolidin]-1 "-yl]carbonyl} cyclopropyl)biphenyl-3-yljacetonitrile; 1'-({1-[4-(6-Aminopyridin-3-yl)phenyl]cyclopropyl} carbonyl)-3H-spiro[2-benzofuran-1 3 pyrrolidin]-3-one;
1'-({1 _[4-(6-Hydroxypyridin-3-y )phenyl]cyclopropyl}carbonyl)-3H-spiro[2-benzofuran- 1,3'- pyrrolidin]-3-one; ‘ 1-({1 -[4<(5-Methylpyridin-2-y)phenyl}cyclopropyl }carbonyl)-3H-spiro[2-benzofuran-1 3 pyrrolidin}-3-one; 1'-{(1-{4-[(Pyridin-2-yloxy) methyl]phenyl} cyclopropyl)carbonyl}-3H-spiro[2-benzofuran- 1,3'-pyrrolidin]-3-one; 1*-[(1-{4-[(Pyridin-3-yloxy)methy!]phenyl} cyclopropyl)carbonyl}-3H-spiro[2-benzofuran- 1,3'-pyrrolidin]-3-one; 1'-[(1 -{4-[(Pyridin-4-yloxy)methyl]phenyl} cyclopropyl)carbonyl]-3H-spiro[2-benzofuran- B 1,3'-pyrrolidin}-3-one; 3-(1-{[3-Oxo-1'H,3H-spiro[2-benzofuran-1,3 *-pyrrolidin]-1'-yl]carbonyl} cyclopropyl)benzonitrile; 1'-[(1-Biphenyl-3 -ylcyclopropy!)carbony!]-3H-spiro[2-benzofuran- 1,3'-pyrrolidin]-3-one; 1'-{[1-(1-Naphthyl)cyclopropy!] carbonyl}-3H-spiro[2-benzofuran-1 J3"-pyrrolidin}-3-one; 1'-[(1-Quinolin-6-ylcyclopropyl) carbonyl]-3H-spiro[2-benzofuran-1 ,3-pyrrolidin]-3-one; : 1'-[(1-{4-[(5-Methylisoxazol-3 -yDmethoxy]phenyl} cyclopropyl)carbonyl]-3H-spiro[2- _benzofuran-1,3'-pyrrolidin}-3-one; 1'-({1-[4-(2-Pyridin-3-yl-1,3 -thiazol-4-yl)phenyl]cyclopropyl} carbonyl)-3 H-spiro[2- benzofuran-1,3'-pyrrolidin]-3-one; 1'-[(1-{4-[5-(Trifluoromethyi)-1,3 .4-oxadiazol-2-yl]phenyl} cyclopropyl)carbonyl]-3H- spiro[2-benzofuran-1,3'-pyrrolidin]-3-one; 1'-{[1-(4-tert-Butyl-1,3-thiazol-2-yl)cyclopropyl] carbonyl} -3H-spiro[2-benzofuran-1,3'- pyrrolidin]-3-one; 1'-({1-[4-(4-Chlorophenyl)-1 ,3-thiazol-2-ylJcyclopropyl}carbonyl)-3H-spiro[2-benzofuran- 1,3'-pyrrolidin]-3-one; 1',1"-[1,4-Phenylenebis(cyclopropane-1,1 -diylcarbonyl)]bis(3H-spiro[2-benzofuran-1,3'- pyrrolidin]-3-one); 4-Hydroxy-1'-[(1 -quinolin-4-ylcyclopropyl)carbonyl]-3H-spiro[furo[3,4-c]pyridine-1 3 . pyrrolidin]-3-one; 4-Methoxy-1'[(1-quinolin-4-ylcyclopropyl)carbonyl] -3H-spiro[furo[3,4-c]pyridine-1,3'- pyrrolidin]-3-one; 1'-[(1-Pyridin-3-ylcyclobutyl) carbonyi}-3H-spiro[2-benzofuran-1 ,3-pyrrolidin]-3-one; 1'-{[1-(4-Chlorophenyl)cyclobutyl] carbony1}-3 H-spiro[2-benzofuran-1,3'-pyrrolidin}-3-one; 1'-{[1-(4-Chlorophenyl) cyclobutyl]carbony1}-7 H-spiro[furo[3,4-b]pyridine-5,3"-pyrrolidin]- 7-one; 1-{[1<(4-Chlorophenyl)cyclopropyl] carbony!}-4-phenylpyrrolidin-3-ol; 6-{[1-(4-Chlorophenyl)cyclopropyl] carbonyl}-1 ,3,3-trimethyl-6-azabicyclo[3.2.1]octane;
(1-{[1-(4-Chloropheny?) cyclopropyl]carbonyl} -3-phenylpyrrolidin-2-yl)methanol; (1-{[1-(4-Chlorophenyl) cyclopropyl] carbonyl} -4-phenylpyrrolidin-2-yl)methanol; (1-{[1-(4-Chlorophenyl) cyclopropyljcarbo nyl}-4-phenylpyrrolidin-2-yl)methanol;
1-{[! (4-Chlorophenyl)cyclopropyl] carbonyl}pyrrolidine;
1-{{1 (4-Chlorophenyl)cyclopentyl] carbonyl}azepane;
3-Chloro-N-(1-{[1 ~(4-chlorophenyl)cyclopropyljcarbonyl} pyrrolidin-3-yl)-2-methylbenzene sulfonamide; - 1-{[1-(4-Chlorophenyl) cyclopropyl]carbonyl}-4-phenylpyrrolidine-3-carboxylic acid;
(1-{{1-(4-Chloropheny!) cyclopropyl]carbonyl} -4-phenylpyrrolidin-3 -yl)methanol;
2-[1-{[1 -(4-Chlorophenyl)cyclopropyl] carbonyl}-4-(hydroxymethyl) pyrrolidin-3-yl]phenol; 2-{[1-(4-Chlorophenyl)cyclopropyl} carbonyl}-1,2,3,3a,4,9b-hexahydro chromeno(3,4-
c]pyrrole;
2-{[1-(4-Chlorophenyl)cyclopropyl) carbonyl}-8-(methylsulfonyl)-2,8-diazaspiro[4.5]decane; 8-Acetyl-2-{[1-(4-chlorophenyl) cyclopropyljcarbonyl}-2,8-diazaspiro[4.5]decane; 31-{[1-(4-Chlorophenyl)cyclopropyl] carbonyl} pyrrolidin-3-yl)pyridine; 3-(1-{[1-(4-Phenoxypheny!) cyclopropyl]carbony!} pyrrolidin-3-yl)pyridine; 3-[1-({1-[4-(Cyclopentyloxy)phenyl] cyclopropyl} carbonyl)pyrrolidin-3-yljpyridine; tert-Butyl 4-(5-{1-[(3-pyridin-3-ylpyrrolidin-1-yl)carbonyl] cyclopropyl} pyridine-2-
yl)piperazine-1-carboxylate;
1-{[1-(4-Chlorophenyl)cyclopropyl] carbonyl }-3-isopropylpyrrolidine; Methyl 3-(1-{[1-(4-chlorophenyl) cyciopropyljcarbonyl} pyrrolidin-3-yl)benzoate; 1-{[1-(4-Chlorophenyl)cyclopropyl] carbonyl} -3-(2-methylphenyl) pyrrolidine; 1-{[1-(4-Chloropheny!)cyclopropyl] carbonyl}-3-(2 -methoxyphenyl) pyrrolidine; 1-{[1-(4-Chloropheny!)cyclopropyl] carbonyl} -3-(2,6-dimethylphenyl) pyrrolidine;
; 1-(4-{1-[(3-Pyridin-4-ylpyrrolidin-1-yl)carbonyl]cyclopropyl} phenyl)pyrrolidin-2-one; 3-(4-{1-[(3-Pyridin-4-ylpyrrolidin-1-yl)carbonyl]cyclopropy!} phenyl)-1 ,3-oxazolidin-2-one; 4-{1-[(3-Pyridin-4-ylpyrrolidin-1 -yDcarbonyl]cyclopropyl} phenol; 4-[1-({1-[4-(Benzyloxy)phenyl] cyclopropyl} carbony)pyrrolidin-3-yl]pyridine; 4-[1-({1-[4-(Allyloxy)phenyl] cyclopropyl} carbonyl)pyrrolidin-3-yljpyridine; 4-[1«{1-[4-(Pyridin-4-yloxy)phenyl] cyclopropyl }carbony!)pyrrolidin-3-yl]pyridine; 4-{14({1-[4-(3-Furyloxy)phenyl]cyclopropyl} carbonyl)pyrrolidin-3 -yl)pyridine; 4-[1({1-[4-(Cyclopentyloxy)phenyl] cyclopropyl}carbonyl) pyrrolidine-3-yl]pyridine; 4-[1({1-[4-(Cyclohex-2-en-1-yloxy)phenyl]jcyclopropyl} carbonyl) pyrrolidine-3-yl]pyridine;
3-[(4-{1-[(3-Pyridin-4-ylpyrrolidin-1-yl)carbonyl]cyclopropyl} phenoxy) methyl]pyridine; 2-[(4-{1-[(3-Pyridin-4-ylpyrrolidin-1-yl)carbonyl]cyclopropyl} phenoxy) methyl]pyridine; 4-[2-(4-{1 -[(3-Pyridin-4-ylpyrrolidin-1 -yl)carbonyl]cyclopropyl} phenoxy) ethyljmorpholine; 4-(1-{[1-(4-Chlorophenyl) cyclopropyl]carbonyl} pyrrolidin-3-yl)pyridine 1-oxide;
4-(1-{{1 -(4-Chlorophenyl)cyclopropyl] carbonyl} pyrrolidin-3-yl)-3-fluoropyridine; 1-{[1-(4-Chlorophenyl)cyclopropy! carbonyl} -3-isopropylpyrrolidin-3-ol; 3-tert-Butyl-1- {[1-(4-chlorophenyl) cyclopropyljcarbonyl} pyrrolidine-3-ol; 1-{[1-(4-Chlorophenyl)cyclopropyl} carbonyl}-3-(2-methylphenyl) pyrrolidin-3-o}; Methyl [(1-{[1«4-chlorophenyl) cyclopropyl]carbonyl}-3-phenylpyrrolidin-3-yljoxyJacetate; [{(1-{[1-(4-Chlorophenyl)cyclopropyl] carbonyl}-3-phenylpyrrolidin-3-yloxyJacetic acid; 1-{[1{4-Chlorophenyl)cyclopropyl] carbonyl}-3-(3 -chloropyridin-4-yl)pyrrolidine-3-ol; - 1’-{[1-(4-Chlorophenyl)cyciopropyl] carbonyl} spiro[pyrido[3,4-d][1,3]oxazine-4,3’- pyrrolidin]-2(1H)-one trifluoroacetate; 1'-{[1-(2,4-Dichlorophenyl) cyclopropy!icarbonyl} spiro[pyrido([3,4-d][1,3)oxazine-4,3'- pyrrolidin)-2(1H)-one trifluoroacetate; 1'-{[1<(4-Bromophenyl)cyclopropyl] carbonyl} spiro[pyrido[3.4-d][1,3]oxazine-4,3"- pyrrolidin]-2(1 H)-one trifluoroacetate; 1'-{[1-(4-Methoxyphenyl)cyclopropyl] carbonyl} spiro[pyrido[3,4-d][1,3)oxazine-4,3'- pyrrolidin]-2(1H)-one trifluoroacetate; 1'-{[1-(4-Phenoxyphenyl)cyclopropyl] carbonyl} spiro[pyrido[3,4-d][1,3]oxazine-4,3’- pyrrolidin}-2(1 H)-one trifluoroacetate; . . 1'“[(1-{4-[(Trifluoromethyl)thio] phenyl}cyclopropyl)carbonyl]spiro[pyrido[3,4- d][1,3]oxazine-4,3’-pyrrolidin]-2(1H)-one trifluoroacetate; 1'-{[1-(3-Bromophenyl)cyclopropyl] carbonyl} spiro[pyrido[3,4-d][1,3Joxazine-4,3'- pyrrolidin]-2(1H)-one trifluoroacetate; 1'-{[1-(3-Methoxyphenyl)cyclopropyl] carbonyl} spiro[pyrido[3,4-d}{1,3Joxazine-4,3'- pyrrolidin]-2(1H)-one trifluoroacetate; 1'-{[1-(6-Chloropyridin-3 -yD)cyclopropyl]carbony!}-7H-spiro[furo[3,4-b] pyridine-5,3'- pyrrolidin]-7-one; 1'-{[1-(4-Methylphenyl)cyclopropyl] carbonyl} -7H-spiro[furo[3,4-b]pyridine-5,3’- pyrrolidin}-7-one; and 1'-({1-[4-(Trifluoromethyl)phenyl] cyclopropyl} carbony!)-7H-spiro[furo[3,4-b]pyridine-5,3'- pyrrolidin]-7-one, or pharmaceutically acceptable salt thereof.
30. A compound of claim 1 selected from: 1'-{[1-(4-Methoxyphenyl)cyclopropyl] carbonyl }-7H-spiro[furo[3,4-b]pyridine-5,3’- pyrrolidin]-7-one; 1°-({1-[4-(Trifluoromethoxy)pheny!] cyclopropyl} carbonyl)-7H-spiro[furo[3,4-b]pyridine- 5,3’-pyrrolidin]-7-one; 1'-{[1-(4-Fluorophenyl)cyclopropyl] carbonyl}-7H-spiro[furo[3,4-b] pyridine-5,3'-pyrrolidin]- 7-one;
1-{[1 {(2-Chloro-4-fluoropheny}) cyclopropyl]carbonyl}-7H-spirof furo[3,4-b]pyridine-5,3"- pyrrolidin]-7-one; 1'-{[1+(2,4-Difluorophenyl) cyclopropyljcarbonyl}-7H-spiro[furo[3,4-b]pyridine-5,3"- pyrrolidin]-7-one; 1'-{{1-(3-Chlorophenyl)cyclopropy!] carbonyl}-7H-spiro[furo[3,4-b]pyridine-5,3’- pyrrolidin]-7-one; 1'-{[1-(3,4-Dichloropheny!) cyclopropyl]carbonyl}-7H-spiro[furo[3,4-b]pyridine-5,3"- pyrrolidin]-7-one; 1'-{[1-(2,3-Difluorophenyl) cyclopropyllcarbonyl}-7H-spiro{furo(3 ,A-blpyridine-5,3"- pyrrolidin]-7-one; 1'-{[1-(2,4-Dichlorophenyl) cyclopropyl]carbonyl}-7H-spiroffuro[3,4-b]pyridine-5,3"- pyrrolidin}-7-one; ) Ethyl 4-[5-(1-{[3-0x0-1 'H,3H-spiro[2-benzofuran-1,3-pyrrolidin]-1'- yl]carbonyl}cyclopropyl)pyridin-2-yl]piperazine-1-carboxylate; 1'-[(1-{6-[4-(ethylsulfonyl) piperazin-1 -yl]pyridin-3-yl} cyclopropylcarbonyl]-3H-spiro[2- benzofuran-1,3'-pyrrolidin}-3-one; 1'-({1-[6-(4-Methylpiperazin-1 -yl)pyridin-3-yl]cyclopropyl}carbonyl)-3H-spiro[2- benzofuran-1,3'-pyrrolidin}-3-one; 1'-({1-[6-(4-Pheny!piperazin-1-yl)pyridin-3 -yl]cyclopropyl} carbonyl)-3H-spiro[2- benzofuran-1,3'-pyrrolidin]-3-one; 1'-[(1-{6-[4~(3-Methylbutanoyl) piperazin-1 -ylpyridin-3-yl} cyclopropylcarbonyl]-3H- spiro[2-benzofuran-1,3'-pyrrolidin]-3-one; 1'-[(1-{6-[4-(Cyclopropylmethyl) piperazin-1 -ylJpyridin-3-yl} cyclopropyl)carbonyl]-3H- spiro[2-benzofuran-1,3"-pyrrolidin]-3-one; 1'-({1-[6-(2,5-Dihydro-1H-pyrrol-1-yl)pyridin-3-yljcyclopropyl} carbonyl)-3H-spiro[2- benzofuran-1,3'-pyrrolidin}-3-one; 1'-{[1«(6-Piperidin-1-ylpyridin-3-yl)cyclopropyl]carbonyl}-3 H-spiro[2-benzofuran-1,3'- pyrrolidin}-3-one; 1'-({1-[4-(4-Methyl-2-oxopiperazin-1-yl)phenyl]cyclopropyl} carbonyl)-3 H-spiro[2- benzofuran-1,3'-pyrrolidin]-3-one; : 1'-({1-[4-(4-Acety]-2-oxo-piperazin-1-yl)phenyl]cyclopropy!} carbonyl)-3H-spiro[2- benzofuran-1,3’-pyrrolidin]-3-one; tert-Butyl 4-[4-(1-{[3-ox0-1'H,3H-spiro[2-benzofuran-1,3'-pyrrolidin]-1 *-yl]Jcarbonyl} cyclopropyl)phenyl]piperazine-1-carboxylate; 1'-({1-{4-(4-Isobutyrylpiperazin-1-yl)phenyl]cyclopropyl}carbonyl)-3H-spiro [2-benzofuran- 1,3"-pyrrolidin]-3-one;
1'-[(1-{4-[4-(Cyclopropyl carbonyl)piperazin-1-yljphenyl} cyclopropyl)carbonyl}-3H- spiro[2-benzofuran-1 ,3'-pyrrolidin]-3-one; 1'-[(1-{4-[4-(Methylsulfonyl) piperazin-1 -yl}phenyl}cyclopropyl carbonyl}-3H-spiro[2- benzofuran-1,3"-pyrrolidin}-3-one; 1'-({1-[4-(4-Methylpiperazin-1 -yl)phenyl]cyclopropyl}carbonyl)-3 H-spiro[2-benzofuran-1,3'- pyrrolidin}-3-one; N-Methyl-N-{4-(1-{[3-oxo0-1 'H,3H-spiro[2-benzofuran-1,3'-pyrrolidin]-1 '-yl]carbonyl} cyclopropy [)phenyl]cyclopropanecarboxamide; N-[4-(1-{[3-Oxo-1'H,3H-spiro[2-benzofuran-1 3-pyrrolidin]- 1'-yijcarbonyl} cyclopropyl) phenyl]acetamide; 1-({1-[4-(2-Oxopyrrolidin-1 -yl)phenyl]cyclopropyl} carbonyl)-3H-spiro[2-benzofuran-1 ,3'- pyrrolidin]-3-one; 1-({1-[4-(2-Ox0-1,3-0oxazolidin-3 -yl)phenyl]cyclopropyl} carbonyl)-3H-spiro[2-benzofuran- 1,3'-pyrrolidin}-3-one; 1'-({1-{4-(1H-Pyrazol-1-yl) phenyl]cyclopropyl} carbonyl)-3H-spiro[2-benzofuran-1,3" pyrrolidin]-3-one; 1'-({1-[4«2-Oxopiperidin-1-yl)phenyl]cyclopropy!} carbonyl)-3H-spiro[2-benzofuran-1,3'- pyrrolidin]-3-one; 1-Methyl-3-[4-(1-{[3-oxo0-1'H,3H-spiro[2-benzofuran-1,3'-pyrrolidin]-1'- } yl]carbonyl}cyclopropyl)phenyl] imidazolidine-2,4-dione; 1'-{[1-(4-Morpholin-4-ylphenyl)cyclopropyl]carbonyl}-3H-spiro[2-benzofuran-1,3'- pyrrolidin]-3-one; 1-[4-(1-{[3-Phenylpyrrolidin-1-yl]jcarbonyl} cyclopropyl)phenyl] pyrrolidine-2-one; * 3-[4-(1-{[3-Phenylpyrrolidin-1-yl]carbonyl}cyclopropyl)phenyl]-1 ,3-oxazolidin-2-one; Methyl 4-(4-{1-[(3-phenylpyrrolidin-1-yl)carbonyl]cyclopropyl} phenyl)piperazine-1- carboxylate; Ethyl 4-(4-{1-[(3-phenylpyrrolidin-1 -yl)carbonyl]cyclopropyl} phenyl)piperazine-1- carboxylate; 1-Isobutyryl-4-(4-{1-[(3-phenylpyrrolidin-1-yl)carbonyl] cyclopropyl} phenyl)piperazine; 1-Acetyl-4-(4- {1-{(3-phenylpyrrolidin-1-yl)carbonyijcyclopropy!} phenyl) piperazine; 1-(Cyclopropylcarbonyl)-4-(4-{1-{(3-phenylpyrrolidin-1-yl)carbonyl] cyclopropyl} phenyl)piperazine; 1-Isobutyryl-4-(5-{1-[(3-phenylpyrrolidin-1-yl)carbonyl] cyclopropyl} pyridin-2- yl)piperazine; 1-(Cyclopropylcarbonyl)-4-(5-{1-[(3-phenylpyrrolidin-1-yl)carbonyl]cyclopropyl} pyridin-2- yl)piperazine; 1'-{(1-Pyridin-3-ylcyclopropyl) carbonyl]-3H-spiro[2-benzofuran-1,3'-pyrrolidin}-3-one;
N-Methyl-4-[5-(1-{{3-oxo0-1'H,3H-spiro[2-benzofuran-1 ,3-pyrrolidin]-1'-yl]carbonyl} cyclopropyl)pyridin-2-yl]benzamide; N,N-Dimethyl-4-[5-(1-{[3-0x0-1'H,3H-spiro[2-benzofuran-1 3'-pyrrolidin]-1'-yl]carbonyl} cyclopropyl)pyridin-2-yl]benzamide; 1"-[(1-{6-[4-(Methylsulfonyl) phenyl}pyridin-3-yl} cyclopropyl) carbonyl]-3H-spiro[2- benzofuran-1,3'-pyrrolidin]-3-one; 1'-{[1-4-Methoxyphenyl) cyclopropyl]carbonyl} -3H-spiro[2-benzofuran-1,3"-pyrrolidin}-3- one; 1'-({1-{4-(Pyridin-2-yloxy)phenyl] cyclopropyl }carbonyl)-3H-spiro[2-benzofuran-1 3 pyrrolidin}-3-one; 1 ( {1-[4-(Pyridin-3-ylmethoxy) phenyl]cyclopropyl} carbonyl)-3H-spiro[2-benzofuran-1,3'- pyrrolidin]-3-one; 1'-({1-[4-(Isoquinolin-] -ylmethoxy)phenyl]cyclopropyl}carbonyl)-3H-spiro[2-benzofuran- 1,3'-pyrrolidin]-3-one; 1'-{[1-(4-Vinylpheny!) cyclopropyl]carbony!}-3 H-spiro[2-benzofuran-1 ,3'-pyrrolidin}-3-one; Methyl 4-[4-(1-{[3-0x0-1"H,3H-spiro[2-benzofuran-1,3'-pyrrolidin]-1 ‘-yl]carbonyl} cyclopropyl)phenyl]-3,6-dihydropyridine-1(2H)-carboxy late; Ethyl 4-[4-(1-{[3-0x0-1'H,3H-spiro[2-benzofuran-1,3"-pyrrolidin]-1 *-yl]carbonyl} cyclopropyl)phenyl}-3,6-dihydropyridine-1(2H)-carboxylate; 1'-({1-[4-(1-Acetyl-1,2,3 6-tetrahydropyridin-4-yl)phenyl] cyclopropyl} carbonyl)-3H- spiro[2-benzofuran-1,3"-pyrrolidin]-3-one; 1'-[(1-{4-[1-(3-Methylbutanoyl)-1,2,3,6-tetrahydropyridin-4- yl)phenyl} cyclopropyl)carbonyl]-3H-spiro{2-benzofuran-1,3'-pyrrolidin}-3-one; 5-Hydroxy-1'-{[1-(4-methylphenyl) cyclopropyljcarbonyl}-3H-spiro[2-benzofuran-1,3'- pyrrolidin}-3-one; 1'-{[1-(4-Methylphenyl)cyclopropyl]carbony!}-3H-spiro[2-benzofuran-1,3'-pyrrol idin}-5-0l; 1'|({1-[4-(Pyrrolidin-1-ylmethyl)phenyl]cyclopropyl} carbonyl)-3H-spiro[2-benzofuran-1,3'- pyrrolidin]-3-one; . 1'-{[1-(6-Pyrrolidin-1-ylpyridin-3-yl)cyclopropy!]carbony1}-3H-spiro[ furo[3,4-c]pyridine- 1,3'-pyrrolidin]-3-one; 1'<({1-[6-(4-Phenylpiperazin-1-yl)pyridin-3-yl]cyclopropyl} carbonyl)-3H-spiro{ furo[3,4- c]pyridine-1,3'-pyrrolidin]-3-one; Methyl 4-[5-(1-{[3-0x0-1'H,3H-spiro{furo[3,4-c]pyridine-1,3"-pyrrolidin}]-1'- ylJcarbonyl}cyclopropyl)pyridin-2-yl]piperazine-1-carboxylate ; Ethyl 4-(5-{1-[(3-0x0-1'H,3H-spiro[furo[3,4-c]pyridine-1,3'-pyrrolidin]-1'-yl)carbonyl] cyclopropyl} pyridin-2-yl)piperazine-1-carboxylate;
Isopropyl 4-(5-{1-{(3-0x0-1'"H,3H-spiro[furo[3,4-c]pyridine-1,3"-pyrrolidin]-1'-yl)carbonyl] cyclopropyl} pyridin-2-yl)piperazine-1-carboxylate; 1'-({1-[6-(4-Chlorophenyl)pyridin-3-yl]cyclopropyl} carbonyl)-3H-spiro {furo[3,4-c]pyridine- 1 ,3'-pyrrolidin]-3-one; 1'-({1 -[6-(4-Fluorophenyl)pyridin-3-yl]cyclopropyl}carbonyl)-3H-spiroffuro([3 ,4-c]pyridine- 1,3'-pyrrolidin}-3-one; 1'-({1-[6-(4-Fluoro-2-methylphenyl)pyridin-3-yl] cyclopropy!}carbonyl)-3 H-spiro[ furof3,4- : c]pyridine-1,3'-pyrrolidin]-3-one; 1'-[(1-Quinolin-4-ylcyclopropyl) carbonyl}-3H-spiro[furo[3,4-c]pyridine-1,3'-pyrrolidin}-3- B one; 4-Chloro-1'-[{1 -quinolin-4-ylcyclopropyl)carbonyl}-3H-spiro[ furo (3,4-c]pyridine-1,3'- pyrrolidin]-3-one; 4-Hydroxy-1'-[(1-quinolin-4-ylcyclopropyl)carbonyl]-3H-spiro[furo[3,4-c] pyridine-1,3'- pyrrolidin]-3-one; 4-Methoxy-1'-[(1-quinolin-4-yicyclopropyl)carbonyl]-3H-s piro[ furo[3,4-c]pyridine-1,3'- pyrrolidin}-3-one; 1'-[(1-{4-[(4-Fluorobenzyl)oxy]phenyl} cyclopropyl)carbonyl]-3H-spiroffuro [3,4-c]pyridine- 1,3'"-pyrrolidin}-3-one; 1'-{[1-(4-{[4(Trifluoromethyl)benzyl] oxy} phenyl)cyclopropyl]carbonyl}-3 H-spiro|furo{3,4- c]pyridine-1,3"-pyrrolidin]-3-one; 1'4{(1-{4-[(2-Chioro-4-fluorobenzyl) oxy]phenyl} cyclopropyl)carbonyl}-3H-spiro[furo[3,4- c]pyridine-1,3"-pyrrolidin]-3-one; 1'-[(1-{4-[(4-Bromo-2-fluorobenzyl) oxy|phenyl}cyclopropyl)carbonyl}-3H-spiro[furo[3,4- c]pyridine-1,3'-pyrrolidin}-3-one; 3-Fluoro-4-[(4-{ 1 -[(3-0x0-1H,3H-spiro[furo[3,4-c]pyridine-1 ,3'-pyrrolidin]-1'-yl)carbonyl] cyclopropyl} phenoxy)methyl]benzonitrile; 1-[(1-{4-[1«2-Fluorophenyl)ethoxy] phenyl} cyclopropyl)carbonyl]-3H-spiro[furo[3,4- c]pyridine-1,3"-pyrrolidin}-3-one; 4-[1-(4-{1-[(3-Oxo-1'H,3H-spiro[furo[3,4-c]pyridine-1 ,3'-pyrrolidin]-1'-yl)carbenyljcyclo- propyl} phenoxy)ethyljbenzonitrile; 1'«({1-[4-(Quinolin-2-ylmethoxy) phenyl]cyclopropyl} carbony )-3H-spiroffuro[3,4- c]pyridine-1,3"-pyrrolidin]-3-one; 1'-{[1-(4-Methoxyphenyl)cyclopropyl] carbonyl}-3H-spiro[furo[3,4-c] pyridine-1,3'- pyrrolidin]-3-one; 6-Chloro-1'-{[1-(4-methoxyphenyl) cyclopropyl]carbonyl}-3H-spiro[furo{3,4-c]pyridine-1,3'"- pyrrolidin}-3-one;
1'-{[1 -(4-Methoxyphenylycyclopropyl] carbonyl}-6-(trifluoromethyl)-3H-spiro{furo[3,4- c]pyridine-1,3"-pyrrolidin}-3-one; 1'-({1-[4-(Cyclopentyloxy)phenyl] cyclopropyl}carbonyl)-3H-spiro [furo[3,4-c]pyridine-1,3'- pyrrolidin]-3-one; 1'-({1-[4-(Allyloxy)phenyl]cyclo-propyl} carbonyl)-3H-spiro[ furo[3,4-c] pyridine-1,3'- pyrrolidin]-3-oney 1'({1-[4-(2-Methoxyethoxy)phenyl] cyclopropyl} carbonyl)-3H-spiro[furo[3,4-c]pyridine- . 1,3"-pyrrolidin]-3-one; 1'({1-[4-(Cyclopropylmethoxy) phenyljcyclopropyi}carbonyl)-3H-spiro[furo[3,4-c]pyridine- 1,3'-pyrrolidin}-3-one; 1'-{[1-(4-Methylpheny cyclopropyl] carbonyl} -6-(trifluoromethyl)-3H-spiro[furo(3,4- c]pyridine-1,3'-pyrrolidin]-3-one; 1'-{[1-(4-Methylphenyt)cyclopropyl] carbonyl}-3H-spiro[furo[3,4-c]pyridine-1,3'- pyrrolidin]-3-one; 1'-({1-[4-(Triflucromethyl)pheny!] cyclopropyl}carbonyl)-3H-spiro[furo[3,4-c]pyridine-1,3'- pyrrolidin]-3-one; 1'-{[1-(4-Vinylphenyl)cyclopropyl] carbony!}-3H-spiro[ furo[3,4-c]pyridine-1 ,3'-pyrrolidin]- 3-one; 1'-[(1-{4-[(E)-2-Pyridin-2-ylvinyl] phenyl}cyclopropyl)carbonyl}-3H-spirof furo[3,4- ¢]pyridine-1,3'-pyrrolidin]-3-one; 1'-({1-[4-(1-Isobutyryl-1,2,3 6-tetrahydropyridin-4-yl)phenyl] cyclopropyl} carbonyl)-3H- spiro[furo[3,4-c]pyridine-1,3"-pyrrolidin}-3-one; 1'({1-[4-(1-Acetylpiperidin-4-y1) phcnyl]cyclopropyi} carbonyl)-3H-spiroffuro{3,4- c]pyridine-1,3'-pyrrolidin]-3-one; Ethyl 4-(4-{1 -[G -oxo0-1'H,3H-spiro[furo[3,4-c]pyridine-1,3"-pyrrolidin]-1 ‘.ybhcarbonyl] cyclopropyl} phenyl)piperidine-1-carboxylate; 1-({1 -[4-(1-Isobutyrylpiperidin-4-yl)pheny!]Jcyclopropyl}carbonyl)-3H-spiro[ furo[3,4- ¢]pyridine-1,3"-pyrrolidin]-3-one; 1'-({1 -[4-(1-Propionylpiperidin-4-yl)phenyl]cyclopropyl} carbonyl)-3H-spiro[furo(3,4- c]pyridine-1,3'-pyrrolidinj-3-one; 1-[(1-{4-[1-(3-Methylbutanoyl) piperidin-4-yl]phenyl} cyclopropyl) carbonyl]-3H- spiro[furo[3,4-c]pyridine-1,3"-pyrrolidin]-3-one; 1'-({1-[4-(2-Isopropyl-1 ,3-thiazol-4-yl)phenyljcyclopropyl} carbonyl)-3H-spiro[furo{3,4- c]pyridine-1,3'-pyrrolidin]-3-one; 1'-[(1-{4-[2-(Dimethylamino)-1 ,3-thiazol-4-y{}phenyl} cyclopropyl) carbonyl]-3H- spiro[furo[3,4-c]pyridine-1,3'-pyrrolidin]-3-one;
1’-({1-[4-(2-Amino-1,3-thiazol-4-yl)phenyl]cyclopropyl}carbonyl)-3H-spiro[ furo[3,4- c]pyridine-1,3’-pyrrolidin]-3-one; 3-Fluoro-4-{1-[(3-0x0-1'H,3H-spiro[furo[3,4-¢]pyridine-1,3'-pyrrolidin}-1'-yl)carbonyl]cyclo- propyl}benzonitrile; : 1'«({1-[2-Fluoro-4-(4-methyl-1,3-thiazol-2-y)phenyl}cyclopropyl} carbonyl)-3H- spiro[furo[3,4-c]pyridine-1,3"-pyrrolidin]-3-one; and 1'-[(1-{4-[5-(Triflucromethyi)-1,3,4-oxadiazol-2-yl]phenyl} cyclo-propyl)carbonyl]-3H- _ spiro[furo[3,4-clpyridine-1,3'-pyrrolidin]-3-one, or pharmaceutically acceptable salt thereof. _
31. A compound of claim 1 selected from: 1'-({1-[4-(3-Methylisoxazol-4-yl)phenyl}cyclopropyl}carbonyl)-3H-spiro[ furo[3,4- ¢]pyridine-1,3'-pyrrolidin]-3-one; 1'<({1-[4<2-Pyridin-2-ylethyl) phenyl]cyclopropyl}carbonyl)-3H-spiro[furo[3,4-c]pyridine- 1,3'-pyrrolidin]-3-one; 1'-({1-[2-Fluoro-4-(1H-pyrazol-1-yl)phenyl]cyclopropyl} carbonyl)-3 H-spiroffurof3,4- c]pyridine-1,3"-pyrrolidin]-3-one; 1'-({1-[2-Fluoro-4-(3-methyl-1H-pyrazol-1-yl)phenyl]cyclopropyl} carbonyl)-3H- spiro[furo[3,4-c]pyridine-1,3"-pyrrolidin]-3-one; 1'-({1-[4-(3-Amino-1H-pyrazol-1 -yl)phenyl]cyclopropyl}carbonyl)-3H-spiro[furo[3,4- c]pyridine-1,3"-pyrrolidin]-3-one; 1'-({1-[4-(1H-Benzimidazol-1-y I)-2-fluorophenyli]cyclopropyl}carbonyl)-3H-spiro [furo[3,4- c]pyridine-1,3'-pyrrolidin]-3-one; 1'-[(1-{2-Fluoro-4-[2-(trifluoro-methyl)-1H-benzimidazol-1- yi] phenyl}cyclopropyl)carbonyl]-3H-spiro[furo[3,4-c}pyridine- 1,3'-pyrrolidin]-3-one; 1'-({1-[4-(2-Methoxy-1H-benzimidazol-1-yl)phenyl} cyclopropyl}carbonyl)-3H- spiro[furo(3,4-c]pyridine-1,3'-pyrrolidin]-3-one; Ethyl 4-(4-{1-[(3-oxo-1"H,3H-spiro{furo{3,4-c]pyridine-1,3 pyrrolidin]-1 "-yhcarbonyl]cyclo- propy!} phenyl)piperazine-1-carboxylate; Isopropyl 4-[4-(1-{[3-ox0-1'H,3H-spiro{furo[3,4-c]pyridine- 1 ,3-pyrrolidin]-1'- yl]carbonyl}cyclo-propyl)phenyl]piperazine-1 -carboxylate; 1'-({1-[4-(4-Propionylpiperazin-1-yl)phenyI] cyclopropyl} carbonyl)-3H-spiro[furo{3,4- ¢]pyridine-1,3"-pyrrolidin}-3-one; 1'({1 -[4-(4-Isobutyrylpiperazin-1-yl)phenyl]cyclopropy!}carbonyl)-3H-spiro[furo[3,4- c]pyridine-1,3'-pyrrolidin]-3-one; 1'-[(1-{4-[4-(Cyclopropy! carbonyl)piperazin-1-ylJphenyl} cyclopropyl)carbonyl]-3H- spiro[furo[3,4-c]pyridine-1,3'-pyrrolidin]-3-one;
1'-[(1-{4-[4-(Methylsulfony!) piperazin-1-yl]phenyl}cyclopropyl) carbonyl]-3H- spiro[furo[3,4-c]pyridine-1,3'-pyrrolidin}-3-one; 1'-({1-[4-(2-Oxopyridin-1 (2H)-yl)phenyl]cyclopropy!}carbonyl)-3H-spiro[furo[3,4- ¢]pyridine-1,3"-pyrrolidin]-3-one; Methyl [{4-(1-{[3-0x0-1"H,3H-spiro[furo[3,4-c]pyridine-1 ,3'-pyrrolidin}-1"-ylJcarbonyl}cyclo- propyl)phenyljcarbamate; N-[4-(1-{[3-Ox0-1'H,3 H-spiro[furo[3,4-c]pyridine-1,3"-pyrrolidin}-1 ‘-yl}carbonyl}cyclo- propyl)phenyl]methanesulfonamide; 1'-{[1-(2-Fluorophenyl)cyclo-propy [Jcarbonyl}-3H-spiro[furo[3,4-c]pyridine-1,3'-pyrrolidin]- 3-one; 1'-{[1-(2-Chlorophenyl)cyclopropyl] carbonyl}-3H-spiro[furo[3,4-c]pyridine-1 ,3'-pyrrolidin]- 3-one; 1'-{[1-(2-Bromophenyl)cyclopropyl] carbonyl} -3H-spiro[furo[3,4-c]pyridine-1,3"-pyrrolidin]- 3-one; 1'«({1-[2-(Trifluoromethyl)phenyl] cyclopropyl} carbony!)-3H-spiro[furo[3,4-c]pyridine-1 3 pyrrolidin]-3-one; 1'-{[1-(2-Methoxyphenyl)cyclopropyl] carbonyl} -3H-spiro[furo[3,4-c]pyridine-1,3"- pyrrolidin]-3-one; 1-{[1 (2-Methylphenyl)cyc lopropyl] carbonyl}-3H-spiro[furo(3,4-c]pyridine-1,3'- pyrrolidin}-3-one; I-{{1 -(2,3-Difluorophenyl)cyclo-propyljcarbonyl}-3H-spiro[ furo[3,4] pyridine-1,3'- pyrrolidin]-3-one; 1'-{[1-(2-Chloro-6-fluorophenyl)cyclo-propyljcarbonyl} -3H-spiro[furo[3,4-c]pyridine-1,3'- pyrrolidin]-3-one; 1'-{[1-(1-Naphthyl)cyclopropyl] carbonyl}-3H-spiro[furo[3,4-c]pyridine-1 ,3"-pyrrolidin]-3- one; 1'-{[1<2-Fluorophenyl)cyclopropyl] carbonyl} -6-(trifluoromethyl)-3H-spiro[furo[3,4- ¢]pyridine-1,3'-pytrolidin]-3-one; 6-Chloro-1'-{[1-(4-methylphenyl) cyclopropyljcarbonyl}-3H-spiro[furo[3,4-c]pyridine-1,3'- pyrrolidin]-3-one; 6-Chloro-1'-({1-[4-(trifluoro-methyl)phenyl]cyclopropyl} carbonyl)-3 H-spiro[furo[3,4- c]pyridine-1,3'-pyrrolidin]-3-one; 6-Chloro-1'-{{1 -(2,4-difluoropheny I) cyclopropyl]carbony!}-3H-spiro[furo[3,4-c]pyridine- 1,3'-pyrrolidin}-3-one; 6-Chloro-1'-( { 1-[3-(difluoromethoxy )phenyl]cyclopropyl}carbonyl)-3H-spiro[furo[3,4- ¢]pyridine-1,3'-pyrrolidin]-3-one;
1'-{[1-(2,4-Dichlorophenyl)cyclo-propyl]carbonyl} -3H-spiroffuro[3,4-c]pyridine-1,3'- pyrrolidin}-3-one; 1'-{[1-(4-Chlorophenyl)cyclopropyl] carbonyl}-4-methoxy-3H-spiro{ furo[3,4-c]pyridine- 1,3’-pyrrolidin]-3-one; 1'-{[1-(4-Chloropheny!)cyclopropyl] carbony!}-4-hydroxy-3H-spiro[furo[3,4-c]pyridine-1,3"- pyrrolidin}-3-one; 6-Chloro-1'-{[1-(3,4-dichlorophenyl) cyclopropyl]carbonyl}-3H-spiro[furo[3,4-c]pyridine- : 1,3'-pyrrolidin]-3-one; 1'-{[1-(4-Chloro-2-fluorophenyl) cyclopropy!]carbonyl}-3H-spiro[furo[3,4-c]pyridine-1,3'- pyrrolidin]-3-one; 6-Chloro-1'-{[1-(2,4-difluoropheny!) cyclopropyl]carbonyl}-3H-spiro[furo[3,4-c]pyridine- 1,3'-pyrrolidin]-3-one; 1-§ [1-(2-Chloro-4-fluorophenyl)cyclo-propyl]carbonyl}-3H-spiroffuro[3 ,4-c]pyridine-1,3'- pyrrolidin}-3-one; 1'-{[1-(2,4-Difluorophenyl)cyclo-propyl]carbony!}-3H-spiro{furo[3 ,4-c]pyridine-1,3'- ~~ pyrrolidin]-3-one, 1'-({1-[4-(Methylthio)phenyl]cyclo-propyl}arbonyl)-3 H-spiro[furo[3,4-c]pyridine-1,3"- pyrrolidin]-3-one; 1'-[(1-{4-[(Trifluoromethyl)thio] phenyl} yclopropyl)carbony!]-3H-spiro[furo[3 ,4-c]pyridine- 1,3'-pyrrolidin]-3-one; 1'-{[1-(4-Chlorophenyl)cyclo-pentyl]carbonyl}-3 H-spiro[2-benzofuran-1,3'-pyrrolidin}-3- one; 1-{[1-(4-Chlarophenyl)cyclohexyl] carbonyl} azepane; Methyl 4-[5-(1-{[3-0xo0-1'H,3H-spiro[2-benzofuran-1 ,3'-pyrrolidin]-1'- yl]carbonyl}cyclopropyl)pyridin-2-yl]piperazine-1 -carboxy late; N,N-Dimethyl-4-[4-(1-{[3-0xo0-1'H,3H-spiro[2-benzofuran-1,3"-pyrrolidin}-1'- yl]carbonyl}cyclo-propy I)phenyl]piperazine-1-carboxamide; Methyl 4-[3-fluoro-4-(1-{[3-oxo-1'H,3H-spiro[2-benzofuran-1 ,3"-pyrrolidin]-1'- yl]carbonyl}cyclo-propyl)phenyl]piperazine-1 -carboxylate; 1'-({1-[2-Fluoro-4-(4-propionylpiperazin-1-yl)phenyl]cyclo-propyl} carbonyl)-3H-spiro[2- benzofuran-1,3'-pyrrolidin]-3-one; 1'<({1-[2-Fluoro-4-(4-isobutyrylpiperazin-1 -yl)phenyl]cyclo-propyl}carbonyl)-3H-spiro[2- benzofuran-1,3'-pyrrolidin]-3-one; 1'-[(1-{4-[4-(Cyclopropy| carbonyl)piperazin-1 -yl]-2-fluoro-phenyl} cyclopropyl) carbonyl] 3H-spiro[2-benzofuran-1,3-pyrrolidin]-3-one; 1'-({1-[4-(4-Acetylpiperazin-1 -yl)-2-fluorophenyl]jcyclopropyl} carbonyl)-3 H-spiro{2- benzofuran-1,3"-pyrrolidin}-3-one;
4-[3-Fluoro-4-(1-{[3-oxo-1'H,3H-spiro[2-benzofuran-1,3'-pyrrolidin]-1'- ylJcarbonyl} cyclopropyl)phenyl]-N,N-dimethylpiperazine-1-carboxamide; 1'({1-[4-(4-Hydroxypiperidin-1-yl)phenyl}cyclopropyl} carbonyl)-3H-spiro[2-benzofuran- 1 3-pyrrolidin]-3-one; N,N-Dimethy!-1-[4-(1-{[3-0ox0-1"H,3H-spiro[2-benzofuran-1,3 >-pyrrolidin]-1’- ylJcarbonyl}cyclo-propy!)phenyl]piperidine-4-carboxamide; Methyl 4-[4-(1-{[3-0x0-1"H,3H-spirof2-benzofuran-1 ,3'-pyrrolidin]-1'- _ yl]carbonyl} cyclopropyl) phenyl]piperidine- 1 carboxylate; Ethyl 4-[4-(1-{[3-ox0-1'H,3H-spiro[2-benzofuran-1 J3-pyrrolidin]-1'- yl]carbonyl} cyclopropyl) phenyljpiperidine-1 -carboxylate; 1'-({1-[4-(1-Acetylpiperidin-4-yl)phenyl]cyclopropyl} carbonyl)-3H-spiro[2-benzofuran-1,3'- pyrrolidin]-3-one; 1'-({1-[4-(1-Isobutyry Ipiperidin-4-yl)phenyl]cyclopropyl}carbonyl)-3H-spiro [2-benzofuran- 1,3'-pyrrolidin]-3-one; 1'-({1-[4-(1-Propionylpiperidin-4-yl)phenyljcyclopropyl} carbonyl)-3H-spiro[2-benzofuran- 1,3"-pyrrolidin}-3-one; 1'-[(1-{4-[1-(3-Methylbutanoy!) piperidin-4-yljphenyl} cyclopropyl) carbonyl]-3H-spirof{2- benzofuran-1,3'-pyrrolidin]-3-one; 1'-({1-[4-(1-Acetylpiperidin-4-yl)phenyl] cyclopropyl} carbonyl)-3H-spiro[furo(3,4- c]pyridine-1,3"-pyrrolidin]-3-one; 1'-({1-[4-(1-Isobutyrylpiperidin-4-yl)phenyl]cyclopropyl} carbonyl)-3H-spiroffuro{3,4- c]pyridine-1,3"-pyrrolidin]-3-one; 1-({1-{4-(1 -Propionylpiperidin-4-yl)phenyl]cyclopropyl}carbonyl)-3H-spiro[furo(3,4- ¢]pyridine-1,3'-pyrrolidin}-3-one; : 1-[(1-{4-[1 -(3-Methylbutanoy!) piperidin-4-yl]phenyl} cyclo-propyl)carbonyl]-3H- spiro[furo[3,4-c]pyridine-1,3'-pyrrolidin]-3-one; Methyl 4-[4-(1-{[3-0x0-1"H,3H-spiro[furo[3,4-c]pyridine-1,3'-pyrrolidin]-1'- yl]carbonyl}cyclopropyl)phenyllpiperidine-1-carboxylate; Ethyl 4-[4-(1-{[3-0oxo-1'H,3H-spiro[furo[3,4-c]pyridine-1 ,3'-pyrrolidin]-1'- ylcarbonyl} cyclopropyl)phenyl]piperidine-1-carboxylate; Isopropyl 4-[4-(1-{[3-0x0-1'H,3H-spiro[furo[3,4-¢]pyridine-1 ,3-pyrrolidin]-1'- yl]carbonyl}cyclo-propyl)phenyl]piperidine-1-carboxylate; Methy! 4-hydroxy-4-[4-(1-{[3-0x0-1'H,3H-spiro[2-benzofuran-1,3'-pyrrolidin]-1'- yl]carbonyl}cyclo-propyl)phenyl]piperidine- 1 -carboxylate; Ethyl 4-hydroxy-4-[4-(1-{[3-0x0-1'H,3H-spiro[2-benzofuran-1 ,3'-pyrrolidin]-1'- yl]carbony1}cyclo-propyl)phenyl]piperidine-1-carboxylate;
Methyl 4-(5-{1-[(3-pyridin-3-ylpyrrolidin-1-yl)carbonyl]cyclo-propy!} pyridin-2- yDpiperazine-1-carboxylate; Ethyl 4-(5-{1-[(3-pyridin-3-ylpyrrolidin-1-yl)carbonyl]cyclo-propyl} pyridin-2-yl)piperazine- 1-carboxylate; 1-Acetyl-4-(5-{1-[(3-pyridin-3-ylpyrrolidin-1 -yl)carbonyl]jcyclo-propyl}pyridin-2- yl)piperazine; 1-Isobutyryl-4-(5-{1-[(3-pyridin-3-ylpyrrolidin-1-yl)carbonyl] cyclo-propyl} pyridin-2- _ yl)piperazine; 1-(Cyclopropylcarbonyl)-4-(5-{1-[(3-pyridin-3-ylpyrrolidin-1-yl) carbonyl]cyclopropyl} pyridin-2-yl)piperazine; Isopropy! 4-{4-(1-{[3-ox0-1"H,3H-spiro[2-benzofuran-1 ,3"-pyrrolidin]-1'-yl]Jcarbonyl}cyclo- propyl)phenyl]piperazine-1-carboxylate; 1'-[(1-{4-[6-(Pyrrolidin-1-ylcarbonyl)pyridin-3-yl} phenyl} cyclo-propyl)carbonyl}-3H- spiro[2-benzofuran-1,3'-pyrrolidin}-3-one; N-Ethyl-N-methyl-5-{4-(1-{[3-0x0-1 'H,3H-spiro[2-benzofuran-1,3"-pyrrolidin]-1"- yl]carbonyl} cyclo-propyl)pheny!]pyridine-2-carboxamide; N,N-Diethyl-5-[4-(1-{[3-0x0-1'H,3H-spiro{2-benzofuran-1 ,3'-pyrrolidin}-1'- yljcarbonyl} cyclo-propyl)phenyl]pyridine-2-carboxamide; tert-Buty!l {4-[5-(1-{[3-0x0-1 *H,3H-spiro[2-benzofuran-1,3'-pyrrolidin]-1'-yl]carbonyl} cyclo- propyl)pyridin-2-yl]phenyl} carbamate; N,N-Dimethyl-1-[5-(1-{[3-0xo0-1'H,3H-spiro[2-benzofuran- 1,3"-pyrrolidin]-1'- yl]carbonyl}cyclo-propyl)pyridin-2-yllpiperidine-4-carboxamide; and 1'-{[1 (6-Piperidin-1-ylpyridin-3-yl)cyclopropyllcarbonyl}-3H-spiro[furo[3,4-c]pyridine-1 J'- pyrrolidin}-3-one, or pharmaceutically acceptable salt thereof.
32. A compound of claim 1 selected from: 1'-({1-[2-Fluoro-4-(2-oxopyrrolidin-1 -yl)phenyl]cyclopropyl}carbonyl)-3H-spiro[2- benzofuran-1,3'-pyrrolidin]-3-one; 1'<({1-[2-Fluoro-4-(2-oxo0-1,3-0xazolidin-3 -yl)phenyljcyclopropyl}carbonyl)-3H- spiroffuro[3,4-c}pyridine-1,3"-pyrrolidin]-3-one; 1'-({1-[4-(2-Oxoazetidin-1-yl)phenyl]cyc lopropyl}carbonyl)-3H-spiro[2-benzofuran-1,3'- pyrrolidin]-3-one; 1'-({1-[2-Fluoro-4-(2-oxoazetidin-1 -yl)phenyljcyclopropyl}carbonyl)-3H-spiro(2- benzofuran-1,3'-pyrrolidin]-3-one; ’ 1'-({1-[4-(2-Oxoazetidin-1-yl)phenyl]cyclopropyl}carbonyl)-3H-spiro[furo (3,4-c]pyridine- 1,3'-pyrrolidin]-3-one;
1'-({1-[2-Fluoro-4-(2-oxoazetidin-1-yl)phenyl]cyclopropyl} carbonyl)-3H-spiro[furo[3,4- c]pyridine-1,3"-pyrrolidin]-3-one; Propyl 4-[5-(1-{[3-0x0-1"H,3H-spiro[2-benzofuran-1,3'-pyrrolidin]-1'- yl]carbonyl}cyclopropyl)pyridin-2-yl]piperazine-1-carboxylate; 1sobutyl 4-[5-(1-{[3-ox0-1"H,3H-spiro[2-benzofuran-1,3"-pyrrolidin]-1'- yl)carbonyl}cyclopropyl)pyridin-2-yl]piperazine-1-carboxylate; - Isopropyl 4-[5-(1-{[3-0x0-1'H,3H-spiro[2-benzofuran-1 ,3'-pyrrolidin]-1'- yl]carbonyl}cyclopropyl)pyridin-2-yl]piperazine-1-carboxylate; Ethyl 4-[4-(1-{[3-0x0-1'H,3H-spiro[2-benzofuran-1 ,3'-pyrrolidin]-1'- yl]carbonyl} cyclopropy!l)phenyl]piperazine-1-carboxylate; Propyl 4-[4-(1-{[3-0ox0-1"H,3H-spiro[2-benzofuran-1 ,3'-pyrrolidin]-1'- yl]carbonyl} cyclopropyl)phenyl]piperazine-1-carboxylate; Isobutyl 4-[4-(1-{[3-0x0-1'H,3H-spiro[2-benzofuran-1 ,3"-pyrrolidin]-1'- yl]carbonyl}cyclopropyl)pheny!jpiperazine-1-carboxylate; 1'-[(1-{4-[4-(Cyclopropylacetyl)piperazin-1-yl]phenyl} cyclopropyl)carbonyl]-3H-spiro[2- benzofuran-1,3"-pyrrolidin}-3-one; 1'-[(1- {4-[4-(Cyclopropylacetyl)piperazin-1-yl)-2-fluorophenyl} cyclopropyl) carbonyl}-3H- spiro[2-benzofuran-1,3'-pyrrolidin]-3-one; 1'-[(1-{4-[4-(3-Methylbutanoyl)piperazin-1 -ylphenyl}cyclopropyli)carbonyl]-3H-spiro{2- benzofuran-1,3"-pyrrolidin]-3-one; 1'-{(1-{2-Fluoro-4-[4-(3-methylbutanoyl)piperazin-1 -yl]phenyi} cyclopropyl) carbonyl]-3H- spiro[2-benzofuran-1,3'-pyrrolidin}-3-one; 1'-[(1-{4-[4«Tetrahydro-2H-pyran-4-ylcarbonyl)piperazin-1- yl}phenyl} cyclopropyl)carbonyl]-3H-spiro[2-benzofuran-1,3'-pyrrolid in}-3-one; Ethyl 4-[3-fluoro-4-( 1-{[3-oxo-1'H,3H-spiro[2-benzofuran-1 ,3'-pyrrolidin]-1'- yl]carbonyl}cyclopropyl)phenyl]piperazine-1-carboxylate; Propyl 4-[3-fluoro-4-(1-{[3-oxo-1'H,3H-spiro[2-benzofuran-1 ,3"-pyrrolidin]-1'- yl]carbonyl} cyclopropyl)phenyl]piperazine-1-carboxylate; 4-[3-Fluoro-4-(1-{[3-oxo0-1'H,3H-spiro[2-benzofuran-1,3"-pyrrolidin]-1'- yl]carbonyl}cyclopropyl)phenyl]-N-methylpiperazine-1-carboxamide; 1'-({ 1-[2-Fluoro-4-(4-isobutyrylpiperazin-1-yl)phenyl]cyclopropyl} carbonyl)-3H-spiro[2- benzofuran-1,3'-pyrrolidin]-3-one; 1'-[(1-{4-[4-(Cyclopropylacetyl)piperazin-1-yl]-2-fluorophenyl} cyclopropyl) carbonyl]-3H- spiro[2-benzofuran-1,3'-pyrrolidin]-3-one; Methyl 4-[3-fluoro-4-(1- {[3-ox0-1"H,3H-spiro[furo[3,4-c]pyridine-1,3'-pyrrolidin]-1'- yllearbonyl}cyclopropyl)phenyl]piperazine-1-carboxylate;
Ethyl 4-[3-fluoro-4-(1-{[3-oxo-1'H,3H-spiro[furo{3,4-c]pyridine-1,3'-pyrrolidin]-1'- yllcarbonyl}cyclopropyl)phenyl]piperazine-1-carboxylate; Propyl 4-[3-fluoro-4-(1-{[3-oxo-1'H,3H-spiro[furo[3,4-c]pyridine-1,3"-pyrrolidin]-1'- yljcarbonyl}cyclopropyl)phenyl]piperazine-1-carboxylate; iso-Propyl 4-[3-fluoro-4-(1-{[3-oxo-1"H,3H-spiro[furo[3,4-c]pyridine-1,3"-pyrrolidin]-1'- yljcarbonyl} cyclopropyl)phenyl]piperazine-1 -carboxylate; iso-Butyl 4-[3-fluoro-4-(1-{[3-o0x0-1'H,3H-spiro[furo[3,4-c]pyridine-1,3"-pyrrolidin]-1'- yl]carbonyl}cyclopropyl)phenyl]piperazine-1-carboxylate; 1'-[(1-{4-[4-(Cyclopropylcarbonyl)piperazine-1-yl]-2-fluorophenyl}cyclopropyl) carbonyl]- 3H-spiro[furo{3,4-c]pyridine-1,3’-pyrrolidin]-3-one; 1'-[(1-{2-Fluoro-4-[4-(3-methylbutanoyl)piperazin-1-yl]phenyl} cyclopropyl) carbonyl]-3H- spiro[furo[3,4-c]pyridine-1,3'-pyrrolidin]-3-one; N,N-Dimethyl-5-[4-(1-{[3-0x0-1'H,3H-spiro[2-benzofuran-1,3"-pyrrolidin]-1'- yllcarbony!}cyclopropyl)phenyl]pyridine-2-carboxamide; N-Ethyl-5-[4-(1-{[3-0x0-1'H,3H-spiro[2-benzofuran-1,3"-pyrrolidin]-1'- yl]carbony!} cyclopropyl) phenyl]pyridine-2-carboxamide; N-Tsopropyl-5-[4-(1-{[3-0x0-1'H,3H-spiro[2-benzofuran-1,3'-pyrrolidin]-1'- yllcarbonyl}cyclopropyl)phenyllpyridine-2-carboxamide; 5-[3-Fluoro-4-(1-{[3-oxo-1'H,3H-spiro[2-benzofuran-1,3'-pyrrolidin]-1'- yljcarbonyl!}cyclopropyl)phenyl]-N-methylpyridine-2-carboxamide; 5-[3-Fluoro-4-(1-{[3-oxo-1'H,3H-spiro[2-benzofuran-1,3"-pyrrolidin}-1'- ylJcarbonyl}cyclopropyl)phenyl]-N-ethylpyridine-2-carboxamide; 5-[3-Fluoro-4-(1-{[3-oxo-1'H,3H-spiro[2-benzofuran-1,3'-pyrrolidin}-1'- yl]carbonyl} cyclopropyl)phenyl]-N-i-propylpyridine-2-carboxamide; 5-[3-Fluoro-4-(1-{[3-oxo0-1"H,3H-spiro[2-benzofuran-1,3"-pyrrolidin}-1'- yl]carbonyl}cyclopropyl)phenyl]-N,N-dimethylpyridine-2-carboxamide; 5-{3-Fluoro-4-(1- {[3-oxo-1'H,3H-spiro[furo[3,4-c]pyridine-1,3'-pyrrolidin]-1'- yl]carbony!}cyclopropyl)pheny!]-N-methy Ipyridine-2-carboxamide; N-Ethy!-5-[3-fluoro-4-(1-{[3-oxo0-1'H,3H-spiro{furo[3,4-c]pyridine-1,3"-pyrrolidin]-1'- yl]carbonyl}cyclopropyl)phenyl]pyridine-2-carboxamide; 5-[3-Fluoro-4-(1- {[3-oxo-1'H,3H-spiro[furo[3,4-c]pyridine-1,3-pyrrolidin]-1'- yljcarbony!}cyclopropyl)phenyl]-N-isopropylpyridine-2-carboxamide; 5-[3-Fluoro-4-(1-{[3-oxo-1'H,3H-spiro[furo[3,4-c] pyridine-1,3'-pyrrolidin]-1'- : yljcarbony!}cyclopropyl)pheny!]-N,N-dimethylpyridine-2-carboxamide; 6-[3-Fluoro-4-(1-{[3-oxo-1"H,3H-spiro[2-benzofuran-1 ,3'-pyrrolidin]-1'- yljcarbonyl} cyclopropyl)phenyl]-N-methyInicotinamide;
6-[3-Fluoro-4-(1-{[3-0x0-1'H,3H-spiro[2-benzofuran-1,3'-pyrrolidin]-1'- yllcarbonyl}cyclopropyl)phenyl]-N,N-dimethylnicotinamide; N-Methyl-6-[4-(1-{[3-0ox0-1'H,3H-spiro[2-benzofuran-1,3'-pyrrolidin}-1'- yl]carbonyl}cyclopropyl)phenyi]nicotinamide; N,N-Dimethyl-6-{4-(1-{[3-0x0-1'H,3H-spiro[2-benzofuran-1,3"-pyrrolidin]}-1'- yllcarbonyl}cyclopropyl)phenyl]nicotinamide; 1'-({1-{4-(1 -Isobutyryl-1,2,3,6-tetrahydropyridin-4-yl)phenyl]cyclopropyl} carbonyl)-3H- spiro[2-benzofuran-1,3'-pyrrolidin]-3-one; : 1'-({1-{4-(1-Propiony!-1,2,3,6-tetrahydropyridin-4-yl)phenyl}cyclopropyl} carbonyl)-3H- spiro[2-benzofuran-1,3"-pyrrolidin}-3-one; 1'«({1-[3-Fluoro-4-(3-methyl-1H-pyrazol-1-yl)phenyl]cyclopropyl}carbonyl)-3H- spiro furo{3,4-c]pyridine-1,3'-pyrrolidin]-3-one; Methy! 4-(4-{1-[(4,4-dimethyl-2-0x0-1-0xa-7-azaspiro[4.4]non-7-yl)carbonyl] cyclopropyl}- 3-fluorophenyl)piperazine- I -carboxylate; Ethyl 4-(4-{1-[(4,4-dimethy]-2-ox0-1-0xa-7-azaspiro{4.4]non-7-yl)carbonyl]cyclopropyl}-3- fluorophenyl)piperazine-1-carboxylate; 7-{[1-(4-Chlorophenyl)cyclopropyl]carbonyl} -4,4-dimethyl-1-oxa-7-azaspiro[4.4]nonan-2- one; Methyl 4-(3-fluoro-4-{ 1-[(3-pyridin-3-yipyrrolidin-1-yl)carbonyl]cyclopropyl} phenyl)piperazine-1-carboxylate; Methyl 4-(5-{1-[(3-pyridin-3-ylpyrrolidin-1-yl)carbonyljcyclopropyl} pyridin-2- yl)piperazine-1-carboxylate; Ethyl 4-(5-{1-[(3-pyridin-3-ylpyrrolidin-1 -yl)carbonyl]cyclopropyl} pyridin-2-yl)piperazine- 1-carboxylate; 1-Acetyl-4-(5-{1-[(3-pyridin-3-ylpyrrolidin-1-yl)carbonyl]cyclopropyl} pyridin-2- yl)piperazine; 1-(3-Methylbutanoy!)-4-(5-{1-[(3-pyridin-3-ylpyrrolidin-1 -yl)carbonyl]cyclopropyl} pyridin- 2-yl)piperazine; 1-(Cyclopropylcarbonyl)-4-(5-{1-[(3-pyridin-3-ylpyrrolidin-1 -yl)carbonyljcyclopropyl} pyridin-2-yl)piperazine; Methyl 4-(3-fluoro-4-{1-{(1,3,3-trimethyl-6-azabicyclo[3.2. 1Joct-6-yl)carbonyl] cyclopropyl} phenyl)piperazine-1-carboxylate; 1-{[1-(6-Azetidin-1-ylpyridin-3-yl)cyclopropyljcarbonyi}-3H-spiro [furo[3,4-c]pyridine-1,3'"- pyrrolidin]-3-one; 1'-({1-{6-(2-Oxoazetidin-1-yDpyridin-3-yljcyclopropy!} carbonyl)-3 H-spiro[2-benzofuran- 1,3'-pyrrolidin]-3-one;
Methy! {3-fluoro-4-(1-{[3-oxo-1'H,3H-spiro[furo[3,4-c]pyridine-1,3'-pyrrolidin]-1'- yl]carbonyl}cyclopropyl)phenyl]carbamate; Methyl [3-fluoro-4-(1-{[3-0x0-1"H,3H-spiro[2-benzofuran-1,3"-pyrrolidin]-1'- yl]carbonyl}cyclopropyl)phenyljcarbamate; 1'-({1-[4-(2-Oxopyrrolidin-1-yl)phenyl]cyclopropyl} carbonyl)-3H-spiro[ furo[3,4-c]pyridine- 1,3'-pyrrolidin]-3-one; 1'-[(1-{4-[4-(Cyclopropylcarbonyl)piperazin-1-yl]phenyl} cyclobutyl)carbonyl]-3H-spiro[2- benzofuran-1,3'-pyrrolidin]-3-one; Ethyl 4-[4-(1-{[3-0oxo-1"H,3H-spiro[furo[3,4-c]pyridine-1,3'-pyrrolidin]-1'- ylJcarbonyl}cyclopropyl)phenyl]piperazine-1-carboxylate; 1-{[1-(4-Chlorophenyl)cyclopropyljcarbonyl}-3-(1,1 -dimethylpropy)pyrrolidin-3-ol; 7-{[1-(4-Chlorophenyl)cyclopropyl]carbonyl}-4,4-dimethyl-1-oxa-7-azaspiro[4.4]nonane; Methyl 4-(4-{1-[(3-tert-butyl-3-hydroxypyrrolidin-1-yl)carbonyl]cyclopropyl}-3- fluorophenyl)piperazine-1-carboxylate; N,N-Diethyl-5-[3-fluoro-4-(1-{[3-oxo-1'H,3H-spiro[2-benzofuran-1,3"-pyrrolidin]-1'- yl}carbonyl}cyclopropyl)phenyl]pyridine-2-carboxamide; 1'-({1-[4-(2-Oxopyrrolidin-1-yl)phenyl]cyclopropyl} carbony 1)-3H-spiro[2-benzofuran-1,3'- pyrrolidin]-3-one; 1-({1-[2-Fluoro-4-(1H-1,2,3-triazol-1-yl)phenyl]cyclopropyl} carbonyl)-3H-spiro[2- benzofuran-1,3'-pyrrolidin]-3-one; 1'-({1-[2-Fluoro-4-(2H-1 ,2,3-triazol-2-yl)phenyl]cyclopropy!}carbonyl)-3H-spiro [2- benzofuran-1,3'-pyrrolidin]-3-one; 1'-({1-[2-Fluoro-4-(1H-1,2,4-triazol-1 -yl)phenylicyclopropyl} carbony!)-3H-spiro[2- benzofuran-1,3'-pyrrolidin]-3-one; 1'-({1-[2-Fluoro-4-(4H-1 2,4-triazol-4-yl)phenyl]cyclopropy!} carbonyl)-3H-spiro[2- benzofuran-1,3'-pyrrolidin}-3-one; N-Ethyl-5-[3-fluoro-4-(1-{{3-oxo-1'H,3 H-spirof2-benzofuran-1,3'-pyrrolidin]-1'- yl]carbonyl}cyclopropyl)phenyl]pyridine-2-carboxamide; and 5-[3-Fluoro-4-(1-{[3-0ox0-1 'H,3H-spiro[2-benzofuran-1,3"-pyrrolidin]-1'- yljcarbonyl}cyclopropyl)phenyl]-N-isopropylpyridine-2-carboxamide; or pharmaceutically acceptable salt thereof.
33. A method of modulating activity of 11BHSD1 or MR comprising contacting said 11pHSD!1 or said MR with a compound of Formula I:
R! R2 3 oN Nope 0) 1 or pharmaceutically acceptable salt or prodrug thereof, wherein:
Cy is aryl, heteroaryl, cycloalkyl or heterocycloalkyl, each optionally substituted by 1,2, 3, 4 or 5 -W-X-Y-Z;
R' and R? together with the C atom to which they are attached form a 3-, 4-,'5-, 6- or 7- membered cycloalkyl group or a 3-, 4-, 5-, 6- or 7-membered heterocycloalkyl group, each optionally substituted by 1, 2 or 3 R’;
R’® and R* together with the N atom to which they are attached form a 4-15 membered heterocycloalkyl group optionally substituted by 1,2, 3 or 4 -W-X'-Y’-Z',
R® is halo, C, alkyl, Cy. alkenyl, Cy. alkynyl, Cy. haloalkyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, CN, NO,, OR’, SR?, C(O)R®, C(O)NR'R’, C(O)OR?, OC(O)R®, OC(O)NR'R’, NRCR?, NR°C(O)RY, NR°C(O)OR?, S(O)R®, S(OYNR'R?, S(OX.R’, or S(O),NR°R%;
W, W’ and W*’ are each, independently, absent, C6 alkylenyl, Ci. alkenylenyl, Cis alkynylenyl, O, S, NR®, CO, CS, COO, CONR’, QCONR¢, SO, SO,, SONR®, or NRCONR', wherein said Cy. alkylenyl, Cy alkenylenyl, Ca alkynyleny! are each optionally substituted by 1, 2 or 3 halo, OH, C,., alkoxy, C,. haloalkoxy, amino, C, alkylamino or C,s dialkylamino;
X, X’ and X*’ are each, independently, absent, Cys alkylenyl, Cys alkenylenyl, Cy.3 alkynylenyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, cycloalkylalkyl, heteroarylalkyl, heterocycloalkylalkyl, arylalkenyl, cycloalkylatkenyl, heteroarylalkenyl, heterocycloalkylalkenyl, arylalkynyl, cycloalkylalkynyl, heteroarylalkynyl, heterocycloalkylalkynyl, each of which is optionally substituted by one or more halo, CN, NO,, OH, C,.4alkoxy, C;.4 haloalkoxy, amino, Ci4 alkylamino or Cys dialkylamino;
Y, Y’ and Y’’ are each, independently, absent, Cs alkylenyl, Cs ¢alkenylenyl, Ca alkynylenyl, O, $, NR¢, CO, CS, COO, CONR’, OCONR?®, SO, SO,, SONR’, or NRCONR', wherein said C,.¢ alkylenyl, C.s alkenylenyl, Ca alkynylenyl are each optionally substituted by 1, 2 or 3 halo, OH, C,.s alkoxy, Cy.4 haloalkoxy, amino, C4 alkylamino or C4 dialkylamino;
Z,Z’ and Z"’ are each, independently, absent, H, halo, oxo, sulfido, CN, NO,, OH, C,., alkoxy, Ci.4 haloalkoxy, amino, C;.4 alkylamino or C,.g dialkylamino, C,.salkyl, C,¢alkenyl, Cag alkynyl, aryl, cycloalkyl, heteroaryl or heterocycloalkyl, wherein said Cs alkyl, Cos alkenyl, Ca alkynyl, aryl, cycloalkyl, heteroaryl or heterocycloalkyl is optionally substituted by 1, 2 or 3 halo, Cy. alkyl, C,.¢ alkenyl, Cy. alkynyl, Ci haloalkyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, CN, NO,, OR’, SR’, C(O)R”, C(O)NR°RY, C(O)OR®, OC(O)R®, OC(O)NRR?, NRR’, NRC(O)RY, NRC(O)OR®, S(O)R®, S(O)NRR, S(O):R”, or S(O)2NRR’,;
PCT/US2005/015539 wherein two ~W-X-Y-Z attached to the same atom optionally form a 3-14 membered cycloalkyl or heterocycloalkyl group optionally substituted by 1,20r3 -W».X>.Y>.2": wherein two —-W’-X’-Y’-Z" attached to the same atom optionally form a 3-14 membered cycloalkyl or heterocycloalky! group optionally substituted by 1, 2 or 3 -W».X’-Y"*.2""; wherein —~W-X-Y-Z is other than H; wherein —W’-X’-Y’-Z’ is other than H; wherein -W’’-X"’-Y"’-Z" is other than H; R®is H, C,¢ alkyl, Cy haloalkyl, Cy alkenyl, (C,.¢ alkoxy)-C,.s alkyl, Cy. alkynyl, aryl, cycloalkyl, heteroaryl or heterocycloalkyl: Ris H, C4 alkyl, Cy haloalkyl, C, 4 alkenyl, Cy alkynyl, aryl, cycloalkyl, heteroaryl or heterocycloalkyl; R® and R? are each, independently, H, C4 alkyl, C,¢ haloalkyl, Cy alkenyl, C4 alkynyl, aryl, cycloalkyl, arylalkyl, or cycloalkylalkyl; or R° and RY together with the N atom to which they are attached form a 4-, 5-, 6- or 7- membered heterocycloalkyl group; and R® and Rf are each, independently, H, C,; alkyl, C, haloalkyl, Cy. alkenyl, Cy. alkynyl, aryl, cycloalkyl, arylalkyl, or cycloalkylalkyl; or R® and R together with the N atom to which they are attached form a 4-, 5-, 6- or 7- membered heterocycloalkyl group.
34. The method of claim 33 wherein said modulating is inhibiting.
35. Use of a compound of Formula I: R! R2 Rr?
I . or pharmaceutically acceptable salt or prodrug thereof, wherein: Cy is aryl, heteroaryl, cycloalkyl or heterocycloalkyl, each optionally substituted by 1, 2, 3, 4 ors -W-X-Y-Z; R' and R? together with the C atom to which they are attached form a 3-, 4-,5-,6- or 7- membered cycloalkyl group or a 3-, 4-, 5-, 6- or 7-membered heterocycloalkyl group, each optionally substituted by 1, 2 or 3 RY; 248 AMENDED SHEET
: PCT/US2005/015559 R’ and R* together with the N atom to which they are attached form a 4-15 membered heterocycloalky! group optionally substituted by 1, 2,30r4-W-X'-Y*-2Z’; Riis halo, C,¢ alkyl, C,4 alkenyl, Cy alkynyl, C4 haloalkyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, CN, NO,, OR, SR, C(O)R®, C(O)NR'RY, C(O)OR’, OC(O)R®, OC(O)NRRY, NRR’, NR°C(O)R?, NR°C(O)OR?, S(O)R?, S(O)NR°R?, S(0),R", or S(O),NR°R: W, Wand W*’ are each, independently, absent, Cygalkylenyl, Cis alkenylenyl, Cp alkynylenyl, O, S, NR*, CO, CS, COO, CONR?, OCONR?S, SO, SO, SONR®, or NR‘CONR', wherein : said Cy alkylenyl, Cy alkenylenyl, Cy alkynyleny! are each optionally substituted by 1, 2 or 3 halo, OH, C4 alkoxy, C4 haloalkoxy, amino, C4 alkylamino or C,.4 dialkylamino; X, X’ and X’* are each, independently, absent, C, 4 alkylenyl, Cg alkenylenyl, C,4 - alkynylenyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, cycloalkylalkyl, heteroarylalkyl, heterocycloalkylalkyl, arylalkeny!, cycloalkylalkenyl, heteroarylalkenyl, heterocycloalkylalkenyl, arylalkynyl, cycloalkylalkynyt, heteroarylalkynyl, heterocycloalkylalkynyl, each of which is optionally substituted by one or more halo, CN, NO,, OH, C,, alkoxy, C4 haloalkoxy, amino, C, 4 alkylamino or C,.4 dialkylamino; Y,Y’ and YY" are each, independently, absent, C, 4 alkylenyl, Cy alkenylenyl, C,. alkynylenyl, O, S, NR¢, CO, CS, COO, CONR’, OCONR®, SO, SO,, SONR®, or NR°CONR', wherein said Cig alkylenyl, Cy alkenylenyl, Cy. alkynylenyl are each optionally substituted by 1, 2 or 3 halo, OH, C4 alkoxy, C4 haloalkoxy, amino, C,, alkylamino or Cy 4 dialkylamino; Z,Z’ and Z”’ are each, independently, absent, H, halo, oxo, sulfido, CN, NO,, OH, C4 alkoxy, C4 haloalkoxy, amino, C, 4 alkylamino or C,.4 dialkylamino, C4 alkyl, Cy alkenyl, Cy alkynyl, aryl, cycloalkyl, heteroaryl or heterocycloalkyl, wherein said Cis alkyl, Cys alkenyl, Cy alkynyl, aryl, cycloalkyl, heteroaryl or heterocycloalkyl is optionally substituted by 1, 2 or 3 halo, C, alkyl, Cy alkenyl, Cp alkynyl, C4 haloalkyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, CN, NO,, OR, SR*, C(O)R’, C(O)NR°RY, C(O)OR?, OC(O)R?, OC(O)NR‘RY, NR°RY, NR°C(O)RY, NR*C(O)OR", S(O)R®, S(O)NR°RY, S(O),R?, or S(0),NR°R?: wherein two —W-X-Y-Z attached to the same atom optionally form a 3-14 membered cycloalkyl or heterocycloalkyl group optionally substituted by 1, 2 or 3 Wr XLylz, wherein two —-W’-X’-Y’-Z" attached to the same atom optionally form a 3-14 membered cycloalkyl or heterocycloalkyl group optionally substituted by 1, 2 or 3 -W». XYZ wherein -W-X-Y-Z is other than H; wherein —W’-X’-Y’-Z’ is other than H; : wherein —-W”’-X*’-Y**-Z*’ is other than H; Ris H, C4 alkyl, C,.¢ haloalkyl, Cs alkenyl, (Cy. alkoxy)-C, 4 alkyl, Cy. alkynyl, aryl, cycloalkyl, heteroaryl or heterocycloalkyl; R®is H, Cis alkyl, Cy haloalkyl, Cy alkenyl, C,.4 alkynyl, aryl, cycloalkyl, heteroaryl or heterocycloalkyl, 249 AMENDED SHEET
PCT/US2005/015559 R® and R* are each, independently, H, Cis alkyl, Cy haloalkyl, Cy alkenyl, C,4 alkynyl, ! aryl, cycloalkyl, arylalkyl, or cycloalkylalkyl; or R® and R¢ together with the N atom to which they are attached form a 4-, 5-, 6- or 7- membered heterocycloalky! group; and R® and Rare each, independently, H, Ci. alkyl, C4 haloalkyl, Cy. alkenyl, Cas alkynyl, aryl, cycloalkyl, arylalkyl, or cycloalkylalkyl; or R°and Rf together with the N atom to which they are attached form a 4-,5-,6-or7- BN membered heterocycloatkyl group, in the manufacture of a medicament for treating a disease In a patient, wherein said disease is associated with expression of activity of 11BHSDI or
MR. oo
36. Use of claim 35 wherein said disease is obesity, diabetes, glucose intolerance, insulin resistance, hyperglycemia, hypertension, hyperlipidemia, cognitive impairment, dementia, glaucoma, hypertension, cardiovascular disorders, osteoporosis, or inflammation.
37. Use ofclaim 35 wherein said disease is hypertension, a cardiovascular, renal or inflammatory disease, heart failure, atherosclerosis, arteriosclerosis, coronary artery disease, thrombosis, angina, peripheral vascular disease, vascular wall damage, stroke, dyslipidemia, hyperlipoproteinaemia, diabetic dyslipidemia, mixed dyslipidemia, hypercholesterolemia, hypertriglyceridemia, type 1 diabetes, type 2 diabetes, obesity, metabolic syndrome, insulin resistance or general aldosterone-related target organ damage.
38. A composition comprising a compound of claim | and a pharmaceutically acceptable carrier,
39. Use of a compound of Formula I: R! R2 i N 0 I or pharmaceutically acceptable salt or prodrug thereof, wherein: 250 : AMENDED SHEET :
PCT/US2005/015559 Cy is aryl, heteroaryl, cycloalkyl or heterocycloalkyl, each optionally substituted by 1,2,3,4 or5 -W-X-Y-Z; R' and R? together with the C atom to which they are attached form a 3-,4-,5-,6-0r7- membered cycloalkyl group or a 3-, 4-, 5-, 6~ or 7-membered heterocycloalkyl group, each optionally substituted by 1, 2 or 3 R®; R’ and R* together with the N atom to which they are attached form a 4-15 membered heterocycloalkyl group optionally substituted by 1, 2, 3 or 4 ~W-X-Y'.Z’; R’ is halo, C4 alkyl, Cy.6 alkenyl, Cy6 alkynyl, C,., haloalkyl, aryl, cycloalkyl, heteroaryl, + heterocycloalkyl, CN, NO,, OR?, SR?, C(O)R, C(O)NR'R!, C(O)OR?, OC(O)R", OC(O)NR°R’, NR‘R’, NR‘C(O)R", NR°C(O)OR?, S(O)R®, S(O)NRR', S(O);R", or S(O),NRR; W, W’ and W*” are each, independently, absent, C4 alkylenyl, C4 alkenylenyl, C, alkynylenyl, O, S, NR", CO, CS, COO, CONR®, OCONR®, SO, SO,, SONR®, or NR°CONR', wherein said Cg alkylenyl, C,4 alkenylenyl, C; 4 alkynylenyl are each optionally substituted by 1, 2 or 3 halo, OH, C4 alkoxy, Cy, haloalkoxy, amino, C, alkylamino or C,. dialkylamino; X, X" and X’ are each, independently, absent, C4 alkylenyl, C, 4 alkenylenyl, C,4 alkynylenyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, cycloalkylalkyl, hetercarylalkyl, heterocycloalkylalky!, arylalkenyl, cycloalkylalkenyl, heteroarylalkenyl, heterocycloalkylalkenyl, arylalkynyl, cycloalkylalkynyl, heteroarylalkynyl, heterocycloalkylalkynyl, each of which is optionally substituted by one or more halo, CN, NO,, OH, C,, alkoxy, Cy, haloalkoxy, amino, Cis alkylamino or C, 4 dialkylamino; Y,Y’ and Y” are each, independently, absent, C, alkylenyl, Cy alkenylenyi, Cy alkynylenyl, O, S, NR*, CO, CS, COQ, CONR®, OCONRS, SO, SO,, SONR?, or NR°CONR', wherein said Cy galkylenyl, Cy4 alkenylenyl, C,.¢alkynylenyl are each optionally substituted by 1, 2 or 3 halo,
.- OH, C,., alkoxy, C4 haloalkoxy, amino, C, 4 alkylamino or C, 4 dialkylamino; Z,Z and Z*’ are each, independently, absent, H, halo, oxo, sulfido, CN, NO,, OH, Cig alkoxy, C4 haloalkoxy, amino, C14 alkylamino or Cag dialkylamino, C, 4 alkyl, C4 alkenyl, Cp alkynyl, aryl, cycloalkyl, heteroaryl or heterocycloalkyl, wherein said Cisalkyl, Cygalkenyl, Cp alkynyl, aryl, cycloalkyl, heteroaryl or heterocycloalkyl is optionally substituted by 1, 2 or 3 halo, C4 : alkyl, Cy alkenyl, Cy.6 alkynyl, C,, haloalkyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, CN, NO, OR, SR*, C(O)R®, C(O)NR°RY, C(O)OR?, OC(O)R’, OC(O)NRR?, NR°R*, NRC(O)R, NR'C(O)OR, S(O)R®, S(O)NRR?, S(O),R®, or S(0),NR°RY; 251 AMENDED SHEET
PCT/US2005/015559 wherein two —W-X-Y-Z attached to the same atom optionally form a 3-14 membered cycloalkyl or heterocycloalkyl group optionally substituted by 1, 2 or 3 “WXYZ wherein two ~W’-X’-Y’-Z’ attached to the same atom optionally form a 3-14 membered cycloalkyl or heterocycloalkyl group optionally substituted by I,20r3 -W».X.¥.2; wherein ~W-X-Y-Z is other than H; wherein —W’-X’-Y’-Z’ is other than H; wherein ~W"-X"’-Y>>-Z"" is other than H; : Ris H, Cg alky!, C4 haloalkyl, Cy alkenyl, (C6 alkoxy)-C 6 alkyl, Cy alkynyl, aryl, cycloalkyl, heteroaryl or heterocycloalkyl; R" is H, Cig alkyl, C,¢ haloalkyl, Cy alkenyl, Cy alkynyl, aryl, cycloalkyl, heteroaryl or heterocycloalkyl; R® and R? are each, independently, H, C, 4 alkyl, C,.¢ haloalkyl, C,. alkenyl, Cy alkynyl, aryl, cycloalkyl, arylalkyl, or cycloalkylalkyl; : or R® and R¢ together with the N atom to which they are attached form a 4-, 5-,6-or 7- membered heterocycloalkyl group; and R° and Rf are each, independently, H, C,¢ alkyl, C4 haloalkyl, Cs. alkenyl, C,.¢ alkynyl, aryl, cycloalkyl, arylalkyl, or cycloalkylalkyl; or R® and R together with the N atom to which they are attached form a 4-, 5-, 6- or 7- membered heterocycloalkyl group, in the manufacture of a preparation for modulating activity of 11BHSDI or MR.
40. Use of claim 39 wherein said modulating is inhibiting,
41. A compound of any one of claims | to 32, substantially as herein described with reference to and as illustrated in any of the examples.
42. A method of claim 33 or claim 34, substantially as herein described with reference to and as illustrated in any of the examples.
43. Use of any one of claims 35 to 37 or 39 or 40, substantially as herein described with reference to and as illustrated in any of the examples.
44. A composition of claim 38, substantial ly as herein described with reference to and as illustrated in any of the examples. 252 AMENDED SHEET
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US56927304P | 2004-05-07 | 2004-05-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200609236B true ZA200609236B (en) | 2008-06-25 |
Family
ID=38693324
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200609236A ZA200609236B (en) | 2004-05-07 | 2006-11-06 | Amido compounds and their use as pharmaceuticals |
Country Status (3)
Country | Link |
---|---|
CN (1) | CN101001842B (en) |
UA (1) | UA89043C2 (en) |
ZA (1) | ZA200609236B (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UY33001A (en) * | 2009-11-06 | 2011-05-31 | Boehringer Ingelheim Int | ARYL AND HETEROARILCARBONYL HIVAHYDROINDENOPIRIDINE AND OCTAHYDROBENZOQUINOLINE DERIVATIVES |
CN102675101B (en) * | 2012-05-16 | 2014-01-29 | 王蕾 | Preparation method of 2-(4-haloethyl) phenyl-2-methyl propionic ester and synthesis method of bilastine |
JP6990657B2 (en) * | 2016-02-08 | 2022-01-13 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | Spiroindrinone as a DDR1 inhibitor |
CN108341823A (en) * | 2017-01-22 | 2018-07-31 | 中国科学院兰州化学物理研究所苏州研究院 | A kind of spiro indole -3,3 '-pyrrolidines and its synthetic method |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6547958B1 (en) * | 2001-07-13 | 2003-04-15 | Chevron U.S.A. Inc. | Hydrocarbon conversion using zeolite SSZ-59 |
AU2002360561A1 (en) * | 2001-12-11 | 2003-06-23 | Sepracor, Inc. | 4-substituted piperidines, and methods of use thereof |
-
2005
- 2005-05-04 CN CN200580022687.8A patent/CN101001842B/en active Active
- 2005-05-04 UA UAA200612885A patent/UA89043C2/en unknown
-
2006
- 2006-11-06 ZA ZA200609236A patent/ZA200609236B/en unknown
Also Published As
Publication number | Publication date |
---|---|
CN101001842A (en) | 2007-07-18 |
CN101001842B (en) | 2015-10-07 |
UA89043C2 (en) | 2009-12-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9957229B2 (en) | Amido compounds and their use as pharmaceuticals | |
TWI400239B (en) | Lactam compounds and their use as pharmaceuticals | |
EP1957494A2 (en) | Lactam compounds and methods of using the same | |
AU2005306476A1 (en) | Inhibitors of 11-beta hydroxyl steroid dehydrogenase type 1 and methods of using the same | |
NZ551602A (en) | Amido compounds and their use as pharmaceuticals | |
US20090291946A1 (en) | Lactam compounds and their use as pharmaceuticals | |
ZA200609236B (en) | Amido compounds and their use as pharmaceuticals | |
AU2012211351A1 (en) | Amido compounds and their use as pharmaceuticals |